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Abstract
Membrane transporters are essential for the transfer of hydrophobic molecules across 
the plasma membrane of ceUs; therefore active and facilitated transport processes can 
determine the absorption, distribution, metabolism and excretion profile of drugs. 
Preclinical assays are used to determine the effects of transport on the pharmacokinetics 
and toxicology of a new compound during drug development. However cells in culture 
often give erroneous results due to the differential expression of important proteins 
within them. It was therefore the aim of this work to assess the differences in drug 
transporter expression in a variety of human and rat hepatocellular systems compared to 
liver.
RT-PCR analysis of drug transporter levels in vitro and in vivo showed huge differences, 
with influx transporters generally being under-expressed and efflux transporters over­
expressed in vitro compared to in vivo. Further study established that lack of the influx 
transporter OATPIBI in Huh7 cells could limit the cellular access of pravastatin. This 
work also showed that pravastatin could increase the expression of the drug transporter 
Abcc2 but not ABCBl or GYP3A4, aU of which are regulated by PXR suggesting 
differential gene regulation by the same nuclear receptor is ligand dependent. Expression 
analysis of rat hepatocytes showed that sandwich cultured cells expressed a more ‘liver­
like’ level of drug transporters than those grown in monolayer. Further work showed 
that the Abcc family have similar regulatory pathways involving PXR, while Abcg2 was 
shown to be regulated by PPARa. Finally, an in silico model of
carboxydichlorofluroscein transport through a rat hepatocyte was established.
In conclusion, differential expression of drug transporters in cell lines may affect the 
disposition of drugs, however information regarding expression can be used to make 
informed predictions on the functional effect such transport processes may have. Once 
in the cell, compounds may activate nuclear receptors to increase levels of transporter 
expression suggesting a system of coordinate regulation, as the same nuclear receptors 
are known to regulate the expression of drug metabolising enzymes.
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1 Introduction
1.1 Transport Across Membranes
Membranes act to compartmentalise biological processes and act as selectively permeable 
barriers to both endogenous molecules and xenobiotics, by preventing movement in or 
out of a cell or intracellular compartment unless the molecule can cross the membrane 
(Voet and Voet, 1997). The basic components of biological membranes are lipids, 
amphipathic molecules that form büayers in aqueous solution and therefore the 
physiochemical properties of molecules determine how efficiently they cross a büayers 
membrane, with un-ionised, lipophiUic molecules being able to passively diffuse into or 
out of ceUs (Rang et al., 1999; TimbreU, 2000).
Within lipid bÜayers proteins act to regulate the transfer of more polar, hydrophilic 
molecules from one side of the membrane to the other, as they must be substrates for 
either facilitated diffusion or active transport via a membrane protein. Passive and 
facilitated diffusion require a concentration gradient for the movement of molecules 
while active transport can move molecules against a concentration gradient with the 
hydrolysis of ATP (Figure 1-1) or the co-transport of ions such as Na"*" or down their 
concentration gradients (TimbreU, 2000). Some of these transport proteins also accept 
xenobiotics as substrates, thereby affecting the disposition of drugs.
Alternative ways for molecules to cross plasma membranes include endocytosis where 
molecules attach to specific membrane receptors triggering an area of membrane to be 
internalised thus taking the molecule into the cell. For example, transferrin is a plasma 
protein that binds iron and transports it round the body. It binds to specific receptors 
on the surface of cells, which causes endocytosis of a lipid vesicle containing the 
transferrin receptor with transferrin bound to it. Once in the ceU the vesicle is acidified 
releasing the iron into the cell and the receptor and transferrin are returned to the cell 
surface for further iron uptake (van Renswoude et al., 1982).
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Figure 1-1 Mechanisms of crossing the lipid bilayer of cells or cellular compartments.
Molecules may cross lipid bilayers by passive diffusion, facilitated diffusion or active transport. 
(Plant, 2003). Passive and facilitated diffusion occur along a concentration gradient, while active 
transport derives energy from the hydrolysis o f ATP and can therefore transport molecules 
against a concentration gradient.
1.1.1 Polarised Membranes
The plasma membranes of some cell types, including hepatocytes, kidney epitheha and 
intestinal epithelia are polarised, which means that different parts of the membrane are 
specialised for different functions within the organ. These membranes are generally 
composed of different lipids and proteins to allow them to undertake these roles, and are 
referred to as either apical or basolateral (Alberts, 1994); the apical membrane faces the 
lumen, for example for intestinal epithelial cells this is the intestinal lumen and for 
hepatocytes this is the bile canalicular lumen. The basolateral membrane makes up the 
rest of the cells surface and usually faces extracellular fluid such as blood. In the case of 
hepatocytes, the apical membrane can be called the canalicular membrane and the 
basolateral membrane can be called the sinusoidal membrane as it faces onto the 
sinusoidal blood supply to the liver. Tight junctions prevent the movement of 
membrane proteins from the apical to the basolateral membrane or vice versa, thus 
maintaining this polarity (Alberts, 1994).
1.1.2 Xenobiotic Transport
Xenobiotics such as drugs must cross a number of membranes before they can reach 
their site of action. For example, if a drug is dosed orally it must first cross the apical 
membrane of epithelial cells in the intestine, followed by crossing the basolateral 
membrane to gain access to the systemic blood circulation. Further distribution of a 
compound to tissues around the body will also require it to cross the plasma membranes 
of many different cell types. If a drug is metabolised then both metabolite and 
unmetabolised parent drug will need to be removed from cells and excreted from the 
body. Therefore, the disposition, and ultimately efficacy, of a compound is highly 
dependent on it being able to diffuse across lipid bilayers or on it being a substrate for 
transport proteins (Plant, 2003).
During the initial stages in the development of a new drug, the efficacy and potential 
toxicity of the compound are first assessed in an ADME (absorption, distribution, 
metabolism and excretion) study. ADME is the overall process that the body will have 
on the drug and includes predictions of a drugs absorption into the body, its distribution 
around the body, the metabolism of the compound and how either parent drug or its 
metabolites are excreted from the body (Gibson and Skett, 2001). Each of these stages 
will be considered below, with particular reference to the role that membrane transport 
plays in each stage.
1.1.2.1 Absorption
The body can be exposed to xenobiotics by a number of routes, for example by 
inhalation, through the skin or intravenously by injection; however, oral administration 
of drugs is the most commonly used and convenient method of drug delivery, as it allows 
self-medication by the patient, and has a high rate of patient compliance (Rang et al., 
1999). However orally dosed compounds must be adequately absorbed from the 
gastrointestinal (Gl) tract in order to have high enough bioavailability to be of 
therapeutic use. The main barrier to oral drug absorption is the lipid bilayer of intestinal 
epithelial cells (Plant, 2003).
A few drugs are absorbed from the gut lumen by moving between epithelial cells, known 
as paracellular transport (Rang et al., 1999), but this form of transport is minimal, and 
limited, due to the presence of tight junctions between cells. Therefore most drug 
absorption occurs by the compound passing though cells. Transcellular absorption, from 
the lumen to the blood, requires compounds to cross the apical membrane of the 
enterocytes, be transported across the cytosol and exit the cell into the blood across the 
basolateral membrane (Rang et al., 1999). However drug absorption may be limited if 
the compound is a substrate for an efflux protein in the apical membrane, which 
removes compound from the cells back into the GI tract (Benet et al., 1999).
Optimally drugs are designed to cross the membrane by passive diffusion (Lipinski et al., 
2 0 0 1 ) because using a membrane protein to transport the drug can impact both the 
pharmacokinetic and pharmacodynamic properties of the compound once the transport 
process is saturated (Riviere, 1999). However it can be advantageous to target a drug to a 
specific transporter expressed only in the drug target, for example, pravastatin is a 
compound used in the treatment of hypercholesterolemia and is targeted to the liver, the 
major site of cholesterol synthesis, by being a substrate for a liver-specific uptake 
transporter (Nakai et al., 2001). In addition, it is becoming increasingly clear that a large 
number of compounds are subject to at least some protein-mediated transport across 
membranes, and hence it is important to take this into account when understanding their 
potential disposition within the body.
1.1.2.2 Distribution
Once compounds have been absorbed, they are distributed around the body to the sites 
of their therapeutic action in the blood. As blood flow is not equal throughout all 
tissues, neither is the distribution of drugs. Drugs will be distributed well into highly 
perfused organs such as the heart and Hver and less well into those areas that have low 
perfusion such as ligaments and teeth (Rang et al., 1999). As with the absorption of 
compounds across the gut wall, the majority of compounds are able to passively diffuse 
into cells of these organs, with disposition being largely driven by blood flow to the 
organ. However, as is seen for absorption, transport protein-mediated effects may also 
be important, with expression of specific transporters, both influx and efflux, potentially 
impacting on compound disposition within specific cells (Plant, 2003). Another factor 
that affects distribution of compounds is plasma protein binding; binding of compounds 
to plasma proteins such as albumin wiU limit their distribution, as only free drug is able to 
diffuse or be transported across membranes (Rang et al., 1999).
The blood brain barrier (BBB) is a particular problem for the distribution of drugs in the 
central nervous system (CNS). The barrier consists of a continuous layer of endothelial 
cells joined by tight junctions (Rang et al., 1999), which express very few transport 
proteins. As paracellular and protein mediated transport are limited, lipophilicity is the 
driving factor in compound distribution into the CNS. Therefore permeability across 
the BBB is roughly equal to the octanol-water partition coefficient (Abbott and Romero,
1996), a measurement of the Hpophilicity of compounds (Figure 1-2). Compounds that 
have low BBB permeability but are highly soluble such as vincristine, are substrates for 
efflux transport proteins (Borst et al., 2000), which limit distribution into the BBB 
(Loscher and Potschka, 2005). Some CNS drugs are targeted to specific transporters in 
order for them to reach their site of action, for example levodopa is transported into the 
brain by the facilitative amino acid transporter (LI) (Oldendorf and Szabo, 1976). Once 
in the brain levodopa is converted to dopamine, which relieves the symptoms of 
Parkinsons disease (Neal, 2002).
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Figure 1-2 A correlation of BBB permeability and the lipophilicity of a number of 
compounds.
The permeability o f compounds into the BBB is positively correlated with their octanol/water 
partition coefficient, which is a measure o f lipophilicity. Exceptions include compounds such as 
vincristine and vinblastine, which are substrates o f efflux transport proteins (Figure taken from 
(Abbott and Romero, 1996).
1.1.2.3 Metabolism
Metabolism is the process that converts lipophiUic molecules that were ideal for 
absorption across membranes into hydrophiUc molecules that can be excreted from the 
body in the urine or faeces. Orally administered drugs, such as felodipine (Regardh et al.,
1989) and midazolam (Paine et al., 1996), can be metaboUsed in intestinal enterocytes, 
which can Umit the bioavaUabiUty of these drugs. Once in the systemic circulation 
compounds pass through the Uver, the major site of drug metaboUsm in the body. 
Active drug that is removed during its initial transport from the GI tract to the post- 
hepatic systemic circulation is said to undergo first pass metaboUsm (Rang et al., 1999).
Drug molecules enter hepatocytes either through diffusion or via uptake transporters and 
can then be metaboUsed by enzymes present in the ceU. Drug metaboUsm reactions can 
be spUt into two groups consisting of phase I and phase II reactions. Phase I reactions 
involve the oxidation, reduction or hydrolysis of the drug to unmask or introduce a 
functional group such as a hydroxyl group, therefore phase I reactions are sometimes 
referred to as functionaUsation reactions (Gibson and Skett, 2001).
Cytochrome P450 (GYP) enzymes are the major phase I metaboUsing enzymes and 
convert parent drugs into oxidised metaboUtes. CYPs are found in high concentrations 
in the endoplasmic recticulum of hepatocytes as weU as gut and kidney epitheUal ceUs 
(Nelson et al., 1996). In humans the most abundant GYP subfamUies are GYP2G and 
GYP3A, which together metaboUse up to 80 % of drugs that are subject to oxidation. 
GYP3A4 is the major member of the GYP3A family and metaboUses approximately 50 % 
of drugs (Gholerton et al., 1992) and makes up 30% of the total GYP content in Uver 
(Watkins, 1992; Shimada et al., 1994). In the GYP2G family, GYP2G9, 2G8 and 2G19 are 
the major members and together make up 20 % of the total GYP content (Shimada et al., 
1994), while GYT2B6 and GYP2D6 make up only a smaU proportion of the total GYP 
content (0.5 —5 % and 1 . 5 - 4  % respectively) but metaboUse up to 25 % and 30 % of 
drugs respectively (Shimada et al., 1994; Zuber et al., 2002; Wang et al., 2003).
Genetic polymorphisms in GYP genes can result in inactive enzymes or enzymes with 
reduced or increased function. This is a particular problem with GYP2D6 as its major 
variant, GYP2D6*4, is expressed in up to a fifth of the Caucasian population and results 
in an inactive enzyme (Ingelman-Sundberg, 2005), while GYP2D6*1 results in a
‘ultrarapid metaboliser’ phenotype that may contribute to toxicity from the recreational 
drug, ecstasy (3,4-Methylenedioxymethamphetamine, MDMA) as toxic metabolites are 
produced more quickly in this group (Carmo et al., 2005). However genetic 
polymorphisms account for only a small amount of the difference in GYP variability 
between people, as non-genetic factors such as age and diet can play a role. For example, 
the major cause of GYT3A4 variability is the activation of gene transcription by drugs; it 
is a well conserved gene and only a few polymorphisms have been identified to result in 
altered enzyme activity, with these alterations resulting in no known clinically significant 
change to drug pharmacokinetics (Wandel et al., 2000; Spurdle et al., 2002). Activation 
of gene transcription will be discussed further in section 1.1.4.
The products of phase I reactions become substrates for phase II enzymes, which 
modify the newly introduced functional group by conjugating it to another molecule to 
increase the water solubility of the compound, which can then be excreted into the bile 
or urine (Gibson and Skett, 2001). Alternatively, if the parent drug contains a suitable 
functional group it may be direcdy modified by phase II reactions without first being 
metabolised by phase I enzymes. The major phase II reactions are conjugations to 
glucuronide, sulphate or glutathione moieties and are carried out by UDP- 
glucuronosyltransferases (UGTs), sulphotransferases (SULTs) and glutathione S- 
transferases (GSTs), respectively (Plant, 2003). Glucuronidation and sulphation reactions 
are referred to as type I or ‘high energy’ reactions as the conjugated molecule contains 
the reactive energy and will react with relatively unreactive groups such as the hydroxyl 
groups introduced by phase I reactions. Glutathione tends to be conjugated to 
molecules with high chemical reactivity, as it is relatively unreactive itself. Glutathione 
conjugation is therefore known as a type II or ‘low energy’ phase II reaction and is 
usually used to detoxify highly reactive chemical species that could, for example, easily 
damage cells by reacting with DNA (Gibson and Skett, 2001).
1.1.2.4 Excretion
The major routes of excretion of compounds from the body are urinary and biliary 
excretion (Rang et al., 1999), which require water-soluble compounds, hence why 
metabolism of drug molecules produces metabolites with a higher hydrophilicity. 
However such hydrophilic molecules cannot passively diffuse across lipid büayers and 
therefore transport proteins play a vital role in excretion, being required in the canalicular 
membrane of hepatocytes and the renal tubular membrane in the kidney in order for 
drugs to be excreted in the büe or urine (Plant, 2003). The transport proteins in these 
membranes are relatively unselective and wiU ‘pump out’ a wide range of chemicals.
1.1.2.4.1 Urinary Excretion
SmaU, water soluble drugs can be removed from the blood as it passes through the 
kidneys; blood first passes through the glomerulus, which fUters molecules of molecular 
weight of less than 20 kDa to pass through pores in the membrane (Rang et al., 1999). 
Therefore only free, unbound drug can be excreted in this way, as albumin, the major 
plasma binding protein, has a molecular weight of approximately 6 8  kDa (Rang et al., 
1999). Compounds can also diffuse or be transported across the basolateral membrane 
of epitheUal ceUs in the proximal and distal tubules. Molecules are then actively effluxed 
across the apical epitheUal membrane into the tubule lumen for excretion in the urine. 
Lipid soluble molecules can be passively reabsorbed into the blood across the tubule and 
so are not efficiently excreted in the urine.
1.1.2.4.2 Biliary Excretion
Excretion of drugs into the büe is the predominant route of excretion for larger, polar 
molecules although smaü water-soluble molecules are also excreted via this route. Büe 
acids are produced by the Uver as by products in the cataboUsm of cholesterol, and are 
actively effluxed out of hepatocytes into the büe canaUcuU, which flow into the bÜe 
ducts. Büe is stored in the gaU bladder before excretion into the intestine; therefore 
compounds excreted into the büe are eUminated from the body in the faeces (Rang et al.,
1999).
Once in the intestine büe acids can be reabsorbed, a process that is essential for the 
absorption of dietary cholesterol and vitamins. Drugs also come into contact with the
gut microflora in the intestine, which may metabolise conjugated drugs back into 
lipophilic molecules or substrates for transporter proteins. Compounds can then be 
reabsorbed across the intestinal epithelial cells into the systemic blood supply. This 
process is known as enterohepatic recirculation (Figure 1-3) and increases the time a drug 
remains in the body, which can be important in prolonging drug action, for example with 
morphine, which undergoes a high rate of first-pass metabolism and would otherwise be 
cleared very quickly from the body (Rang et al., 1999).
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Figure 1-3 Enterohepatoc recirculation of compounds.
Orally administered drugs are absorbed from the duodenum into the portal blood supply, which 
passes through the Uver. Compounds that are distributed into hepatocytes may be metabolised 
and/or effluxed into the bile canalicular network along with bile acids. The büe cananliculi drain 
into the büe duct, which excretes bile acids and drugs back into the intestine from where they can 
be reabsorbed into the blood supply. Figure taken from (Chan et al., 2004).
10
1.1.3 Drug Transport and Toxicity
Whereas as transport across membranes by passive diffusion should not be limited and 
therefore displays first order kinetics, any protein-mediated system can be subject to 
saturation, hence displaying zero order kinetics. Drugs can compete for transport by 
active or facilitated transport systems with co-administered compounds or endogenous 
molecules. Such competition can result in a lower rate of transport into or out of cells 
leading to either increased levels of the drug in the blood or within cells. Increased 
accumulation of compound within the body can cause toxicity, for example before its 
withdrawal from market the HMG CoA reductase inhibitor cerivastatin was often 
prescribed with gemfibrozil both of which are used in the prevention and treatment of 
heart disease. Both are transported into hepatocytes by the same active uptake 
mechanism and they are both metabolised by the same CYP enzyme, therefore 
competition for both processes results in higher concentrations of the drugs in plasma 
(Shitara et al., 2004). Coadministration of cerivastatin and gemfibrozil results in a higher 
incidence of skeletal muscle toxicity, known as rhabdomyolysis, than when each drug is 
administered alone (Graham et al., 2004) and this led to cerivastatin being removed from 
the market.
Digoxin, a cardiac glycoside used to treat cardiac failure, has a very narrow therapeutic 
window so a small increase or decrease in its concentration due to a drug interaction can 
lead to either toxicity or loss of efficacy, respectively (Verstuyft et al., 2003). Digoxin and 
simvastatin, another HMG CoA reductase inhibitor, are both substrates for the same 
efflux transporter (Wang et al., 2001) and when the two are dosed together a dmg-drug 
interaction has been known to occur (Williams and Feely, 2002), due to reduced 
clearance of digoxin resulting from competition for the transporter (Sakaeda et al., 2006).
An example of drugs competing with endogenous molecules occurs in the case of bile 
acid transport, as many of the proteins that can actively transport drugs evolved as part 
of the bile acid recirculation process. Büe acids are unable to passively diffuse across 
membranes, therefore competition for transporters between drugs and/or endogenous 
molecules like büe acids can occasionaUy lead to choleostatic symptoms, due to an 
accumulation of büe acids in hepatocytes. Troglitazone, a compound used in the 
treatment of type II diabetes, was withdrawn from market after it caused fatal cases of 
hepatitis. The toxicity is thought, at least in part, to be due to the fact that troglitazone
11
inhibited bile efflux across the canalicular membrane of hepatocytes resulting in hepatic 
failure (Funk et al., 2001).
It can therefore be seen that drug-transporter interactions can play an important role in 
determining the clinical efficacy and safety of therapeutic agents and their impact on 
endogenous systems. It is thus important to gain a full understanding of how all the 
systems of ADME co-ordinate together in order to better predict the result of any 
competition for components of the system.
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1.1.4 The Coordinate Regulation of ADME Genes
In order to maintain cellular compartmentalisation of biochemical functions, the 
expression of transporters must be under tight control. The regulation of basal 
expression occurs by several mechanisms; first, transcription can be induced or 
suppressed via transcription factors; second, post-translational modifications can be 
made to proteins, regulating the activity level of the translated protein; and finally in the 
case of transporters, protein at the membrane is tightly controlled by endocytic retrieval 
(Gerk and Vore, 2002).
The expression of transporters can also be induced by the presence of their substrates, 
including drugs, as they can act as ligands for members of the nuclear receptor super- 
family of ligand activated transcription factors. These same transcription factors are also 
involved in the regulation of genes involved in drug metabolism, allowing a coordinate 
response to xenobiotics at a transcriptional level, ensuring drugs are cleared from cells 
effectively, which nainirnises the risk of toxicity (Gibson and Skett, 2001). Occasionally 
nuclear receptors are activated by compounds resulting in the increased transcription of a 
gene that has no effect on the compound itself; an example of this is omeprazole, which 
is metabolised by CYP2C19 (Andersson, 1996) but results in the induction of CYP1A2 
(Curi-Pedrosa et al., 1994). It is possible this also occurs with the transcriptional 
regulation of drug transporters although no case has so far been identified. Induction of 
ADME genes, whether it be autoinduction or by a co-adrnirdstered compound, may 
result in a drug being cleared too quickly from the body causing reduced efficacy; 
alternatively toxicity of the compound (or co-administered compound) may be increased 
due to the more rapid production of toxic metabolites.
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1.1.4.1 Nuclear Receptors
When cells respond to extracellular signals with increased transcription of genes, they do 
so by one of two general pathways normally depending on the properties of the ligand. 
Hydrophilic ligands tend to bind to receptors on the cell surface, which triggers a cascade 
of secondary messengers within the cell resulting in the activation of transcription factors 
(Alberts, 1994). Alternatively, ligands for intracellular receptors, commonly called 
nuclear receptors, can either be transported into cells via transport proteins or diffuse 
across the plasma membrane where they activate nuclear receptors directly, which then 
act as transcription factors (Evans, 1988; Schoonjans et al., 1996; Parks et al., 1999).
There are 48 members of the nuclear receptor superfamily expressed in humans (Zhang 
et al., 2004), which have been historically divided into two groups depending on where 
they were localised in the cell when not bound to ligand, however more recent studies 
have shown that nuclear receptor localisation is more complex than initial studies 
suggested (Squires et al., 2004; Saradhi et al., 2005). Type I nuclear receptors are 
generally localised in the cytoplasm and translocate into the nucleus upon binding their 
ligand and include the gluticorticoid (GR), progesterone (PR) and estrogen (ER) 
receptors (Welshons et al., 1984; Tyagi, 2003), as well as the aryl hydrocarbon receptor 
(AhR) (Ramadoss et al., 2005). Type II nuclear receptors are not dependent on ligand 
binding for their subceUular localisation; ligand binding causes a conformational change 
in the receptor allowing co-activators to bind and activate target gene expression (Onate 
et al., 1995; Glass et al., 1997). Nuclear receptors in this group include the 9-cis retinoic 
acid receptor (RXR) and the vitamin D receptor (VDR) (Schoonjans et al., 1996). Many 
members of the nuclear receptor superfantily have known endogenous ligands, however 
a sub-group called orphan nuclear receptors exist for whom endogenous ligands are, or 
were, unknown: this group includes factors such as the peroxisome proliferator-activated 
receptor (PPAR), the pregnane-X receptor (PXR), the constitutive androsterone receptor 
(CAR) and the farsenoid-X receptor (PXR) (Schoonjans et al., 1996).
Members of the nuclear receptor family of transcription factors share structural features 
(Bain et al., 2007) (Figure 1-4); each has a ligand-binding domain (LBD), which is 
responsible for interactions with the ligand. The LBD also contains the region that 
interacts with coactivator and cosuppressor proteins to initiate transcription (Glass et al.,
1997).
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Figure 1-4 Structural domains o f the nuclear receptor superfamily.
A. Nuclear receptors are made up o f five domains consisting of a DNA binding domain (DBD) 
(C) and a ligand-binding domain (LBD) (E), which are separated by a flexible hinge region (D), 
as well as an N- terminal (A/B), and C- terminal ( ) domain.
B. A representation of the crystal structure of the DBD and LBD of the nuclear receptor 
superfamily showing the interaction o f the DBD with DNA and the LBD bound to a ligand. 
The crystal structures of the other regions haven’t been determined and are shown as dashed 
lines (figure taken from Wikipedia: Nuclear Receptors).
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The DNA binding domain (DBD) targets the receptor to specific sequences of DNA 
called response elements (RE), which consist of hexameric repeats of the sequence 
AG(G/T)TCA separated by 1 — 8  nucleotides (Figure 1-5). The repeat can be arranged 
as a direct repeat (DR), an everted repeat (ER) or an inverted repeat (IR).
AG(G/T)TCA n, AG(G/T)TCA Direct Repeat (DR)
ACT(T/G)GA n, AG(G/T)TCA Everted Repeat (ER)
<   ►
AG(G/T)TCA n, ACT(T/G)GA Inverted Repeat (IR)
----------- ► M--------------
Figure 1-5 The response element of nuclear receptors.
The nuclear receptor binding sequence o f AG(G/T)TCA is spaced by x nucleotides (n). The 
repeat can be arranged as a direct repeat (DR), an everted repeat (ER) or an inverted repeat (IR).
Nuclear receptors form homo- or heterodimers in order to bind to DNA and increase 
transcription of their target genes. The most common binding parmer is RXRa 
(Mangelsdorf and Evans, 1995), which acts as a binding partner to nuclear receptors 
involved in several pathways such as fatty acid metabolism by binding with PPAR and 
büe acid homeostasis by dimerising with PXR (Parks et al., 1999), as weU as the 
detoxification of xenobiotics by forming heterodimers with PXR and CAR. The AhR 
forms a heterodimer with the AhR nuclear translocator (ARNT) (Reyes et al., 1992), 
whüe the GR acts as a monomer (Freedman, 1992).
A number of nuclear receptors are involved in transcriptional regulation of ADME genes 
in response to xenobiotics. They include PXR, CAR, PPAR and GR, which wül be 
discussed in more detaü below.
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1.1.4.2 The Pregnane X Receptor
The pregnane-X receptor (PXR; NR1I2) is a nuclear receptor involved in the response of 
cells to xenobiotics (Blumberg et al., 1998; Lehmann et al., 1998). It is also capable of 
binding endogenous substances, for example pregnanes and progesterone (Bertilsson et 
al., 1998; Kliewer et al., 1998), although these are at relatively low (pM) affinities; efforts 
are stiU being carried out to determine if PXR has a single, high affinity endogenous 
ligand and hence, at present, PXR is still termed as an ‘orphan’ nuclear receptor.
PXR was discovered as the central transcriptional regulator of the drug metabolising 
enzyme (DME), CYP3A4; the same compounds that induce expression of CYP3A4 were 
shown to activate PXR (Blumberg et al., 1998; Kliewer et al., 1998) and Cyp3a is not 
induced in PXR knockout mice (Xie et al., 2000a). Other phase I and phase II enzymes 
have also been shown to be regulated by PXR including CYP2C9 (Chen et al., 2004), 
CYP2B6 (Goodwin et al., 2001) and UGTlAl (Sugatani et al., 2005), plus a number of 
transporters capable of drug transport into or out of cells, which will be discussed in 
section 1.2. PXR is expressed in the liver and intestine, thereby mirroring the expression 
of its target genes such as CYP3A4, which is also expressed highly in these tissues 
(Blumberg et al., 1998; Maglich et al., 2002; Bookout et al., 2006). PXR is also expressed 
in the brain where it acts to prevent accumulation of xenobiotics in the CNS by 
increasing metabolism and/or efflux of compounds across the BBB (Lamba et al., 2004).
In order to activate transcription, PXR forms a heterodimer with RXRa and binds to a 
number of different arrangements of the consensus sequence AG(G/T)TCA (Gibson 
and Skett, 2001). For example the PXR:RXRa heterodimer has been shown to bind to 
an ER 6  in the CYP3A4 proximal promoter (Kliewer et al., 1998; Lehmann et al., 1998) 
and to a DR3 in the CYP3A4 enhancer, known as the xenobiotic responsive enhancer 
module (XREM) located approximately 8  kbp upstream of the transcription start site of 
CYP3A4 (Goodwin et al., 1999). In addition, binding of PXR:RXRa heterodimers to a 
DR4 element in the CYP2B6 promoter has also been demonstrated (Goodwin et al., 
2001). A recent study has found that PXR can form a homodimer (Noble et al., 2006) 
but the physiological relevance of this is as yet unclear.
Compounds that have been found to activate PXR mediated transcription consist of a 
wide range of chemically diverse molecules including the antibiotic rifampicin (Bertilsson
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et al., 1998), the synthetic steroid dexamethasone (Pascussi et al., 2000a), the active 
component of St John’s Wort, hyperforin (Moore et al., 2000), and cyproterone acetate 
(CPA) (Lehmann et al., 1998). However, whereas the DNA binding domain of PXR is 
highly conserved between humans and rabbits (94 %), rats (95.5 %) and mice (95.5 %), 
which span over 40 million years of evolutionary divergence, there is considerable 
divergence between the ligand binding domains with only a 75.9 % conserved identity 
between humans and rats (Jones et al., 2000). This lack of similarity contributes to 
species differences in the ligands that wiU activate PXR, for example rifampicin is a 
potent activator of human PXR but has no effect in rodents (Lehmann et al., 1998), 
whüe pregnenolone-16 a-carbonitrüe (PCN) and cypterone acetate (CPA) activate rodent 
PXR but have minimal effect in man (Blumberg et al., 1998; Jones et al., 2000).
1.1.4.3 The Constitutive Androstane Receptor
Like PXR, the constitutive androstane receptor (CAR; NR1I3) is an orphan nuclear 
receptor, for which no endogenous ligand has been found to date. CAR also forms a 
heterodimer with RXRa but unlike PXR, CAR can activate its target genes in the absence 
of ligand. It is kept inactive by binding to androstane in the cytosol, which is displaced 
by activating ligands (Baes et al., 1994).
CAR is activated by an overlapping but distinct group of xenobiotics to PXR (Maglich et 
al., 2002); for example it is activated by the PXR ligands phénobarbital and bilirubin 
(Saini et al., 2005) but also has specific substrates such as l,4-bis(2-(3,5- 
dichloropyridoxyloxy)) benzene (TCPOBOP) (Tzameli et al., 2000), identified as such 
because TCPOBOP has no effect in CAR knockout mice (Wei et al., 2000).
The DBD of CAR has 6 6  % identity with the PXR DBD in humans (Blumberg et al.,
1998) aUowing it to bind to simüar response elements as PXR including the DR4 element 
in CYP2B6 (Goodwin et al., 2001; Chang et al., 2003) and the ER 6  in CYP3A4 (Xie et 
al., 2000b). CAR has also been implicated in the transcriptional regulation of some drug 
transporters, which wül be discussed in section 1 .2 .
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1.1.4.4 The Peroxisome Proliferator Activated Receptor
Three isoforms of the peroxisome proliferator activated receptor (PPAR; N R IC I), 
PPARa, PPARÔ and PPARy, have been identified to date and are involved in the 
regulation of genes involved in lipid and glucose homeostasis (Francis et al., 2003). Fatty 
acids appear to be the most likely endogenous ligands of PPAR (Nolte et al., 1998; Xu et 
al., 1999) but leukotriene is also an agonist of PPARa (Devchand et al., 1996) so debate 
continues as to whether there may also be a single, high affinity and as yet unknown 
ligand. Xenobiotics have been shown to be ligands both for PPARa and PPARy; for 
example the lipid-lowering drugs of the fibrate class (e.g. gemfibrozil) are specific ligands 
for PPARa (Ibabe et al., 2005), whereas the thiazolidinedione class of antidiabetic drugs 
(e.g. troglitazone) are specific agonists of PPARy (Lehmann et al., 1995).
PPARa is highly expressed in the liver, kidney and intestine where it is involved in fatty 
acid metabolism (Corton et al., 2000). PPARy is thought to regulate adipocyte 
differentiation (Corton et al., 2000) and has a more restricted expression profile, being 
found mainly in the adipose tissue. Less is known about PPARÔ but it is expressed 
ubiquitously (Kliewer et al., 1994), which led to a suggestion it was a ‘housekeeping’ gene, 
however PPARô knockout mice rarely survive implying that PPARÔ may have a role in 
embryonic development (Barak et al., 2002).
Like other orphan nuclear receptors PPARs dimerise with RXRa (Kliewer et al., 1992) 
and bind to response elements consisting of a direct repeat of AGGTCA spaced by one 
intervening nucleotide (DRl) (Johnson et al., 2002). DRl motifs are found in the 
regulatory regions of a number of genes, especially those involved in lipid metabolism 
e.g. Acyl CoA synthase responsible for the first step of fatty acid P-oxidation and 
lipoprotein lipase, responsible for the metabolism of triglycerides (Schoonjans et al., 
1996). In addition, members of the CYP4A family are also targets for PPARs, and again 
these are known to be involved in the metabolism of fatty acids (Johnson et al., 2002). 
Other PPAR target genes are involved with drug metabolism include SULT2A1 (Fang et 
al., 2005), and UGT1A9 (Barbier et al., 2003). PPARs may also be involved in the 
regulation of drug transport, which will be discussed in section 1 .2 .
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1.1.4.5 The Glucocorticoid Receptor
The glucocorticoid receptor (GR; NR3C1) is a classical type I nuclear receptor that is 
sequestered in the cytosol by binding to heat shock protein 90 (hsp90) in the absence of 
ligand (Leo and Chen, 2000). Upon ligand binding hsp90 dissociates and the GR 
translocates to the nucleus where it acts as a monomer (Freedman, 1992) to increase the 
expression of target genes, such as CYP2C9 (Gerbal-Chaloin et al., 2002). The GR is 
pardcuarly important in ADME gene regulation as it is a good example of cross-talk 
between nuclear receptors (Pascussi et al., 2003); at low concentrations of 
glutocordcoids, such as dexamethasone and hydrocortisol, the GR is activated (Ohno et 
al., 2000; Falkner et al., 2001) to increase expression of genes such PXR, RXRa and CAR 
(Pascussi et al., 2000a; Pascussi et al., 2000b) thereby indirectly increasing levels of 
PXR/CAR target genes such as CYP3A4 and drug transporters once these nuclear 
receptors are themselves activated by xenobiotics. However at high concentrations, 
glutocorticoids bind directly to PXR resulting in increased CYP3A4 expression (Falkner 
et al., 2001; Pascussi et al., 2003). After intoxication, hydrocortisone is released in 
response to the cellular stress at levels capable of directly activating PXR thereby 
ensuring an upregulation of genes involved in the detoxification and elimination of 
toxicants (Hewitt et al., 2007).
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1.1.5 Summary
Each stage of a compounds passage through the body requires it to cross lipid büayer 
membranes; therefore transport processes are vital in the absorption of drugs and their 
distribution to sites of efficacy. Saturation of drug transporters or lack of a specific 
transporter may limit compound access to hepatocytes, where most drug metabolism 
occurs. Phase I and II DME’s increase the hydrophilicity of compounds making them 
substrates for efflux proteins resulting in biliary or urinary excretion of the compound 
from the body. Therefore drug metabolism and transport combine to affect drug 
clearance, as well as the efficacy and toxicity of the drug; for example toxicity may result 
when the transport of drugs or their metabolites are inhibited, therby causing an 
accumulation of compound within cells. Many of the genes involved in ADME 
processes are regulated at a transcriptional level by ligand activated nuclear receptors, 
which act to co-ordinately regulate the expression of DME’s and transporters to ensure 
xenobiotics are cleared from the cell to reduce the risk of cellular toxicity.
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1.2 Drug Transporters
The plasma membrane transport proteins that are capable of drug transport may be 
subdivided into two major classes; the first group consists of efflux transporters of the 
ATP binding cassette (ABC) superfamily and the second consists of influx transporters 
of the solute carrier (SLC) superfamily. Both superfamilies are made up of families 
(designated by a letter in the case of ABC member or a number in the case of the SLCs) 
and sub-families (SLCs only, designated by a letter) while each family or sub family is 
made up of many members (designated by numbers). The names used in this work are 
those most recently attributed as the correct gene and/or protein name, although each 
transporter is known by many aliases, a list of which can be found in Table 1-1. A brief 
overview of the transporter families follows with further discussion on the specific 
transporters studied in this work. These were chosen based on a report from the FDA 
detailing its guidance to industry regarding the design of drug interaction studies (2006) 
and on the expression or functional role of the transporter in liver with regards to drug 
metabolism.
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Official Gene Symbol Official Protein Symbol 
(where different to gene)
Other Aliases
ABCBl P-glycoprotein (P-gp); MDRl
ABCB4 MDR2; MDR3
ABCBl 1 BSEP; SPGP
ABCCl MRPl
ABCC2 MRP2
ABCC3 MRP3
ABCC4 MRP4
ABCG2 BCRP
SLCOIBI OATPIBI cMGAT; LST-1; GATP2; GATP-C; 
SLC21A6
SLC01B3 OATP1B3 LST-3; GATP8; SLC21A8
SLC02B1 OATP2B1 GATP-B; SLC21A9
SLClOAl NTCP
SLC10A2 ABST IBST
SLC22A1-3 OCTl-3
SLC22A6-9 OATl-3
Slcolal Oatplal Gatpl; Slc21al; Slc21a3
Slcolb2 Gatpla4 Gatp2; Slc21a5
Slcolb2 Gatplb2 Gatp4; Slc21al0; rlst-l
Table 1-1 The official names and aliases of the transporter genes/proteins regularly 
referred to in this work (Dean et al., 2001; Hagenbuch and Dawson, 2004; Hagenbuch 
and Meier, 2004; Koepsell and Endou, 2004). Transporters shown in lower case are rodent 
specific genes/proteins.
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1.2.1 The ABC Superfamily
The ABC superfamily is made up of seven families, designated ABGA to ABCG, 
involved in the ATP-dependent export of a wide range of substances from cells ranging 
from endogenous molecules such as cholesterol, bile acids, nucleosides and sterols to 
xenobiotics, including many drugs. ABC transporters are also found on intracellular 
membranes such as the ER and mitochondrial membranes where they are essential in the 
movement of metabolites around the cell.
Most ABC transporters have two membrane spanning domains consisting of six 
transmembrane (TM) helices in each (Hyde et al., 1990). All ABC transporters have two 
nucleotide binding domains (NBD’s) containing Walker A and B motifs, essential for 
ATP binding and hydrolysis (Walker et al., 1982); this hydrolysis drives the transport of 
substrates across membranes even against an unfavourable concentration gradient. ABC 
genes can be organised as either fuU transporters, with two TM domains and two NBD’s, 
or as half transporters, with one of each domain. Half transporters assemble as either 
hetero- or homo dimers to form a functional transporter protein (Hyde et al., 1990).
1.2.1.1 The ABCB Family
The ABCB family is the only family in the ABC superfantily to contain both fuU and half 
transporters. For example ABCB2 and 3 are half transporters that form a heterodimer in 
the ER membrane and transport peptide fragments from the cytosol into the ER for 
loading onto MHC molecules for presentation to cytotoxic T-cells (Momburg et al., 
1994). In contrast, other transporters in the family are involved in iron transport across 
the mitochondrial membrane (ABCB6 ) (Hamza, 2006) and büe acid efflux from the cell 
(ABCB 11) (Stieger et al., 2007), and are expressed as full transporters. For the purposes 
of xenobiotic efflux, ABCBl and 4 are of greatest relevance, and they will be considered 
below.
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1.2.1.1.1 ABCBl
ABCBl (P-glycoprotein, MDRl) is expressed in a wide range of tissues including kidney, 
liver, lung (Fojo et al., 1987b), intestinal enterocytes (Ambudkar et al., 1999) and the 
epithelia of blood brain barrier (BBB) (Cordon-Cardo et al., 1989). ABCBl is also 
expressed at high level in tumours of epithelial origin such as colon (Cordon-Cardo et al.,
1990), kidney (Fojo et al., 1987a) and breast (Merkel et al., 1989) as would be expected 
for a transporter known for causing drug resistance during cancer chemotherapy. 
ABCBl is also thought to contribute to drug resistance during the treatment of other 
conditions such as epilepsy (van Vliet et al., 2007) and HIV (Jones et al., 2001). Rodents 
express two isoforms of Abcbl, Abcbla and Abcblb, whereas humans express only one 
(Liang et al., 2006). Abcbla the predominant isoform expressed in the rodent blood- 
brain barrier (Regina et al., 1998), while Abcblb is more widely expressed.
In polarised cells ABCBl is localised to the apical membrane (Kipp and Arias, 2000) 
where it is involved in the efflux of a vast range of structurally diverse compounds 
including anti cancer drugs such as vincristine, doxorubicin (Karmer et al., 1983), 
paclitaxel, etoposide (Makhey et al., 1998), methotrexate (de Graaf et al., 1996); the 
cardiac glycoside, digoxin (Tanigawara et al., 1992); protease inhibitors such as ritonavir 
and saquinavir (Jones et al., 2001); antibiotics such as erythromycin (Takano et al., 1998); 
and the immunosupressent, cyclosporin A (Saeki et al., 1993).
In the intestine ABCBl can play a role in limiting the bioavailability of oral compounds 
by effluxing compounds such as digoxin out of enterocytes and into the intestinal lumen 
(Greiner et al., 1999). In addition, ABCBl limits distribution to the brain of its 
substrates by effluxing them back across the BBB (Tatsuta et al., 1992); Abcbla/b 
knockout mice were 16 times more sensitive to paclitaxel compared to control animals 
(Allen et al., 2000). In the kidney and liver ABCBl plays a role in the excretion of 
compounds from the body in the urine or faeces, respectively (Schinkel, 1997).
Regulation of ABCBl expression in response to xenobiotics is mediated via the nuclear 
receptor PXR (Geick et al., 2001; Synold et al., 2001; Dussault and Forman, 2002). 
Dexamethasone, a rodent PXR ligand, has been shown to induce Abcbl expression in 
rodents (Demeule et al., 1999), while rifampicin and hyperforin, two human PXR ligands, 
have been shown to induce ABCBl expression in humans (Synold et al., 2001). Recently
25
CAR has also been implicated in ABCBl regulation (Burk et al., 2005). The combined 
effect of PXR activation on ABCBl and CYP3A4 levels can sometimes lead to drugs 
being cleared too quickly from the body, for example in the case of cyclosporine A, 
where levels of the immunosuppressent feU below the efficacious level resulting in organ 
rejection after transplant (Hebert, 1997).
1.2.1.1.2 ABCB4
ABCB4 (human MDR2, rat Mdr3) is a lipid translocase expressed in the liver where it is 
responsible for the efflux of phophatidylcholine (PC) across the apical membrane of 
hepatocytes into the büe canaliculi (Smith et al., 1994; van Helvoort et al., 1996). Once 
ABCB4 has translocated PC from one side of the canalicular membrane to the other, it is 
taken up into the canaliculi where it reduces the detergent activity of büe salts, preventing 
solubilisation of the membrane and ceU death (Gude Elferink and Paulusma, 2007). 
Mutations in ABCB4 lead to an absence of the protein, which results in progressive 
familial intrahepatic choleostasis type 3 (PFIC3) (de Vree et al., 1998).
As weU as lipid translocation, ABCB4 transports a number of drugs, albeit with a more 
restricted substrate specificity than ABCBl. Vinblastine, paclitaxel and digoxin are aU 
substrates for ABCB4 mediated transport (Smith et al., 2000), however a role for ABCB4 
in drug resistance is yet to be established. ABCB4 contains a PPRE (Chawla et al., 2001) 
and levels of ABCB4 have been shown to increase in response to PPARa activation 
(Chawla et al., 2001).
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1.2.1.2 The ABCC Family
Although the ABCC subfamily was discovered due to their sequence similarity with 
ABCBl and their ability, like ABCBl, to confer drug resistance on tumour cells, they 
differ from ABCBl in the type of substrates they will accept. Conjugated anions are not 
substrates for ABCBl but members of the ABCC subfamily, especially ABCC 1-4, accept 
substrates with glutathione, sulphate or glucuronide conjugates (jedlitschky et al., 1994; 
Hirohashi et al., 1999; Gotoh et al., 2000; Zelcer et al., 2003). Defects in ABCC proteins 
result in a number of disorders including hyperbilurinemia (Mor-Cohen et al., 2001) and 
cystic fibrosis (Greger et al., 2001), indicating the essential nature of ABCC mediated 
transport.
The ABCC (MRP) transporters are aU full transporters and have a core structure of two 
transmembrane (TM) domains containing 6  TM helices in each, but ABCCl, 2, 3, 6  and 
7 have an extra N-terminal domain (TMDq) (Figure 1-6) (Borst et al., 2000). In ABCC2 
the N-terminal domain is essential for targeting of the protein to the apical membrane of 
polarised cells (Fernandez et al., 2002) but the reason for a TMDq in the other ABCC’s is 
less clear given their basolateral localisation, possibly it contains redundant signalling 
motifs (Westlake et al., 2005).
CHO CHO
oui
MRP1
CORE (Pgp-like)L
CHO
NHg
COOH
MRP5
NBD1 NBD2
Figure 1-6 Membrane topology models for ABCCl and ABCC5 (Borst et al., 2000).
ABCCl (MRPl) and ABCC2, 3, 6 and 7 contain an extra N-terminal domain (TMDo), which is 
absent in ABCC5 (MRP5) and ABCC4, 8 and 9. NBD = nucleotide binding domain, Lo = linker 
domain. The core of two transmembrane domains resembles the structure of ABCBl (Pgp).
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This work will concentrate on the first four members of the family, which are involved in 
the majority of drug transport undertaken by the ABCC family and are the best 
characterised transporters of this group: these will be discussed in further detail below. 
Beyond the ABCCl-4 family members, the majority of transporters in the ABCC family 
are ATP-dependent transporters, but the family also contains an ATP-gated channel, 
ABCC7 (CFTR), mutations in which are responsible for causing cystic fibrosis (Greger et 
al., 2001), and two ATP-dependent potassium channel regulators ABCC8  and 9 (Bryan et 
al., 2007). ABCC5 transports cyclic nucleotides, nucleotide/nucleoside analogues and 
glutathione conjugates (Jedlitschky et al., 2000), while ABCC6  transports glutathione 
conjugates and some drugs such as cisplatin (Belinsky et al., 2002). Mutations in ABCC6  
cause the rare connective tissue disorder pseudoxanthoma elasticum (PXE) but the 
reason for this is unclear (Bergen et al., 2000).
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1.2.1.2.1 ABCCl
ABCCl (MRPl) was discovered due to its over-expression in H69AR, a drug resistant 
lung cancer cell line (Cole et al., 1992) but has since been found in a range of tissues 
including lung, kidney, skeletal and cardiac muscle (Flens et al., 1996), although 
expression in liver is comparitavely low (Roelofsen et al., 1997). In most polarised ceUs 
such as kidney epithelia and hepatocytes it is localised on the basolateral membrane 
(Brechot et al., 1998; Wright et al., 1998) but in some cell types, such as placental 
syncydotrophoblasts, ABCCl is localised to the apical membrane (St-Pierre et al., 2000).
Conjugated leukotriene C4 (LTC4) and its metabolites, LTD4 and LTE4, are the 
endogenous substrates o f ABCCl and are transported with a Kj  ^ of around 0.1 pM 
(Leier et al., 1994). Transport via ABCCl is inhibited by the LTD4 analogue MK571, 
which was developed as an antagonist of the LTD4 receptor (Jedlitschky et al., 1994; 
Leier et al., 1994). ABCCl can transport a wide range o f conjugated endogenous 
molecules and xenobiotics including glutathione, sulphate and glucuronide conjugates 
(Jedlitschky et al., 1996), as well as bilirubin and its conjugates (Jedlitschky et al., 1997). 
The anticancer dmg methotrexate is transported by ABCCl (Hooijberg et al., 1999) as 
are vincristine and doxombicin (de Jong et al., 2001).
Very few reports have described induction of ABCCl transcript or protein levels in 
response to dmgs. However Cherrington et al. described a small induction of Abed in 
rat liver in response to PXR and CAR ligands, indicating that these nuclear receptors are 
likely to mediate any observed response (Cherrington et al., 2002). However, a more 
recent study saw no increase in ABCCl mRNA in human hepatocyte cultures exposed to 
rifampicin (Nishimura et al., 2006) so any response may be limited and/or species 
specific.
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1.2.1.2.2 ABCC2
ABCC2 (MRP2, cMOAT) is expressed in the apical membrane of hepatocytes (Mayer et 
al., 1995; Buchler et al., 1996), intestinal epithelia (Ito et al., 1997) and kidney epithelia 
(Schaub et al., 1999) as well as placenta and lung (St-Pierre et al., 2000). ABCC2 has a 
similar substrate specificity profile to ABCCl in that it is responsible for the transport of 
a number of glutathione and glucuronide conjugates (Keppler et al., 1997; Gotoh et al.,
2000) and is involved in drug resistance in tumour ceUs, as anticancer drugs such as 
doxorubicin, etoposide and vincristine are ABCC2 substrates (Cui et al., 1999; Hooijberg 
et al., 1999). Like ABCCl, ABCC2 transports LTC4  (Kawabe et al., 1999) and transport 
via ABCC2 is also inhibited by MK571 albeit with a lower potency (Buchler et al., 1996). 
In addition, ABCC2 exports conjugated bile acids (Akita et al., 2001) and bilirubin 
(Jedlitschky et al., 1997) from hepatocytes as well as a number of unchanged drugs, 
which are not substrates for ABCCl e.g. cisplatin (Cui et al., 1999), pravastatin 
(Yamazaki et al., 1997), ritonavir (Huisman et al., 2002) and adefovir (Miller, 2001).
Mutations in ABCC2 are associated with a lack of ABCC2 being expressed in the apical 
membrane of hepatocytes in humans (Paulusma et al., 1997) and rats (Ito et al., 1997). 
This results in Dubin-Johnson syndrome (DJS), an autosomal recessively inherited 
disorder characterised by hyperbilirubinemia (Dubin and Johnson, 1954) due to deficient 
transport of glucuronidated bilirubin (Kartenbeck et al., 1996). Eisai hyperbilirubinémie 
rats (EHBR) lack Abcc2 and are a model for DJS in humans (Ito et al., 1997).
Dexamethasone is known to induce Abcc2 in rodents (Demeule et al., 1999; Kubitz et 
al., 1999) by a GR independent mechanism, implicating PXR as the regulatory factor 
(Courtois et al., 1999). The involvement of PXR was confirmed by studies In PXR nuU 
mice where no induction of Abcc2 was seen in response to dexamethasone or PCN 
treatment (Kast et al., 2002). Subsequent analysis of the promoter region of Abcc2 
demonstrated an ER 8  element, which PXR:RXRa bound to with high affinity. The 
prototypical human PXR activator, rifampicin also causes a dose dependent increase in 
ABCC2 expression in human hepatocytes (Nishimura et al,, 2006).
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1.2.1.2.3 ABCC3
ABCC3 (MRP3) is expressed in the intestine (Hirohashi et al., 1999), pancreas and 
placenta (St-Pierre et al., 2000) with lower expression observed in the liver (Konig et al.,
1999) and kidney (Kiuchi et al., 1998). In the liver ABCC3 is localised on the basolateral 
membrane of hepatocytes close to bile ducts and in cholangiocytes lining the büe ducts 
(Soroka et al., 2001), where it transports sulphated and glucuronidated büe acids and 
organic anions but unlike ABCCl and 2, glutathione conjugates are not ABCC3 
substrates (Hirohashi et al., 1999). Unconjugated büe acids such as cholate and 
taurocholate are ABCC3 substrates but are not transported by either ABCCl or 2 (Zelcer 
et al., 2003), whereas vincristine, etoposide and methotrexate, which are transported by 
other ABCC transorters, are also ABCC3 substrates (Kool et al., 1999). Transport via 
ABCC3 is again inhibited by the broad specificity ABCC inhibitor, MK571 (Weiss et al., 
2007).
As unconjugated büe acids are substrates for Abcc3 it is logical to hypothesise that this 
protein would be regulated by the nuclear receptor most associated with büe acid 
homeostasis, FXR. However Schuetz et al demonstrated that Abcc3 regulation was 
independent of FXR, using FXR nuü mice (Schuetz et al., 2001). Such a finding 
implicates PXR, which also shows some affinity towards büe acids as ligands, and later 
studies in mice have shown PXR (Staudinger et al., 2003; Maher et al., 2005) and CAR 
(Maher et al., 2005) activation increased Abcc3 levels. However, the involvement of 
CAR is disputed (Cherrington et al., 2003), and Maher et al also demonstrated that 
PPARa ligands cause induction of Abcc3 mRNA in mice (Maher et al., 2005) confusing 
the situation further. A recent study in human hepatocytes showed no increase of 
ABCC3 in response to rifampicin (Nishimura et al., 2006) again indicating that any 
response may be species specific.
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1.2.1.2.4 ABCC4
ABCC4 (MRP4, MOAT-B) is expressed in a range of tissues including the Hver (Lee et 
al., 1998), kidney, intestine, and lung (van Aubel et al., 2002). In some polarised cell 
types ABCB4 is localised on the apical membrane e.g. kidney epithelia (van Aubel et al., 
2002) while in hepatocytes it is localised on the basolateral membrane (Rius et al., 2003).
Endogenous substrates of ABCC4 include the cyclic nucleotides cAMP and cGMP 
(Chen et al., 2001; van Aubel et al., 2002), taurine and glycine conjugated büe acids and 
the unconjugated büe acid choline (Rius et al., 2006), and prostaglandins such as PGE^ 
and PGEg (Reid et al., 2003). It transports sulphated conjugates (Zelcer et al., 2003) and 
a number of xenobiotics such as methotrexate and EglYjlG (Chen et al., 2001; van Aubel 
et al., 2002). The ability of ABCC4 to transport nucleotide analogues and 
phosphorylated metabolites of the mecaptopurines (Chen et al., 2001) leads to resistance 
to anti-cancer drugs in tumour ceUs (Bai et al., 2004). Dmg resistance to anti-HIV dmgs 
such as azidothymidine monophosphate (AZT) (Schuetz et al., 1999) and the anti-viral 
dmg gancyclovir (Adachi et al., 2002) is also due to these dmgs being substrates of 
ABCC4.
Simüarly to Abcc3, the regulation of Abcc4 has been suggested to be via PXR activation, 
as induction occurs in FXR nuü mice (Schuetz et al., 2001). A more recent smdy has 
again implicated CAR (Assem et al., 2004) but little other work has been completed in 
this area.
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1.2.1.3 The ABCG Family
The ABCG family consists only of half transporters, which dimerise to produce 
functional transporters. They each have an N-terminal NBD and a C-terminal TM 
domain, which is the reverse orientation of all other ABC transporters (Sarkadi et al.,
2006). ABCGl is thought to be involved in cholesterol transport while ABCG5 and 8  
combine to form a heterodimer involved in sterol transport (Kusuhara and Sugiyama,
2007). Mutations in either ABCG5 or 8  result in sitosterolemia, a disorder characterised 
by deficient transport of sterols from the intestine and liver (Berge et al., 2000). ABCG2 
is the only member of the family involved in xenobiotic efflux and the only member of 
the family to be expressed on the plasma membrane (Rocchi et al., 2000) as aU the others 
are functional on intracellular membranes (Sarkadi et al., 2006).
1.2.1.3.1 ABCG2
ABCG2 (Breast cancer resistance protein, BCRP) is expressed at high levels in placental 
syncydotrophoblasts (AUikmets et al., 1998) and at lower levels in the apical membrane 
of intestinal epithelia and hepatocytes (MaHepaard et al., 2001) as a homodimer (Kage et 
al., 2002; Janvilisri et al., 2003). Very recent work has also established that ABCG2 is 
expressed on the apical membrane of kidney epithelial cells (Huls et al., 2008). ABCG2 
is expressed in various cancer cells (Turner et al., 2006) and as drugs such as topotecan 
(Maliepaard et al., 1999) and doxorubicin are substrates of ABCG2 (Doyle et al., 1998) it 
is involved in drug resisatnce during cancer treatment. These drugs are also substrates of 
other ABC transporters indicating some cross over of substrate specificity with ABCBl 
and the ABCCs, however ABCG2 doesn’t transport vincristine, which is a substarte of 
members of the ABCB and ABCC family. ABCG2 is also not involved with the efflux 
of conjugated compounds or büe acids (Chan et al., 2004) but can transport the 
antihypertensive agents, nifedipine and nicardipine (Shukla et al., 2006).
A recent study using monocyte derived dendritic ceUs has shown PPARy may play a role 
in the regulation of ABCG2 and identified a DRl site in the distal enhancer of the genes 
promoter (Szatmari et al., 2006), while Hirai et al found PPARa agonists induced 
ABCG2 in mouse liver (Hirai et al., 2007). However the exact regulatory pathways 
involved in ABCG2 expression remain unclear.
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1.2.2 The SLC Superfamily
The solute carrier (SLC) superfamily of transporters is the largest group of membrane 
transporter proteins, with approximately 225 members arranged into 46 families. They 
usually function as influx transporters involved in a wide range of transport processes 
incuding amino acid transport, neurotransmitter uptake and glucose uptake (Hediger et 
al., 2004). However they can be involved in ion exchange and other efflux roles 
depending on substrate concentration gradients or other driving forces (Hewitt et al.,
2007) and are therefore bi-directional transporters. Whereas most transporters in the 
SLC superfamily are highly specific for their substrate, three families, SLC 10, SLCO 
(SLC21) and SLC22 have a broader substrate specificity and are involved in the uptake of 
drugs into cells, most usually of tissues involved in the elimination of compounds i.e. 
hepatocytes and kidney epithelia.
1.2.2.1 The SLCIO Family
The SLIO family are a group of sodium-dependent bile acid cotransporters with five 
members expressed in man (SLClOAl-5), only two of which, SLClOAl and SLC10A2, 
are well characterised (Hagenbuch and Dawson, 2004). SLClOAl encodes the sodium 
taurocholate cotransporting polypeptide (NTCP), which is the major sodium dependent 
uptake transporter of bile acids across the basolateral membrane of hepatocytes. 
SLC10A2 encodes the apical sodium-dependent bile acid transporter (ASBT), which 
carries out the same function in the apical membrane of intestinal epithelial cells as 
NTCP does in hepatocytes. They are therefore key in the enteroheparic recirculation of 
bile acids.
NTCP (SLClOAl) has been found to transport the HMG CoA reductase inhibitor 
rosuvastatin into human hepatocytes but this activity is not seen in rodents (Ho et al., 
2006), while bosentan is a more potent inhibitor of büe acid uptake by rat Ntcp than 
human NTCP (Leslie et al., 2007).
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1.2.2.2 The SLCO Family
The SLCO (SLC21, OATP) family is a large group of proteins involved in the sodium- 
independent transport of organic anions including büe acids, steroid conjugates, 
hormones and xenobiotics (Hagenbuch and Meier, 2003). The genes in this superfarrdly 
are named slightly differently than other drug transport protein superfarrdly members in 
that SLCO is now the official name (HUGO Gene Nomenclature Committee) for the 
farrdly rather than SLC21 and families are determined by a number, families are split into 
sub-families by a letter and individual members are designated a number e.g. SLCOIBI 
(Hagenbuch and Meier, 2003). Protein names are OATP (for organic anion transporting 
polypeptide) foUowed by the unique identifier e.g. OATPIBI. This aUows an increased 
capacity for naming of individual proteins, as many of the human SLGO’s“have~no~ 
orthologue in rodent, therefore each protein, irrespective of species, requires a different 
name.
AU OATP’s are predicted to have 12 transmembrane domains (Hagenbuch et al., 2000) 
and transport a wide range of relatively large substrates (>450 Da) although the exact 
mechanism behind transport remains unclear (Hagenbuch and Dawson, 2004). They 
transport their substrates independently of a sodium concentration gradient (KuUak- 
Ublick et al., 1995), which is used to drive transport by other büe acid transporters such 
as SLClOAl. Anion exchange has been implicated for a number of the farrdly members 
with glutathione and bicarbonate both being suggested as possible exchange partners, at 
least for Oatplal in rodents (Satlin et al., 1997; Li et al., 1998). However recent work 
has shown that human OATP’s are not capable of transporting glutathione and therefore 
the search for an exchange partner continues (Mahagita et al., 2007).
Under the new naming strategy there are 6  families, SLCOl-6 , but for the purposes of 
discussing drug uptake, only SLCOl and SLC02 have members reported to transport 
xenobiotics. Three transporters from human and three from rat were chosen for study 
in this work based on recommendations from the FDA as being important in drug 
transport (FDA recommendations to industry, 2006), as weU as their demonstrated 
expression within liver.
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1.2.2.2.1 Human OATPs
OATPIBI (OATP2, OATPC) and 1B3 (OATPS) are expressed only in the liver where 
they are localised to the basolateral membrane of hepatocytes (Konig et al., 2000; Nakai 
et al., 2001). They are responsible for the Na"^  independent uptake of organic anions into 
hepatocytes with OATP1B3 having a more restricted substrate specificity than 
OATPIBI (Hagenbuch and Meier, 2003). For example OATPIBI transports bile acids 
such as taurocholate (Nakai et al., 2001), LTQ (Sasaki et al., 2002), conjugated and 
unconjugated bilirubin (Cui et al., 2001b) and a number of drugs including pravastatin 
and simvastatin (Nakai et al., 2001) and rifampicin (Vavricka et al., 2002). In comparison 
drugs transported by OATP1B3 include rifampicin (Vavricka et al., 2002) but not 
pravastatin (Konig et al., 2000) while OATP1B3 transports digoxin, which OATPIBI 
does not (KuUak-Ublick et al., 2001).
Unlike OATPIBI and 1B3, OATP2B1 is expressed in a broader range of tissues 
including the liver, intestine and placenta (KuUak-Ublick et al., 2001). However 
OATP2B1 has a much more restricted substrate specificity than OATPIBI and 1B3 
(KuUak-Ublick et al., 2001) but this is thought to be due to OATP2B1 being involved in 
the pH dependent uptake of substrates in the intestine (Nozawa et al., 2004). For 
example OATP2B1 is thought to transport pravastatin but this only occurs at low pH as 
would be found in the duodenum. OATP2B1 does not transport pravastatin into any 
other tissue due to the lack of a pH gradient (Kobayashi et al., 2003).
Very Uttle work has been carried out regarding the regulation of OATP expression in 
response to xenobiotics, although levels of OATP1B3 are kown to be increased by FXR 
activation in response to bUe acids (Jung et al., 2002). Other work has suggested FXR 
indirectly decreases the levels of OATPIBI (Jung and KuUak-UbUck, 2003) suggesting 
regulation may be complex.
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1.2.2.2.2 Rat Oatp’s
Similarly to the human proteins, the rat Oatp’s are expressed on the basolateral 
membrane of polarised cells and transport a distinct but overlapping group of substrates; 
Oatplal is expressed in the Hver and kidney of rats where it transports bile acids such as 
cholate and taurocholate (Jacquemin et al., 1994), LTQ (Li et al., 1998), 
monoglucuronosyl biHrubin (Kamisako et al., 2000) and a range of dugs including 
enalapril (Pang et al., 1998), fexofenadine (Dresser et al., 2002) and pravastatin (Hsiang et 
al., 1999). Oatpla4 is also expressed in the Hver as weU as the BBB (Noe et al., 1997) 
where it transports a similar range of substrates as Oatplal including bile acids, 
fexofenadine (Dresser et al., 2002) but not pravastatin (Hsiang et al., 1999). In the same 
way that only OATP1B3 can transport digoxin in humans only Oatpla4 can transport 
the cardiac glycoside digoxin into rat ceUs (Noe et al., 1997). Oatplb2 is expressed 
mainly in the Hver where it transports bile acids and Hke Oatplal, LTQ (Cattori et al.,
2000). There has been no report of a rat Oatp transporter that is dependent on pH for 
transport.
Most of the work carried out on elucidating regulation of Oatp’s has concentrated on 
Oatpla4, which is regulated by PXR both in rats and mice (Guo et al., 2002; Staudinger 
et al., 2003; Cheng et al., 2005) The promoter of the Slcola4 gene contains four PXR 
response elements, one proximal and three distal. Both the proximal enhancer and the 
distal group are required for a maximum response to PXR Hgands (Guo et al., 2002). In 
addition to its demonstrated role in regulating Oatpla4 expression, PXR activation has 
also been shown to decrease Oatplal levels, suggesting that it may have a repressive 
effect on transcription, wherease no effect on Gatplb 2  levels have been demonstrated 
(Cheng et al., 2005). In summary, whereas the majority of evidence suggests that Oatp 
family members are predominantly regulated by PXR-mediated mechanism, the present 
evidence is far from complete and suggests that regulation of this group of transporters 
may be complex.
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1.2.2.3 The SLC22 Family
Whereas the SLCO family of transporters are restricted to mainly transporting organic 
anions, the SLC22 family consists of a range of genes encoding proteins involved in the 
facilitated diffusion or ion exchange of cations, anions and zwiterions. The proteins 
encoded by this gene family roughly fall into two groups; first, the organic cation 
transporters OCT’s and OCTN’s; and secondly, the organic anion transporters (OAT’s), 
plus a number of related proteins whose transport substrates are unknown (SLC22A9-10, 
SLC22A13-15 and SLC22A17-20) (Koepsell and Endou, 2004). Several members of this 
family are predominantly involved in transport of essential metabolites into cells, for 
example SLC22A12 encodes a urate transporter expressed exclusively in the kidney 
(Enomoto et al., 2002), while SLC22A5 and 16 encode carnitine transporters (Wu et al., 
1998), and therefore they will not be discussed in detail herein.
Many members of the family are capable of drug uptake, for example OCT2 and 3 
(SLC22A2-3), OATl, 2 and 3 (SLC22A6-8) are expressed in the basolateral membrane of 
kidney epithelia where they are involved in renal elimination of drugs into the urine 
(Koepsell and Endou, 2004). In the liver, OCTl (SLC22A1), OCT3 and OAT2 are 
expressed in the basolateral membrane of hepatocytes and take drugs up into the cells for 
metabolism and/or biliary excretion (Koepsell and Endou, 2004). However, while some 
family members are expressed predominantly in these excretory organs e.g. OCTl (liver) 
and OCT2 (kidney), others such as OCT3 are expressed much more widely (Verhaagh et 
al., 1999). For the purposes of this work, only the liver specific OCTl was investigated 
(Zhang et al., 1997).
1.2.2.3.1 OCTl
Similarly to the OATP’s, OCTl has 12 transmembrane domains and is localised to the 
basolateral membrane of hepatocytes in humans, although in its rat orthologue, Octl, is 
expressed in a wider range of tissues including the kidney and intestine as well as the liver 
(Zhang et al., 1997). In general OCTs are responsible for the uptake of small hydrophilic 
compounds 60 to 350 Da in size, which contain at least one positive charged amine 
group. OCTl transports a number of these compounds across the plasma membrane by 
facilitated diffusion, although its substrate specificity is narrower than members of the 
OATP family. Substrates of O ctl/O CTl include the Parkinsons drug amantadine and
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the type II diabetes drug metformin (Wang et al., 2002; Shu et al., 2007). OCTl has been 
found to be higly polymorphic in humans affecting the efficacy of its substrates including 
metformin (Shu et al., 2007).
1.2.3 Polymorphisms in Dmg Transporter Genes
Interindividual variation in the pharmacokinetics of drugs is partly due to polymorphic 
transporter genes, which result in transporters with reduced function. The main 
transport proteins that have ben studied with regards to polymorphisms are ABCBl, 
ABCC2 and OATPIBI and they will be considered in more detail below.
In ABCBl the most commonly reported polymorphism is a ‘süent’ mutation (C3435T) 
that has been associated with decreased transport resulting in a lower rate of clearance of 
compounds such as fexofenadine (Yi et al., 2004) and digoxin (Johne et al., 2002). How 
a mutation that results in no alteration to the amino acid sequence could affect function 
was always a point of some argument until recently when a recent Science paper showed 
that C3435T alters ABCBl function because it uses a rare codon; this causes translation 
to pause allowing the protein more time to fold. This produces a protein with different 
conformation, which alters its interactions with substrates so reducing the rate of 
transport (Kimchi-Sarfaty et al., 2007). To date no ABCBl polymorphism has been 
discovered in humans that results in complete loss of function, however such incidences 
have been found in mice (Kwei et al., 1999) and dogs (Mealey et al., 2001).
In ABCC2 the most common polymorphism is G1249A, which occurs in 24 % of the 
Caucasian population, however this polymorphism is not associated with altered function 
(Hirouchi et al., 2004) and this is largely true for other common polymorphisms in the 
ABCC family (Kerb, 2006). However rare polymorphism have been associated with a 
change in ABCC function, a good example of which can be observed with the multiple 
rare mutations in ABCC2 (Suzuki and Sugiyama, 2002) that cause Dubin-Johnson 
syndrome (DJS) (Dubin and Johnson, 1954).
Over 40 polymorphisms have been detected in OATPIBI with some such as 
Asnl30Asp (OATPIBI*lb) being round in over half the Asian poulation (Nishizato et 
al., 2003). OATPlBl*lb and *5 are associated with reduced uptake of rifampicin 
(Tirona et al., 2003) while OATPlBl*15, another common SNP (Nishizato et al., 2003)
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is associated with the reduced uptake of several substrates including pravastatin (Nozawa 
et al., 2005). Several SNP’s (OATPlBl*5. *9, *15 and *16) are also associated with loss 
of rosuvastatin uptake (Ho et al., 2006). Polymorphisms have been detected in 
OATP1B3 and 2B1 but so far they have not been associated with altered function (Kerb, 
2006).
Although transporter polymorphisms do not appear to have very significant effects on 
the pharmacokinetics of drugs, they can influence toxicity especially where the dose is 
close to the tolerated limit as is often the case in cancer chemotherapy or where the 
therapeutic window is small as it is with digoxin. A decrease in influx or efflux of these 
dmgs could lead to increased incidences of toxicity in susceptible individuals, as dmg 
clearance will be reduced.
1.2.4 Summary
In summary, the ABC and SLC transporter superfamilies are made up of proteins with 
specialised functions to transport substrates across lipid membranes. Within these 
superfamiles, a number of proteins may be designated as ‘dmg’ transporters due to their 
ability to transport substrates with highly varied stmcmre, which are often endogenous in 
namre; these dmg transporters are generally expressed at high levels in tissues such as 
liver, kidney, BBB and intestine. Given the importance of these sites on determining the 
absorption, distribution, metabolism and excretion of exogenous compounds it is 
unsurprising that dmg transporters have a major influence on the disposition of 
xenobiotics. Dmg transporters may limit disposition of a compound but it should also 
be remembered that dmg transporters can help as well as hinder dmg bioavailability, for 
example they can be used to target dmgs to specific organs e.g. pravastatin is targeted to 
the liver by OATPIBI uptake, while the presence of efflux transporters in the BBB can 
prevent CNS access of dmgs with no role there and so prevent any CNS side effects. 
The response of cells to increased expression levels of transporters when challenged with 
xenobiotics, allows them to clear potentially harmful compounds that may otherwise 
accumulate and cause toxicity. However polymorphic transporters may have reduced 
function leading to lower clearance of the dmg and increased incidence of toxicity.
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1.3 Assays to Measure Transporter Function in ADME
The previous sections have highlighted drug transporters as being an important 
determinant in a compounds disposition in the body. Furthermore, as uptake of 
compounds into cells must occur before they can be metabolised, drug transporters may, 
in many cases, limit access of compounds to drug metabolisng enzymes. Transporters 
are also the first step in the pathway by which a compound is excreted from the body. 
Therefore during the discovery and development of new drugs it is important to 
ascertain if a compound is likely to be a substrate or inhibitor of a transport protein.
Discovering new treatments for cancer is a special case in transporter related ADME 
studies, as a number of transporters are known to be upregulated in tumours and 
therefore if a compound is found to be a substrate for one of these transporters the 
concentration of drug within tumour cells may fall below the therapeutic level. Drug- 
drug interactions can also be caused by interactions involving transporters so these assays 
are also used in assessing the risk of DDI’s.
A number of assays ranging from simple membrane assays, in vitro cell based assays and 
animal testing are employed before a compound is clinically tested in humans for safety 
and efficacy. The more information that can be elucidated on compounds ADME 
characteristics, the greater chance of success in the clinic. Reducing the attrition rate of 
compounds in the clinic by improving pre-clinical tests is a major focus of the 
pharmaceutical industry, in order to reduce both the cost and time of bringing new drugs 
to the market.
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1.3.1 Membrane Based Assays
Membrane preparations from cells expressing transporters are used to study the function 
of efflux transporters and determine if compounds are substrates or inhibitors of the 
transporter expressed in the membrane. Membrane based assays include the ATPase 
assay and the membrane vesicle uptake assay and can be run at very high throughput to 
look at the interactions between a large number of potential drugs and a specific 
transporter.
1.3.1.1 The ATPase Assay
Transport of substrates via ABC efflux pumps such as ABCBl and ABCG2 depends on 
the binding and hydrolysis of ATP within the nucleotide-binding domain (NBD) of the 
drug transporter. Substrates or inhibitors directly interact with the transporters and 
stimulate the hydrolysis of ATP, releasing phosphate, which can be measured 
colourimetrically (Shirasaka et al., 2006; Glavinas et al., 2007). However, while the 
ATPase assay is a high throughput assay, it cannot differentiate between, for example, an 
ABCBl substrate such as verapamil and an inhibitor such as ketoconazole, as both will 
cause ATP hydrolysis (Xia et al., 2007).
1.3.1.2 Membrane Vesicle Transport Studies
Membrane vesicles can be prepared not only from cells transfected with a specific 
transporter but also from tissue, for example the hepatic canalicular membrane. They 
can be used to identify substrates and/or inhibitors of ABC drug transporters (Tabas and 
Dantzig, 2002) and sodium/proton dependent influx pumps such as NTCP (SLClOAl) 
(Liu et al., 1998). Substrate is measured via mass spectrometry, fluorescence or 
scintillation counting depending on the properties of the substrate.
Such an assay is very high throughout and can be used to determine kinetic parameters 
of transport (Liu et al., 1998). Unlike the ATPase assay, the membrane vesicle assay will 
differentiate between substrates and inhibitors of a transporter, however the vesicles may 
contain a number of different transporters if produced from tissue and the assay may 
give false positive results for lipophilic compounds, which can passively diffuse into the 
vesicles (Xia et al., 2007).
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1.3.2 Cell Based Assays
Cells can be extracted from tissue by digestion with collagenase to release them from the 
extracellular matrix and used for transport assays in suspension (Soars et al., 2007) or 
alternatively so called ‘primary’ cells can be grown in single cell layers on collagen coated 
multi-well plates and exposed to drugs in cell culture medium (Nishimura et al., 2006). 
The sandwich culture of primary cells between two layers of collagen results in cells with 
polarised membranes and a functioning canalicular network allowing the study of biliary 
efflux (Liu et al., 1999) while technology is being advanced to grow cells on 3D scaffolds 
to replicate tissue structure in a multi-well format for easy exposure to compounds 
(Sivaraman et al., 2005). Transformed cells can be obtained from tumour cells or 
alternatively, cells from normal tissue can be artificially transformed; these cells will 
continue to grow and divide indefinitely, and they can be transfected with the DNA of a 
transporter of interest resulting in its overexpression in the plasma membrane (Liu et al., 
2006). Both cell and membrane vesicle assays can be carried out at 4 °C and compared 
to results from experiments at 37 °C in order to discriminate between active transport 
processes via transporter proteins and passive diffusion, as the former will not take place 
at 4 °C (Thomas et al., 2004).
The liver is the major source of metabolism in the body, with many hepatotoxins 
requiring metabolic activation to reactive species prior to the appearance of their toxic 
effects, for example the sulphate conjugate of troglitazone is more hepatotoxic than the 
parent drug (Funk et al., 2001). Therefore in order to predict hepatotoxicity in vitro, 
metabolically competent cells are highly desirable. Although cell types differ in their 
metabolic capability, hepatocytes and certain cell lines can be used to look at the interplay 
between metabolism and transport are therefore physiologically more relevant models 
than simple membrane extracts. CeU based assays can be used to look at changes drug 
treatment makes to gene expression, which is not possible in membrane assays as 
activation of nuclear receptors takes a number of hours or days to become apparent 
(Plant, 2004).
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1.3.2.1 Hepatocytes
Drug disposition into cells for hydrophilic compounds is initiated by active transport 
across the membrane. However, cellular access is not just important for determining 
which tissues a compound enters, but also if that compound will be metabolised and 
how it win be excreted. As the liver is the main site of metabolism and the route for 
biliary efflux, establishing the route of uptake of drugs into hepatocytes can be important 
for determining these ADME parameters. Hepatocytes are thought of as the ‘gold 
standard’ of in vitro liver systems as they are a whole cell system containing both DMEs 
and transporter proteins, and therefore represent the closest approximation to 
hepatocytes in vivo (Plant, 2004). However, while most of the transcriptome and 
proteome of hepatocytes is similar to liver, the expression of some key proteins is 
different, for example CYP expression falls over time in culture (Binda et al., 2003), and 
hence caution must still be used with such systems.
Several studies have shown that primary cultures of hepatocytes can be used to predict in 
vivo drug metabolism (Hewitt et al., 2001; Salonen et al., 2003). A study by Ponsoda et al. 
compared the metabolites produced by the culture of primary cells with aceclofenac to 
the metabolites produced in urine after the drug was given to the patient from whom the 
cells were taken. This study offered the chance to directly compare, in the same 
individual, the metabolism of a drug in vitro and in vivo and showed a remarkable similarity 
in the metabolic profile produced by the same donor (Ponsoda et al., 2001). Results such 
as this provide evidence that primary cells can be used in ADME studies to predict the in 
vivo characteristics of drugs.
Freshly isolated and cyropreserved hepatocytes in suspension can be used for influx 
studies (Shitara et al., 2003; Hirano et al., 2004), as cells maintain functional uptake 
transporters after hepatocyte isolation. However, cells lose their polarity during isolation 
and efflux transporters tend to be internalised (Hoffmaster et al., 2004), therefore drug 
efflux studies cannot be performed in suspensions of hepatocytes. The sandwich culture 
of cells between two layers of collagen results in hepatocytes that repolarise, have tight 
junctions between cells, express efflux transporters such as ABCBl and ABCC2 on the 
canaclicular membrane and have functional biliary canalicular networks (Hoffmaster et 
al., 2004). The sandwich-cultured cells also maintain functional uptake processes (Liu et 
al., 1998; Hoffmaster et al., 2004). It should be noted however that the layer of collagen
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or matrigel added to sandwich cultured hepatocytes could interfere with the 
bioavailability of some compounds such as polypeptide-based drugs (Hewitt et al., 2007).
An assay developed and patented by Kim Brouwer’s laboratory uses sandwich cultured 
cells to evaluate the biliary efflux of compounds and relies upon the fact that when 
sandwich cultured cells are depleted of calcium, the tight junctions are opened and any 
compound contained in them can be removed. By comparing the accumulation of 
compound in hepatocytes treated in this way, with hepatocytes whose biliary network is 
complete, the percentage of compound excreted into the büe can be determined (Liu et 
al., 1999). Alternatively the specific transporter responsible for the efflux of a compound 
can also be determined in cultured hepatocytes by using specific substrates for each 
transporter. ABCBl transports the fluorescent substrate rhodamine 123 (Shapiro and 
Ling, 1997), whüe ABCC2 transports the fluorescent substrate carboxydichlorofluroscein 
(CDF) (Zamek-GHszczynski et al., 2003). Accumulation of fluorescence in the 
hepatocytes can be use to show competition for efflux with test compound (Annaert et 
al., 2001; Hopwood et al., 2006).
As well as establishing ADME properties such as the büiary efflux of compounds, 
hepatocytes can be used to determine the mechanism of drug-drug interactions (DDI) 
involving transporters. Troglitazone toxicity resulted in several cases of hepatic faüure, 
which ultimately led to its removal from the market, whereas toxicity involving bosentan 
caused trials of the drug to be suspended. Intra-hepatic choleostasis was observed with 
both bosentan and troglitazone in rat studies due in part to the inhibition of büe acid 
export via ABCBl 1, which would cause an intraceüular accumulation of büe acids within 
hepatocytes leading to choleostasis (Fattinger et al., 2001; Funk et al., 2001). Further 
studies showed that the risk of toxicity involving troglitazone and bosentan could have 
been determined pre-cUnicaUy in sandwich-cultured hepatocytes (Kemp et al., 2005). 
Bosentan has since been returned to trials at a lower dose, only achievable once the 
mechanism of toxicity was fuUy understood from this and simüar work.
Drug-induced changes in transporter gene expression can not be conducted in simple 
models of transporter function due to the time it takes for these changes to become 
apparent. Induction of transporter expression can lead to increased clearance as more 
compound is transported into hepatocytes, is metabolised and/or excreted via biliary
45
efflux (Annaert and Brouwer, 2005). Likewise, induction of transporters in the kidney 
would lead to faster clearance via an increase in urinary excretion. For a compound with 
a narrow therapeutic window, this increase in clearance could lead to a fall in the 
concentration of compound below the efficacious concentration. The induction of drug 
transporters can be determined in cultured hepatocytes exposed to the compound of 
interest as is performed routinely during assays for CYP induction (Bi et al., 2006).
Although hepatocytes are the ‘gold standard’ in vitro test, human hepatocytes remain 
difficult to obtain. Different donor livers wül be used for each preparation of cells and 
due partly to genetic polymorphisms may give variable results, although several donors 
can be pooled to reduce the impact of inter-individual variability. Cryopreserved cells are 
expensive and not as predictive as fresh hepatocytes, but they have been used 
successfully in metabolic (Naritomi et al., 2003) and transport studies (Bi et al., 2006), 
and have the added advantage of being an ‘off the shelf preparation so the same donor 
can be used for a number of repeat assays.
Rat hepatocytes provide a good in vitro model for human cells and are easily and cheaply 
obtained but species differences especially in the expression and functionality of influx 
drug transporters and metabolic enzymes can be a drawback (Leslie et al., 2007). 
However, studies have shown that cultured rat hepatocytes are a good model for 
hepatotoxicity compared to the commonly used whole animal models (Kikkawa et al., 
2006). In both rat and human hepatocytes the expression of metabolic enzymes (George 
et al., 1997) and some transporters (figorel et al., 2005) is known to change over time in 
culture, as cells re-polarise, therefore assays completed at different times may not be 
comparable to in vivo transport and metabolism.
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1.3.2.2 Cell Lines
Cell lines that are either artificially transformed or are derived from human carcinomas 
provide a stable, robust assay system against which the effects of drugs can be compared 
over a long period, in terms of both extended time studies and robustness for frequently 
used screening tools. However, cell lines often don’t express a full range of proteins 
compared to primary cells or in vivo tissue and this can lead to the misinterpretation of in 
vitro results. For example when ceU lines lacking CYP3A4 are dosed with omeprazole 
sulphate, the compound antagonises the aryl hydrocarbon receptor (AhR). However in 
primary ceUs, which contain CYP3A4, omeprazole sulphate is metaboUsed to 
omeprazole, an AhR agonist (Gerbal-Chaloin et al., 2006). Therefore the two in vitro 
assays give contrary results and only an understanding of CYP3A4 expression aUows the 
results to be interpretated correctly.
Whereas primary ceUs can be transfected with plasmid DNA containing a gene or 
reporter gene construct of interest, ceU Unes are easier to transfect and withstand the 
transfection process better (Plant, 2004). The transfection of uptake and efflux drug 
transporters that may not be present or active in ceU Unes, aUows the study of transport 
via a specific transporter from which ADME properties of compounds can be deduced, 
as weU as any DDI’s that may occur involving drug transport. However it is currently 
unclear how the transfection effects basal expression of transporters in these systems and 
if this affects assays carried out using them.
1.3.2.2.1 Caco2 CeUs
Caco2 ceUs are derived from human colonic adenocarcinoma enterocytes (Fogh et al., 
1977). After long periods of culture they develop weU-defined brush border membranes 
and tight junctions. Many active transport proteins found in intestinal enterocytes are 
found in Caco2 cells and therefore they can be used for permeability screening for 
prediction of intestinal absorption (Artursson and Karls son, 1991). Caco2 cells express a 
similar range of transporters to those found in the jejunum and colon at both the 
transcript and protein level (Taipalensuu et al., 2001; Xia et al., 2005; Calcagno et al.,
2006). Phase I and II enzymes have also been demonstrated at the protein level 
(Baranczyk-Kuzma et al., 1991; Carrière et al., 1994).
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Caco2 cells have been used to identify compounds that are substrates for ABCBl e.g. 
cyclosporine A (Gan et al., 1996), and also that efflux by ABCBl could act as a limiting 
step in the rate of metabolism of the protease inhibitors saquinavir (Mouly et al., 2004) 
and K77 (Cummins et al., 2002). Uptake transporters such as OATP2B1 are expressed 
in the apical membrane of Caco2 cells (Sal et al., 2006), which have been used to 
elucidate the pH dependent uptake of compounds by this transporter (Kobayashi et al., 
2003; Nozawa et al., 2004).
1.3.2.2.2 MDCKII Cells
MDCKII cells are immortalised kidney epithelial cells from dog, producing a relatively 
‘clean’ background with no expression of human transporters. Once transfected with 
transporter DNA, they are useful for bi-directional drug transport studies as they form 
polarised plasma membranes, with introduced transporters correctly localising to the 
basolateral or apical membranes (Konig et al., 2000). It should be noted that although 
they are described as having a ‘clean’ background, complications can arise from the 
expression of endogenous dog transporters (Bartholome et al., 2007), which may also 
transport test substrates. Single, double and even quadruple transfectants have been 
developed with ABCBl, ABCCl and 2, ABCG2 and several OATP members including 
IBl and 1B3 (Evers et al., 1997; Cui et al., 2001a; Kopplow et al., 2005; Matsushima et 
al., 2005).
1.3.2.2.3 HEK293 Cells
Human embryonic kidney (HEK293) cells are derived from kidney epithelia and are 
widely used in ADME studies with the protein of interest, such as a drug transporter, 
transfected into them. Studies involving HEK293 cells and transporters have focused on 
the uptake of compounds by OATPIBI, SLC22A1 and SLC22A8 (Lohmann et al.,
2007). Most recently however, a novel assay in HEK cells has been developed to 
measure biliary efflux via ABCG2 (Kevin Jones, personal communication), which not 
only affects compound excretion but is also an important transporter in contributing to 
drug resistance during chemotherapy, as ABCG2 is upregulated in a range of cancers 
(Turner et al., 2006) and transports a number of anti-cancer drugs (Doyle et al., 1998). 
Therefore, potential cancer therapies that are substrates for ABCG2 may not achieve a 
therapeutic concentration in the tumour cells and early screening of compounds for
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ABCG2 activity would be advantageous in preventing compounds reaching the clinic 
that are unlikely to be efficacious in patients.
HEK293 cells have also been used to elucidate drug-drug interactions due to inhibition 
of bile acid uptake via OATPIBI, which in vivo would prevent büe acid uptake into 
hepatocytes and cause choleostasis (Campbell et al., 2004). Another assay used HEK293 
cells expressing OATPIBI, 1B3 and 2B1 to examine the molecular mechanism of the 
DDI occasionally seen when gemfibrozil is dosed with fiuvastatin and found that the two 
compounds competed for uptake and so were cleared less quickly from the blood 
increasing their systemic concentration and the likelihood they could cause toxicity (Noe 
et al., 2007).
1.3.2.2.4 HepG2 Cells
HepG2 cells are a Caucasian human hepatoma cell line that retains some metabolic 
function (Aden et al., 1979; Knowles et al., 1980), and they are commonly used in 
hepatotoxicity testing (Chen et al., 1997; Xu et al., 2003; Hassen et al., 2007); In fact 
over 5000 references cite the use of HepG2 cells in their work (Plant, 2004), indicating 
their popularity. HepG2 cells express very low levels of cytochrome P450’s compared to 
human Hver (Westerink and Schoonen, 2007), which can limit their use when they are 
dosed with compounds that have activity only after metabolism by a CYP (Gerbal- 
Chaloin et al., 2006). HepG2 cells have been used as a model of alcohol induced toxicity, 
for example Koo et al. showed that a traditional Chinese remedy used for liver disease, 
reduced the toxicity of ethanol in Hep G2 cells (Koo et al., 2000).
1.3.2.2.5 Huh? Cells
The human hepatoma cell line Huh? expresses very low levels of drug metabolising 
enzymes and the nuclear receptor PXR (Phillips et al., 2005), although these are not 
widely distinct from those observed in HepG2 cells. Huh? cells have been used in many 
studies completed in this laboratory and others to look at the induction of CYP3A4 via 
PXR by transfecting the cells with a reporter gene plasmid containing the XREM 
promoter region of CYP3A4 and a PXR expression plasmid. In one such study, a range 
of compounds were ranked according to their ability to induce CYP3A4 via activation of 
PXR (El-Sankary et al., 2001). Huh? cells transfected with a slighdy different reporter
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gene of CYP3A4 and a PXR expression plasmid were also used to screen retinoids, a 
potential chemotherapy, for their ability to interact with CYP3A4 substrates (Wang et al., 
200&k
1.3.2.3 Oocytes
The 'Kenopus laevis oocyte can be direcdy injected with human mRNA or cDNA and will 
produce the protein in the cell (Rollins and Flickinger, 1972). When they are injected 
with transporter RNA, the protein is expressed in the membrane of the oocyte and they 
have been most often used to characterise the kinetics of transport for newly cloned drug 
influx transporters such as OATPIBI (Abe et al., 1999). Efflux transport can also be 
studied in oocytes by injecting drugs into cells and measuring efflux from the oocytes 
(Jun Otomo, conference communication). Oocytes provide a completely clean 
background with no other mammalian transporters present (Xia et al., 2007) but such an 
advantage must be weighed against the use of a non-mammalian, artificial system.
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1.3.3 Whole Organ Perfusion
An issue with all cell-based assays described previously is that they are aU single cell 
systems, and hence cannot fully model a complex multi-cellular organ such as the liver. 
An alternative to such single cell systems is the perfusion of compound through an 
isolated whole organ, which should allow a more physiologically relevant determination 
of transporter functions in ADME compared to in vitro tests. Compound is added to the 
perfusion fluid and delivered to the organ; once perfusion is stopped the concentration 
of drug is measured in the organ, the perfusate and elimination fluids, such as bile from 
liver. Perfusion studies are most useful when looking at the interplay of drugs with 
multiple transporters and metabolic enzymes, but can be limited in their ability to dissect 
out the individual input of each component of the system (Xia et al., 2007).
For example, studies involving whole liver perfusion have been used to show that 
inhibition of the uptake of digoxin decreased its clearance while inhibition of digoxin’s 
efflux from the liver via ABCBl, caused accumulation of drug in the cell and an increase 
in metabolism. Therefore the clearance of digoxin was actually increased (Lau et al., 
2004). Kidney perfusion studies have shown ABCBl is responsible for the renal 
elimination of digoxin (Hori et al., 1993) and that inhibition of ABCBl by cyclosporin A 
can lead to a DDI with digoxin (Okamura et al., 1993). Information on the elimination 
of drugs like digoxin, which have a narrow therapeutic window, is vital to prevent 
toxicity or loss of efficacy.
In situ perfusion is also of use where no adequate cell culture method exists, for example 
in the study of compound access to the brain across the BBB (Cisternino et al., 2001). 
This is difficult to study in vitro as the BBB is a complex mixture of ceU types including 
polarised endothelial cells with tight junctions that differ to the tight junctions of 
epithelial cells in the intestine.
The disadvantages of whole organ perfusion are that it is obviously low throughput and 
expensive to perform in comparison to in vitro studies, hence it is not routinely 
performed during ADME studies. Organ integrity and enzyme activity also degrade over 
time and the technique requires specialised surgical skill. Species differences in 
expression and function of drug transporters and metabolic enzymes may also affect 
extrapolation to humans (Xia et al., 2007).
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1.3.4 In Models
Genetic knockout mice, where a transporter gene has been disrupted, and natural mutant 
animal models, where the transporter is missing due to a natural mutation, are important 
tools in evaluating drug transport. They have been used to investigate the physiological 
function of transporters; for example, CF-1 mice are naturally deficient in Abcbl (Kwei 
et al., 1999) while Eisai hyperbilirubinémie rats (EHBR) are deficient in Abcc2 (Buchler 
et al., 1996); genetic knockout mice without Abcbl (Schinkel et al., 1997) and Slc22Al 
(Jonker et al., 2 0 0 1 ) have been shown to be viable and have also been used to elucidate 
the function of the absent transporter. Animal models have also been used as models of 
human disease such as the EHBR’s used as a model of Dubin-Johnson syndrome, a form 
of hyerbilirubinemia in humans (Buchler et al., 1996) and Abcc6  knockout mice used as a 
model for pseudoxanthoma elasticum (PXE), a disease of the connective tissue (Gorgels 
et al., 2005).
Another use of such animal models is in evaluating drug absorption and elimination. For 
example Abcbl and Abcg2 knockout animals have been used to show that these 
transporters are involved in the absorption and elimination of Abcbl substrates such as 
paclitaxel (Chen et al., 2003a) and ivermectin (Kwei et al., 1999), as well as the Abcg2 
substrates topotecan and nitrofurantoin (Zaher et al., 2006). Biliary excretion of 
methotrexate via Abcc2 has also been investigated in EHBR (Chen et al., 2003b), whUe 
mice with Slc22 knockouts have been used to examine renal elimination of the organic 
cation tetraethylammonium (TEA) (Jonker et al., 2003).
Drug distribution has also been studied in animal knockouts; Abcbl knockout mice have 
been used to investigate the brain penetration of compounds (Wang et al., 2004), while 
Abcc4 knockout mice have been used to show that Abcc4 prevents exposure of the 
brain to the chemotherapeutic agent topotecan (Leggas et al., 2004). Similarly, knockouts 
of A bed in mice have been used to show that the transporter has a role in the blood- 
cerebrospinal fluid (CSF) barrier (Wijnholds et al., 2000). The lack of Octl in a mouse 
knockout model was used to show that lack of an uptake transporter limits the 
penetration of compounds in the liver (Jonker et al., 2001).
Animal models are also used in toxicology testing of compounds; for example, the 
EHBR model for Abcc2 has been used to show an increased rate of skeletal muscle
52
toxicity when the rats were dosed with pravastatin due to higher systemic exposure of the 
drug (Naba et al., 2004).
However, in vivo models do have limitations; first, altering the expression of one 
transporter has been found to affect levels of cytochrome P450’s (Schuetz et al., 2000) 
and other transporters (Kuroda et al., 2004), which may complicate the interpretation of 
such studies. Second, differences between species can cause problems; for example, 
uptake transporters such OAT3 can have different functions in non-primate species 
compared to humans (Tahara et al., 2005). Third, male and female rats express different 
amounts of transporters for example, Rost et al., 2005 found female rats had higher 
levels of Oatplb2, Abcc2 and Abcc3 protein in liver samples, whereas male rats had 
higher protein levels of Oatpla4 (Rost et al., 2005). Male mice and humans both have 
increased levels of Abcg2/ABCG2 in liver than females (Merino et al., 2005). Such 
differential expression between species can affect ADME properties of drugs when 
tested in different sexes and could also have implications in humans if further differences 
in expression between males and females are found.
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1.3.5 Summary
Methodology to assess drug transporter action in preclinical drug develoment ranges 
from simple membrane based assays which look at a compounds interaction with one 
recombinant transporter, to cell based assays and animal models. The physiological 
relevance of data increases with the complexity of the assay being used, however our 
ability to determine the mechanistic pathway decreases. For example, all factors of a 
recombinant transporter assay can be understood and a detailed mechanism of a 
compounds interaction with that transporter can be elucidated, but the assay gives no 
information on whether that interaction will occur in humans or how it affects a drugs 
disposition or metabolism. More complex systems are evidently needed but a decrease in 
throughput follows increasing complexity, while animal studies may be impacted by 
species and sex differences.
Evidently, no single assay wül give all the information required and so a thorough 
understanding of the biological basis of assays should be sought to enable the correct 
choice of assay to be made and wiU aid the correct interpretation of the data. For 
extrapolation of preclinical studies on transporters this means a better understanding of 
which transporters are expressed in the assays used and how they compare to the animal 
and/or human they are modelling.
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1.4 Aims and Objectives
The expression of drug transporters affects the disposition of molecules within the body. 
The hypothesis of this work is that aberrant expression of drug transporters in cell lines 
may affect predictions of ADME and toxicology parameters made during pre-clinical in 
vitro studies. The aim is therefore to quantitatively assess if different cellular assays affect 
dmg disposition and metabolism due to drug transporter expression and this will be 
achieved through a number of objectives:
• First, by measuring the expression of a number of drug transporters in human 
derived cell lines and assessing if influx transporter expression affects compound 
access into cells.
• Second, by measuring the expression of a similar set of transporters in rat 
hepatocytes cultured in either monolayers or in sandwich culture for up to seven 
days. The cells will also be dosed with PXR and PPARa agonists to assess the 
effect on drug transporter expression in the two types of culture.
• Finally, the cellular disposition of a compound through an hepatocyte wül be 
simulated by designing a simple in silico model from literature data on transporter 
kinetics in order to assess compound disposition under different assay conditions 
as measured in the second section of work.
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2 Materials and Methods
2.1 Materials
2.1.1 General Materials
Unless otherwise mentioned in Table 2-2 all chemicals and materials were purchased 
from Sigma-Aldrich (Dorset, UK) and were of molecular biology standard.
2.1.2 Cells
Huh7 cells were a kind gift from Dr Steve Hood (GSK, Ware, UIQ. HepG2 (ECACC 
85011430) and Caco2 (ECACC 86010202) cells were purchased from ECACC (Porton 
Down, UIQ. AstraZeneca (Alderley Park, Macclesfield, UK) supplied samples of wild 
type HEK cells and HEK cells stably transfected with ABCG2 as well as wildtype 
MDCKII cells or MDCKII cells transfected with ABCBl.
2.1.3 Human Liver Samples
Three samples of human liver RNA were purchased from commercial suppliers. Clinical 
details of the donors are given in Table 2-1.
Sample Supplier Age (years) Sex Clinical Notes
1 Ambion (Huntington, UK) 39 Male Methadone overdose
2 Stratagene (Amsterdam, 
Holland)
45 Male Normal margin to 
trabecular carcinoma
3 Stratagene (Amsterdam, 
Holland)
55 Female None
Table 2-1 Donor details for human liver RNA samples.
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2.1.4 Rat Liver Samples
Freshly isolated Flans-Wistar rat liver was supplied by AstraZeneca for the preparation of 
primary hepatocytes, RNA and protein. Samples of Sprague-Dowley liver and 
hepatocyte cDNA were kindly supplied by Dr. Kate Plant (University of Surrey).
2.1.5 Plasmids
Maps of the plasmids used in this project are shown in appendix 9.2. PXR-pSG5 was a 
gift from Dr Steven Kliewer (GlaxoSmithKline, Research Triangle Park, NC, USA). The 
SEAP-Basic plasmid was purchased from BD Biosciences (Oxford, UIQ. Several 
SEAP constructs have been used in this work and were cloned by previous members of 
the group; CYP3A4-XREM-pSEAP (Hamzeiy et al., 2003), ABCBl-pSEAP (Mrs 
Fadheela Salman) and Abcc2-pSEAP (Miss Ana Sousa Marcelino).
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Item Supplier
PCR and Sub-Cloning
Reverse-iT MAX RTase Blend (cDNA synthesis) 
Prime STAR DNA Polymerase 
Restriction enzymes, DNase I and buffers 
Agarose
DNA MightyMix (T4 Ligase)
DH5a E.coli competent bacteria cells 
Bacterial agar, Tryptone, Yeast extract
ABgene (Epsom, UK) 
Cambrex (Nottingham, UK) 
Promega (Southampton, UK) 
Fisher (Loughborough, UIQ 
TaKaRa Bio Inc. (Otsu, Japan) 
Invitrogen (Paisley, UK)
Oxoid Ltd (Basingstoke, UK)
CeU Culture
Cell culture medium, trypsin-EDTA and medium 
additives
CoUagenase A, FuGENE 6 and LDH Assay Kit 
Matrigel
Lipofectamine RNAiMAX 
siRNA
Phospha-Light Secreted Alkaline Phosphatase 
Chemiluminescent Reporter Gene Assay Kit and 96 
well Optiplates 
CDFDA
Invitrogen GIBCO (Paisley, 
UK)
Roche (Lewes, UK)
BD Bioscience (Oxford UK) 
Invitrogen (Paisley, UIQ 
Ambion (Huntington, UK) 
Applied Biosystems (Foster 
City, LA, USA)
Invitrogen (Paisley, UK)
Quantitative RT-PCR
RNA isolation (RNeasy minikit), RNALater and DNA 
purification (Mini and maxi preps)
Disposable RNase/DNase free pipette tips
dNTP’s, random hexamers, DTT, RNAse OUT, 
Superscript II (and buffers), genomic DNA (rat and 
human)
TaqMan Universal PCR Master Mix, 96 well white 
optical plates, optical adhesive covers 
TaqMan Probes (FAM-TAMRA) and Primers
Qiagen (Crawley, UK)
Alpha Laboratories 
(Hampshire, UK) 
Invitrogen (Paisley, UIQ
Abgene (Epsom, UK)
MWG Biotech (Ebersberg, 
Germany)
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Protein Analysis
Protease Inhibitor Tablets Roche (Lewes, UK)
BCA Protein Assay Kit Pierce (Rockford, IL, USA)
Bis-acrylamide stock solution 2% w/v VWR (Lutterworth, UK)
Acrylamide stock solution 40% w /v VWR (Lutterworth, UIQ
MagicMark Western Protein Standard Invitrogen (Paisley, UIQ
Immobüon-P PVDF membrane MiUipore (Watford, UK)
Chemiluminescent HRP Reagent GE Healthcare
(Buckinghamshire, UK)
Table 2-2 Suppliers of specialist materials used in this work
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2.2 Methods
2.2.1 Polymerase Chain Reaction
The polymerase chain reaction (PCR) was used to amplify the human SLCOIBI gene 
with specific primers so that it could be cloned into an expression vector.
2.2.1.1 Primer Design
Primers were designed to amplify the coding region of SLCOIBI (Table 2-3) using 
Vector NTI 4.0 (Invitrogen, Paisley) and the SLCOIBI sequence from the NCBI 
(National Centre for Biotechnology Information) database. Parameters for primer 
design were set at 40-60 % GC content, a T^ of 50 °C to 65 °C and between 20 to 25 
nucleotides in length. A single mismatch mutation was introduced in the forward 
primer at 120 bp (T"^C) to produce an Ncol restriction site. Primers were resuspended 
in 0.1 % Tris-EDTA (TE) buffer to a stock concentration of 100 pmol/pl and stored at 
minus 20°C.
Position in 
sequence
Forward/Reverse Sequence
SLCOIBI 120 Forward 5’ -  ATC TAT ATT TCA ACC ATG GAC CAA -  3’
SLCOIBI 2246 Reverse 5’ -  GAA ACA CTC GAG CAG AAG TG G  -  3’
Table 2-3 Forward and reverse primer pairs for amplification o f SLCOIBI.
The underlined region shows the Ncol restriction site where a single mutation (T-^C; in bold) 
was introduced to the forward SLCOIBI primer.
2.2.1.2 cDNA Synthesis for SLCOIBI PCR
In order to amplify the coding region of SLCOIBI, cDNA was produced from human 
liver RNA using the SLCOIBI reverse primer (Table 2-3); 2 pmol of reverse primer was 
added to 5 pg adult human liver total RNA and 0.83 mM dNTP mix (from a 10 mM 
stock of dATP, dGTP, dCTP and dTTP) and heated to 65 °C for 5 minutes. After being 
cooled on ice this was added to 22.2 % 5x RT buffer, 5.6 pM DTT and 5.6 % Reverse iT 
MAX RTase blend, which was heated at 47 °C for 50 minutes.
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2.2.1.3 Polymerase Chain Reaction
PCR was initially optimised using Taq Polymerase, however for cloning procedures PCR 
was carried out using a high fidelity polymerase called Prime STAR to reduce the 
potential for mutations caused by PCR. Volumes used in the PCR with Taq Polymerase 
and Prime STAR are shown in Table 2-4 and Table 2-5 respectively.
Reagent Volume (pi) Working Concentration
Taq Polymerase (5 U /pi) 0.6 0.06 U / pi
Primers (10 pmol/pi) 1 .2  (1 :1  primer pair mix) 0.2 pM
dNTP (10 mM) 1 .2 0.25 mM
Buffer (10 x) 6 1 .2  X
BSA (100 x) 1 2 .1  X
cDNA or genomic DNA 2.5
Water 36
Table 2-4 Volumes of reagents used in PCR using Taq Polymerase
Reagent Volume (pi) Working Concentration
Prime STAR Polymerase 0.5 0.06 U / pi
Primers (10 pmol/pi) 1.25 (1:1 primer pair mix) 0.25 pM
dNTP 4 0.8 mM
Prime STAR buffer (10 x) 10 2 x
cDNA or genomic DNA 1
Water 33
Table 2-5 Volumes of reagents used in PCR using Prime STAR polymerase
The PCR was carried out in a PTC-200 DNA Engine (MJ Research, Waltham, MA, 
USA). Reactions were heated to 98 °C for 10 seconds and then 35 cycles of 98 °C for 10 
seconds, 55 °C for 15 seconds, 72 °C for 3 minutes and finally 72 °C for 10 minutes.
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2.2.1.4 Agarose Gel Electrophoresis of DNA
A 1 % agarose gel (w/v) in 1 x TAB (0.04 M Tris acetate, 0.01 M EDTA) containing 0.5 
pg/mg ethidium bromide, was used to separate DNA. The DNA was mixed with 5 x 
Orange G loading dye (0.25 % Orange G, 50 % glycerol) in a 5:1 ratio DNA:Orange G 
and loaded onto the gel. Bands were visualised using the Gene Genius Bio Imaging 
System (Syngene, Cambridge, UK) and compared to an appropriate molecular weight 
marker. The concentration of DNA was calculated using the NanoDrop 
spectrophotometer (NanoDrop Technologies, Delaware USA). DNA was stored at 
minus 20 °C for up to one month.
2.2.1.5 Phenol Chloroform Extraction and Ethanol Precipitation
Phenol chloroform was used to extract enzymes and buffers from the DNA, which was 
precipitated with ethanol. The PCR products were diluted to 100 pi in TE buffer and an 
equal volume of phenol chloroform (1:1 v/v, pH 7.4) was added and vortexed to mix. 
The sample was spun for 5 minutes at 13000rpm in a bench top centrifuge and the 
aqueous layer, which contained the nucleic acids, was removed from the organic layer 
containing the proteins and buffer salts. Three volumes of ice-cold 100% ethanol, 0.1 
volumes 3 M sodium acetate and 1 pi of tRNA (10 mg/ml) were added to the aqueous 
layer and this was spun for 15 minutes at 13000 rpm before the supernatant was 
removed. The pellet was washed with 70 % ethanol and allowed to air dry for 15 
minutes before being resuspended in 10 mM Tris, pH8. Success of extraction was 
checked by visualisation of a 1:10 dilution of the extract on a 1 % agarose gel containing 
ethidium bromide as described in section 2.2.1.4. DNA was stored at minus 20 °C.
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2.2.2 Sub-Cloning Techniques
The SLCOIBI PCR product was ligated into an expression vector, which was then 
amplified after transformation into bacterial cells. Vector DNA was isolated in 
endotoxin free preparations for use in mammalian systems.
2.2.2.1 Ligation
The product from the PCR was ligated into pTriExl.l, an overexpression vector, which 
allows overexpression of the ligated gene in cells that the vector is transfected into. First, 
the vector and the PCR product were digested to produce compatible ends for ligation. 
The insert was digested with the relative enzymes in 10 x buffer at 37 °C overnight while 
the vector was digested with corresponding enzymes at 37 °C for 2 hours. Once 
digested, the vector was phosphatased to prevent vector religation; phosphatase buffer 
(10 x) and 10 units of alkaline phospahtase were added to the digest, which was 
incubated at 37 °C for 30 minutes. Ten more units of alkaline phosphatase were added 
and the incubation repeated. Inserts and vectors were extracted with phenol chloroform 
and precipitated with ethanol (section 2.2.1.5).
A 3:1 ratio of insert to phosphatased vector was added to an equal volume of DNA 
Mighty Mix, a T4 DNA ligase. In addition, a vector control was set up where water 
replaced the insert. The samples were incubated at 16 °C for 30 minutes before being 
stored at minus 20 °C.
2.2.2.2 Transformation of Bacteria
In order to produce large quantities of the plasmid DNA, the plasmid with ligated insert 
was transformed into competent E. coli DH5a. These cells contain mutations making 
them suitable for transformation of plasmid DNA; first, they contain a recAl mutation, 
which reduces the occurrence of unwanted recombination in the cloned DNA; second, 
they contain an endAl mutation, which eliminates non-specific digestion by 
endonuclease so allowing clean preparations of DNA to be made. Competent DH5a 
cells were stored in 50 pi aliquots at minus 80 °C.
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Approximately 2 ng of the plasmid containing the insert or empty plasmid (vector 
control) was added to 50 pi of competent E. coli DH5a cells, incubated on ice for 30 
minutes to allow DNA to enter cells, followed by immersion in a waterbath at 42 °C for 
45 seconds to heat-shock cells. To each sample, 450ul of LB broth (0.17 M NaCl, 0.5 % 
yeast and 1 % tryptone) was added and samples were incubated for 1 hour at 37 °C. The 
cells were spun at 7000 rpm in a bench top centrifuge for 1 minute and resuspended in 
100 ul of LB broth. This was spread on an LB agar plate (LB broth plus 1.5 % bacto- 
agar) containing ampicilHn (50 mg/ml) and grown overnight at 37 °C. Single colonies 
were selected and grown in 5 ml of LB broth at 37 °C overnight with shaking.
2.2.2.3 Mini Preparation of Plasmid DNA - Alkaline Lysis Method
Plasmid DNA was first isolated from bacterial cultures using the alkaline lysis method to 
allow rapid screening for the presence of inserts. One millilitre of bacterial culture was 
centrifuged for 5 minutes at 13000 rpm in a bench top centrifuge and the pellet was 
resuspended in 100 pi solution 1 (50 mM glucose, 25 mM Tris-HCl pH 8, 10 mM 
EDTA). To this, 200 pi of solution 2 (0.2 M NaOH, 1 % SDS) was added followed by 
150 pi solution 3 (3 M KG Ac in glacial acetic acid). The mixture was centrifuged at 
13000 rpm for 5 minutes and the aqueous layer was removed and added to 800 pi 
ethanol. This was centrifuged for a further 5 minutes at 13000 rpm and the pellet was 
washed in 70 % ethanol before being air dried and resuspended in 50 pi TE.
2.2.2.4 Diagnostic Restriction Digest
One microgram of DNA was added to the appropriate buffer and 10 units of each 
enzyme to a final volume of 15 pi. This was incubated at 37 °C for 1-2 hours before 
being separated on a 1 % agarose gel containing ethidium bromide (section 2.2.1.4) at 4-5 
V/cm for 15 minutes. Fragment size was determined by comparison to an appropriate 
molecular weight marker, and compared to the predicted digest given by Vector NTI 4.0.
2.2.2.5 Mini Preparation of Plasmid DNA - Qiagen Method
Plasmid DNA confirmed to contain the insert, was isolated from the bacterial culture 
using a Qiagen miniprep kit. Briefly cells were spun into a pellet and lysed under alkaline 
conditions. Protein was removed by precipitation and the supernatant added to a
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Miniprep column in high salt buffer, causing the DNA to bind to the silica-gel 
membrane. This was washed to remove contaminants and eluted in low-salt TE buffer.
2.2.2.6 Sequencing
Sequencing was carried out using a Beckman Coulter 2000XL by Dr Kate Plant using a 
CEQ 2000 Dye terminator cycle sequencing kit (Beckman Coulter, High Wycombe, 
UK). The SLCOIBI insert was sequenced from 200 ng DNA, which was heated to 96 
°C for 3 minutes and cooled before the kit dNTPs were added. Thirty cycles of 96 °C for 
20 seconds, 50 °C for 20 seconds and 60 °C for 4 minutes were preformed to 
incorporate 3’ dye-labelled dideoxynucleodde triphosphates carrying four different 
fluorescent dye labels into the insert. The insert was extracted and separated by capillary 
electrophoresis and detected via fluorescence emission.
2.2.2.7 Endotoxin-Free Preparation of Plasmid DNA
Once the colony selected for the 5 ml culture was confirmed to contain the plasmid 
DNA, larger quantities of endotoxin free DNA were produced, which could be safely 
transfected into cells. The Qiagen Midiprep or Maxiprep kits were used to produce 
endotoxin free DNA; briefly, 50 pi of the 5 ml culture was added to 100 ml (Midi) or 200 
ml (Maxi) LB broth containing 25 ug/ml ampiciUan and incubated at 37 °C overnight 
with shaking. Cells were spun to form a pellet and lysed before the protein was 
precipitated. The supernatant was added to a Midiprep or Maxiprep column in high salt 
buffer, causing the DNA to bind to the silica gel membrane. This was then washed and 
eluted in low-salt TE buffer. Another restriction digest (section 2.2.2.4) was repeated at 
this stage to ensure the bacteria had not lost the plasmid DNA.
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2.2.3 Cell Culture of Immortalised Cell Lines
2.2.3.1 Huh? CeU Culture
Huh? is a differentiated immortalised ceU line from human hepatoma tissue 
(Nakabayashi et al., 1982). CeUs were cultured in Dulbecco’s modified eagle medium 
(with L-glutamine and phenol red unless stated otherwise) containing 10 % (v/v) foetal 
bovine serum (FBS), 1 % (v/v) non-essential amino acids (NEAA), 100 U/ml penicillin 
and 100 pg/ml streptomycin.
2.2.3.2 Hep G2 CeU Culture
Hep G2 is a differentiated immortaUsed ceU line from human hepatoma tissue (Aden et 
al., 1979; Knowles et al., 1980), which have been shown to maintain some aspects of Hver 
function and metaboHsm (Dawson et al., 1985; Javitt and Budai, 1989). CeUs were 
cultured in modified eagle medium (with L-glutamine and phenol red) containing 10 % 
(v/v) FBS, 1 % (v/v) non-essential amino acids (NEAA), 100 U/ml penicillin and 100 
[xg/ml streptomycin.
2.2.3.3 Caco2 CeU Culture
Caco2 is a differentiated immortaUsed ceU line from human adenocarcinoma tissue 
routinely used to assess intestinal permeabUity of new compounds (Fogh et al., 1977; 
Ffidalgo et al., 1989). CeUs were cultured in modified eagle medium (with L-glutamine 
and phenol red) containing 10 % (v/v) FBS, 1 % (v/v) NEAA and 50 pg/ml 
gentamycin.
2.2.3.4 Recovery of CeUs from Liquid Nitrogen
CeUs were stored in Uquid nitrogen in freezing medium (91 % FBS and 9 % dimethyl 
sulfoxide (DMSO)) at a concentration of approximately 1x10*" ceUs/ml. CeUs were 
recovered by thawing at 37 °C, in a water bath, for 90 seconds before being added to 10 
ml of warm medium. The ceUs were centrifuged at 1000 g for 5 minutes and 
resuspended in 10 ml fresh medium. FinaUy, the ceU suspension was transferred to a 25
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cm  ^vented tissue culture flask and incubated at 37 °C with 5 % CO^. The medium was 
replaced after 24 hours to remove any non-adherent cells.
2.2.3.5 Cell Maintenance
Cells were passaged when they reached approximately 90 % confluence. The medium 
was removed and the cells washed with phosphate buffered saline (PBS). The cells were 
incubated at 37 °C with 2 ml 1 x trypsin-EDTA for 5 minutes. Ten millilitres of medium 
was added to inactivate the Trypsin-EDTA and the cell suspension was split between 
new 75 cm  ^vented cell culture flasks. The exact ratio of cell splitting was dependent on 
both the cell type and the experimental requirement, and varied between 1:2 and 1:6; at 
no time were cells split to produce a confluence below 20 %. In addition, to ensure 
phenotypic consistency throughout experiments, each cell line was only used for a fixed 
number of passages after recovery from liquid nitrogen: Huh7 cells were used up to 12 
passages after receipt. Samples for RNA analysis were taken from other cell lines 
between passage 5 and 10 after receipt.
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2.2.3.6 Transfection of Cells with DNA and RNA
Mammalian cells were transfected with vector DNA prepared using the techniques 
described in sections 2.2.1 and 2.2.2, in order to overexpress SLCOIBI or a reporter 
gene. Small interfering RNA (siRNA) was transfected into cells to knockdown 
SLCOIBI.
2.2.3.6.1 Transfection of DNA
Transfection of Huh? cells with DNA was performed in 96-well tissue culture plates to 
allow greater number of experiments to be performed than would be possible in tissue 
culture flasks. Once cells had reached approximately 90 % confluency in tissue culture 
flasks, they were trypsanised as described in section 2.2.3.S. Once DMEM had been 
added to neutralise the trypsin, cells were counted using a haemacytometer and diluted 
with DMEM to give a final concentration of 10^  cells/ml. One hundred microlitres of 
the diluted cells were added to each well of a 96-weU plate, which was placed in a 
humidified chamber to prevent evaporation of cell culture medium. The chamber was 
incubated at 37 °C, 5 % CO2  overnight to allow attachment of cells to the plate surface.
DNA transfection into Huh? cells took place 24 hours after plating, when cells were at 
approximately 90 % confluence. FuGENE 6 transfection reagent was used to transfect 
DNA into cells. FuGENE is a multi-component lipid-based transfection reagent that 
complexes with plasmid DNA and transports it into cells. In order for the lipid-DNA 
complex to interact with and pass through the negatively charged cell membrane, a net 
positive charge must exist in the Hpid-DNA complex. Therefore the positive charge 
contributed by the cationic lipid must exceed the negative charge of the DNA. A charge 
ratio of 6:2 FuGENE:DNA (100 ng/ul) was found to be optimal in pilot studies.
FuGENE was added to DMEM containing no FBS according to the FuGENE protocol. 
DNA was then added and left to equilibrate for 30 minutes before DMEM containing 10 
% stripped FBS was added. Medium was aspirated from the each well and replaced with 
the stripped serum medium containing the FuGENE:DNA complex. The plate was 
returned to the incubator in a humidified chamber and incubated at 37 °C with 5 % CO2 .
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2.2.3.6.2 Transfection of Small Interfering RNA
Transfection of small interfering RNA (siRNA) into cells results in the reduction of 
protein expression as the siRNA molecules bind the corresponding mRNA preventing 
translation of the protein. This technique is known as interference RNA (RNAi).
Unlike the transfection of cells with DNA, transfection of siRNA takes place at the same 
time as the cells are plated; 1% (v/v) of the transfection reagent, Lipofectamine 
RNAiMAX, was added to Opti-MEM medium and allowed to equiHbriate, before 
SLCOIBI knockdown and control siRNA (20 nM) were added. Following a 15 minute 
incubation at room temperature, 20 ul of the mixture was added to each well of a 96 well 
plate. Eighty microHtres of Huh7 cells in suspension (1 x 10^  cells per ml) were added to 
each well and the plate was incubated at 37 °C with 5 % COg for 24 hours in a 
humidified chamber. CeUs were transfected with DNA as normal the foUowing day 
(section 2.2.3.6.1).
2.23.1 Treatment of CeUs with Xenobiotics
Twenty four hours after transfection of DNA Huh7 ceUs were dosed with medium 
containing either the vehicle control (0.1 % DMSO (LeCluyse, 2001)) or xenobiotic. 
Stock solutions of compounds were made at 100 mM in DMSO, which were dUuted with 
DMSO to produce lower concentration stock solutions as required. Working solutions 
were generated by dUuting stock solutions 1:1000 in DMEM containing 10 % (v/v) 
stripped serum FBS, so maintaining DMSO at 0.1%. CeUs were exposed to xenobiotic 
or vehicle control for 48 hours. Medium was saved for analysis in the reporter gene 
assay both before (pre-dose) and after (post-dose) ceUs were exposed to xenobiotic. 
Post-dose medium was also analysed for indications of ceU death by measuring LDH 
release from ceUs.
2.2.3.7.1 Reporter Gene Assay
The pSEAP2-basic vector contains a reporter gene for secreted alkaUne phosphatase 
(SEAP) with no heterologous promoter upstream. Therefore, when a regulatory region 
of interest is cloned into the vector, it is the sole controlling element of SEAP 
transcription. Expressed SEAP protein contains a secretory tag, and is hence secreted 
from ceUs into the medium, from where it can be quantified; SEAP metabolises the 
substrate luminol, producing light, which can be measured and is direcdy proportional to
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the activation of the promoter. Therefore this acts as a measure of promoter activation 
or repression.
Secreted Alkaline Phophatase activity was measured using the Phospha-Light 
Chemiluminescent Reporter Gene Assay Kit; briefly, the method involved destroying the 
endogenous alkaline phosphatase activity in the cell medium by heating it with buffer at 
65 °C for 30 minutes followed by rapid cooling on ice for 2 minutes. As SEAP has been 
engineered to be heat-stable it is not damaged by this procedure. Assay buffer was then 
added to each well and incubated at room temperature for 5 minutes. The 
chemiluminescent substrate was added and incubated for a further 20 minutes at room 
temperature before chemiluminescence was read in a Lumicount II plate reader (Packard 
Instrument Co. Inc., Ramsey, MN, USA). Data was analysed using Plate Reader (version 
2.10) software.
For analysis, ‘post-dose’ data was first normalised against the ‘pre-dose’ data on a well-to- 
weU basis to compensate for differential transfection efficiency or plating number in 
individual wells. Next, non-insert effects were removed by deducting the mean 
background activity of the blank pSEAP2 basic plasmid from the alkaline phosphatase 
activity of the pSEAP construct containing the promoter of interest. Finally, the mean 
effect of compound was derived as the fold-change relative to vehicle control.
2.2.3.8 Assessment of Cell Death using the LDH Assay
An important control whenever cells are dosed with a potentially toxic chemical is to 
ensure that the concentration used does not lead to unacceptably high levels of cell 
death; this is achieved through measuring lactate dehydrogenase (LDH) activity in 
medium. LDH is a cytosolic enzyme that is only released into the medium following 
cellular membrane damage. Medium was taken from cells treated with xenobiotics and 
the amount of LDH quantified in order to assess the level of cell death under certain 
conditions. The LDH level was quantified using the LDH assay kit (Roche Diagnostics 
Ltd., Lewes, UIQ; briefly, medium from treated cells was added to an equal volume of 
the kit reagents (1:45 bottle 1 : botde 2) in a 96 well ELISA plate and left, protected from 
light, at room temperature for 30 minutes. The plate was then read at 490 nm in an 
ELISA plate reader (BioTEK ELxSOO). Results were adjusted for background and 
compared to a positive control of cells lysed in 2 % triton-X 100.
70
2.2.4 Culture of Primary Rat Hepatocytes
All preparation and dosing of primary rat hepatocytes were undertaken within the 
DMPK facilities of AstraZeneca, Alderley Park, UK.
2.2.4.1 Preparation of Sandwich Cultured Primary Rat Hepatocytes
Freshly isolated rat liver was obtained in ice-cold saline from Han-Wistar rats of 
approximately 300 g in weight. Only male rats liver was used in order to reduce variation 
in expression of drug transporters between the sexes (Rost et al., 2005). The right 
median and left median lobes were taken for perfusion and placed on a plastic grid over 
the perfusion chamber, which consisted of a hollow chamber with an integral water 
jacket to keep the Hver warm during perfusion. Cannulae connected to the buffer 
reservoirs were inserted into the blood vessels of the lobes and buffer warmed to 40 °C 
was perfused through the Hver.
The tissue was perfused with general buffer (1 x Hanks balanced salts solution (HBSS; 
without Ca^ "^ , Mg^  ^ or phenol red) with 0.03 % (w/v) NaHCO^ and 0.3 % (w/v) 
HEPES, adjusted to pH 7.4) for 10-15 minutes, foUowed by perfusion with digestion 
buffer (general buffer with 0.5% (v/v) 1 M CaClg, 0.05 % (w/v) coUagenase A and 0.007 
% trypsin inhibitor) for a further 10-15 minutes.
At the end of the digestion the Hver was transferred to a petri dish containing 
centrifugation buffer (general buffer with 0.01 % (w/v) DNase) and the capsule was 
broken with sharp tweezers to aHow the ceUs to be released into solution. The solution 
was filtered fine nylon mesh to remove undigested Hver.
The filtered ceUs were centrifuged for 3 minutes at 20 x g. The supernatant was removed 
and the ceHs resuspended in centrifugation buffer. The centrifugation was repeated and 
the ceUs were resuspended in general buffer before being centrifuged at 50 x g for 3 
minutes at 4 °C. The supernatant was removed and the ceUs resuspended in attachment 
medium cooled to 4 °C (AM; WilHams E medium, 100 U/ml penicilHn, 100 [xg/ml 
streptomycin, 10 % (v/v) FBS, 0.17 |iM insuHn, 0.03 pM dexamethasone, 50 pg/ml 
gentamycin and 1 % (v/v) 1 M Hepes). The centrifugation at 50 x g for 3 minutes at 4 
°C was repeated six times with the ceUs resuspended in fresh 4 °C AM after each spin.
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Following the centrifugation steps, dead cells were removed by centrifugation through 
percoU. The cell suspension was layered on top of 25 ml percoU (percoll with 0.4 % 
(v/v) HCl and 10 % (v/v) 10 x HBSS) and inverted to mix before being centrifuged at 60 
X g for 10 minutes at 4 °C. The supernatant was removed and the cells resuspended in 
AM before being spun at 30 x g for 3 minutes at 4°C. The spin was repeated with fresh 
AM. Cells were counted using a haemacytometer and the concentration adjusted to 
approximately 0.5 million per ml. Two point five millilitres of the cell suspension was 
added to each well of collagen I coated 6 well plates and incubated at 37 °C, 5 % COg in 
a humidified incubator for 1 hour.
For cells cultured in sandwich culture, matrigel was thawed on ice and diluted to 250 
ug/ml in basement medium cooled to 4 °C (BM; Williams E medium, 100 U/ml 
penicillin, 100 pg/ml streptomycin, 0.17 pM insulin, 0.03 pM dexamethasone, 50 pg/ml 
gentamycin and 1 % (v/v) 1 M Hepes). Medium was removed from cells attached to the 
6 well plates and replaced with 2.5 ml BM-matrigel. For cells cultured in monolayers, 
AM was removed and replaced with cold BM. The cells were incubated at 37 °C, 5 % 
CO2  in a humidified incubator overnight and medium was changed every 24 hours with 
fresh BM.
2.2.4.2 Treatment of Rat Hepatocytes with Xenobiotics
During dosing studies, hepatocytes were exposed to 50 pM dexamethasone, cyproterone 
acetate (CPA), Wy-14,643 or vehicle control (0.1% DMSO) in basement medium (BM) 
24 hours after plating. Every 24 hours medium was changed to fresh BM containing the 
respective compound. At 0, 12, 24, 48, 72 and 96 hours samples of cells (in triplicate) 
were taken for analysis of RNA expression levels.
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2.2.4.3 Carboxydichlorofluroscein Diacetate Assay
The carboxydichlorofluroscein diacetate (CDFDA) assay was carried out using sandwich 
cultured rat hepatocytes, in order to measure efflux via the biliary drug transporter 
Abcc2. CDFDA is hydrolysed to carboxydichlorofluroscein (CDF) in cells and effluxed 
via Abcc2 into büe canaliculi, which are formed when primary hepatocytes are sandwich 
cultured. CDF is a fluorescent molecule aUowing measurement of efflux via a 
fluorescent endpoint.
CDFDA was reconstituted in DMSO to give a 10 mM stock solution. This in turn was 
düuted to give lower concentration stock solutions as required: Working solutions were 
generated by düuting these stock solutions 1:1000 in HBSS to maintain the amount of 
DMSO in the solution at 0.1 %. DMSO at 0.1 % in HBSS was used as vehicle control.
Medium was aspirated from ceUs and they were washed with HBSS. This wash was 
repeated and the ceUs were returned to the incubator for 10 minutes covered in HBSS. 
After removal of the HBSS, the appropriate working solution of CDFDA was added to 
the ceUs, which were incubated at 37 °C, 5 % COg for 5 to 40 minutes depending on the 
experiment (see results for detaüs). CeUs were washed three times with HBSS and an 
image was taken at 10 x magnification using as Axiovert 200 microscope. During 
imaging ceUs were exposed to fluorescence at 480 nm using a FITC filter for 2 seconds. 
A phase contrast image was taken of the same area of cells. Images were taken using an 
AxioCam MRm Rev digital camera connected to the microscope.
2.2.4.3.1 Inhibition of CDF Efflux
During inhibition experiments, 10 pM of CDFDA was added to cells along with 
increasing concentrations of pravastatin or MK571 (0 -  300 pM). Drug solutions were 
made as described for CDFDA (section 2.2.4.3) so the concentration of DMSO could be 
maintained at 0.1 %. CeUs were incubated for 25 minutes before washing and imaging 
as stated in section 2.2.4.3.
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2.2A.3.2 Digital Image Processing of CDF Fluorescence
The fluorescent images produced from the CDFDA assay were analysed using the 
Axiovert 4.5 software. An area was defined on each image using a circle and the density 
of fluorescent pixels within that area measured. The area of the circle was constant 
within each experiment. An example of the images produced and the circular 
measurement tool is shown in Figure 2-1. Fluorescence within bile canaliculi is due to 
effluxed CDF but dead cells also exhibit fluorescence and can be observed as rounded 
areas of fluorescence. Wherever possible large areas of dead cells were avoided in the 
analysis.
2.2.4.4 CDFDA Conversion to CDF in HBSS
To measure the conversion rate of CDFDA to CDF in HBSS, stocks of CDFDA over a 
concentration range of 0 — 20 mM were prepared in DMSO and diluted 1:1000 in HBSS. 
One hundred microlitres of each dilution was added to a 96 well plate in triplicate. The 
fluorescence was measured (À,ex = 485 nm; Xem = 590 nm) from the plate over 1 hour 
with readings every 2 minutes in a Molecular Dynamics SpectraMax plate reader. The 
fluorescence was compared to a CDF standard curve over 0 — 20 pM in HBSS.
2.2.4.5 Diffusion of CDF into Octanol
The rate of diffusion of CDF into octanol from HBSS was measured to estimate if CDF 
could passively diffuse across cell membranes. CDF over a concentration range of 0 -  
20 mM was diluted 1:1000 in HBSS and vortexed with an equal volume of octanol. 
When the octanol and HBSS had separated, aliquots were taken of both fractions (in 
triplicate) and the fluorescence measured (Àex = 485 nm; lem  = 590 nm). The 
fluorescence was compared to a CDF standard curve over 0 — 20 pM either in HBSS or 
octanol.
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Figure 2-1 Example images o f primary rat hepatocyte cultures taken through a 
fluorescent filter (A) or by phase contrast (B).
Hepatocytes were incubated with 10 [jlM  CDFDA for 30 minutes, washed with HBSS and 
exposed to fluorescence via a FITC filter (485 nm) on an Axiovert 200 microscope for 2 seconds 
before images were taken (A) with an AxioCam MRm Rev digital camera. The corresponding 
phase contrast image is shown (B). Images show scale and the circular measurement tool within 
which fluorescence was measured. In the fluorescent image, fluorescence is due to CDF 
accumulation within the bile canaliculi o f the hepatocytes, although round areas of fluorescence 
are due to dead cells.
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2.2.5 Characterisation of Liver and Cells at the RNA Level
The expression of proteins is normally, although not always, regulated at a transcriptional 
level. Therefore the amount of a particular mRNA wiU give an estimate of the 
expression level of the corresponding protein. In this study RNA levels of drug 
transporter genes were measured by quantitative RT-PGR in human and rat liver, primary 
hepatocytes and tlie cell lines mentioned in section 2.2.3, in order to compare expression 
between cells used in in vitro ADME screening and liver.
2.2.5.1 Sample Collection
Samples of freshly isolated rat liver (approximately 0.1 g) were homogenised in a glass 
homogeniser with lysis buffer from the RNeasy minikit. Samples of human Hver total 
RNA from three different donors, were obtained at a concentration of 1.1 pg/pi.
Medium was aspirated from adherent cells, which were washed with PBS and either lysed 
directly with lysis buffer on cell culture plates or flasks, or removed from cell culture 
plates in RNALater. Samples in RNALater were stored at minus 80 °C for up to 6 
months before isolation. Once defrosted samples were spun at 13000 rpm in a bench 
top centrifuge for 15 minutes at 4 °C to pellet the cells. RNALater was removed and the 
cells lysed with lysis buffer.
2.2.B.2 RNA Isolation
RNA was isolated using the RNeasy mini kit procedure; Following lysis, ceU were 
homogenised before being applied to a silica-gel based membrane, which binds RNA of 
>200 nucleotides in the presence of ethanol. The RNA was washed three times to 
remove contaminants before being eluted in 60 pi water. The concentration of RNA 
was calculated using the NanoDrop spectrophotometer (NanoDrop Technologies, 
Delaware USA) and was stored at minus 80 °C for up to 6 months prior to analysis.
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2.2.5.3 Removal of contaminating DNA with DNasel
Five micrograms of total RNA was added to 10 % (v/v) DNase buffer and 10 units of 
DNase I. The mixture was incubated at 37 °C for 30 minutes after which 2 mM EGTA 
was added and the mixture was heated to 65 °C for 10 minutes.
2.2.5.4 Reverse Transcriptase cDNA Synthesis
One microgram of the DNased RNA was added to 1.25 mM dNTP’s and 225 ng 
random hexamers. The reaction was heated to 65 °C for 5 minutes and cooled on ice. 
The reverse transcriptase reaction mixture (50 % (v/v) 5x RT buffer, 25 mM DTT, 12.5 
% (v/v) RNase OUT, 3.125 % (v/v) Superscript II) was added and incubated for the 
following cycle: 10 minutes at 25 °C, 50 minutes at 42 °C, 15 minutes at 70 °C. A 
control containing no superscript II (RT minus) was included for all reactions, as this 
allowed for the control of contaminating genomic DNA in samples: Quantitative analysis 
of RT minus samples showed negligible levels of genomic DNA contamination. 
Generated cDNA was stored at minus 20 °C for a maximum of 1 month prior to analysis
2.2.5.5 Quantitative Reverse Transcriptase Polymerase Chain Reaction
Five microlitres of cDNA was added to 20 pi of the real time Reverse Transcriptase - 
Polymerase Chain Reaction (RT-PGR) reaction mixture (10 pmol forward primer, 10 
pmol reverse primer, 2.5 pmol probe, 62.5 % (v/v) 2 x TaqMan Universal PGR 
MasterMix in a white 96 well optical reaction plate sealed with an optical adhesive cover. 
Sequences of TaqMan probes and primers are given in Table 2-6 and Table 2-7. The 
plate was centrifuged at 1000 x g for 1 minute to collect the reaction mixture at the 
bottom of the wells. The plate was then cycled in an ABI Prism 7000HT Sequence 
Detection System (Applied Biosystems, Foster Gity, GA, USA) for the following 
program: 50 °G for 2 minutes, 95 °G for 15 minutes and 40 repeats of 95 °G for 15 
seconds and 60 °G for 1 minute. Results were compared to standards of human or rat 
genomic DNA, as appropriate, over five orders of magnitude. Data was analysed using 
the ABI Prism software to calculate the number of copies of RNA per well compared to 
the standard curve.
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2.2.6 Characterisation of Cells at the Protein Level
Regulation of protein expression is not always regulated at a transcriptional level, for 
example proteins can be modified post-translationally, and in these cases RNA levels will 
not give an accurate estimate of protein expression. Therefore protein expression of 
some transporters was qualitatively determined in certain samples to ensure the RNA 
data was representative of the protein expression.
2.2.6.1 Protein Extraction
Medium was aspirated from adherent cells, which were washed in PBS and lysed with 
PBS containing 1 x protease inhibitors, 2 % (v/v) triton-X 100, 2 % (v/v) Nonidet p40 
and 1 pM dithiothrietol (DTT). Lysate was homogenised by passing it through a 21 G 
needle before being spun at 1 0 0 0  x g for 1 0  minutes to remove debris.
To separate a crude membrane fraction, the total protein was centrifuged for 30 minutes 
at 100000 X g. The precipitate was resuspended in 0.1 M Tris-HCl and centrifuged for a 
further 30 minutes at 100000 x g. The pellet was resuspended in O.IM Tris-HCl 
containing protease inhibitors with 5 strokes of a mechanical homogeniser (the crude 
membrane fraction). A fraction was also saved from the supernatant (crude cytosolic 
fraction), and aU protein samples were stored at minus 80 °C for a maximum of 6  
months prior to analysis.
2.2.6.2 Determination of Protein Concentration by the Lowry Assay
From pilot experiments it is known that the supernatant fraction needs to be diluted 50 
fold and the crude membrane fraction 20 fold in 0.5 M NaOH to bring them within the 
range of easy measurement by the Lowry assay. All samples were further diluted 2 fold 
in 0.5 M NaOH in duplicate. Five millilitres of copper sulphate solution (0.5 ml 1% 
CU2 SO4 5 H 2 O, 0.5 ml 2 % potassium sodium tartrate, 50 ml 2 % Na2 C0 3 ) was added to 
each sample and left for 10 minutes. Folin-Ciocalteau reagent (diluted 1:1 in water) was 
added to the samples, which were left at room temperature for 2 hours. The absorbance 
was read at 720 nm in a Kontron Uvikon 860 spectrophotometer. Sample quantity was 
determined by comparison to bovine serum albumin (BSA) standards over a 
concentration range of 0 — 250 pg/ml.
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2.2.6.3 Determination of Protein Concentration by the BCA Kit Assay
For higher throughput determination of protein concentration the BCA kit was used 
allowing total protein concentrations to be measured in a 96-well format. Briefly, protein 
samples were diluted 10 fold in lysis buffer and loaded into a 96 well plate. Reaction 
mixture was added to each well and the plate was incubated at 37 °C for 30 minutes. 
Once cooled to room temperature the absorbance was read at 560 nm in an ELISA plate 
reader (BioTEK ELxSOO). Sample quantity was determined by comparison to BSA 
standards over a range of 0 — 2000 pg/ml.
2.2.6.4 Separation of Proteins by SDS-PAGE
A 12.5 % resolving gel (12.5 % acrylamide, 0.3 % bisacrylamide, 0.375 M Tris HCl pH 
8.8, 0.1 % SDS, 0.1 % ammonium persulphate, 0.01 % TEMED) and a 6 % stacking gel 
(6 % acrylamide, 0.16 % bisacrylamide, 0.125 M TrisHCl pH 6.8, 0.1 % SDS, 0.1 % 
ammonium persulphate, 0.02 % TEMED) were used to separate protein samples, which 
had been mixed with an equal volume of loading buffer (60 mM Tris HCl pH 6.8, 0.2 % 
SDS, 12 % glycerol, 0.7 M mecaptoethanol, 0.003% pyronin Y) and denatured by heating 
to 60 °C for 10 minutes. After being loaded onto the stacking gel the samples were 
separated at 0.1 A for approximately 1 hour, until the dye front reached the end of the 
glass plates. MagicMark molecular weight standards were used to calculate the mass of 
the separated proteins.
2.2.6.5 Identification of Proteins by Western Blotting
The gels were transferred onto PVDF membrane at 100 V overnight. The membrane 
was blocked in 20 ml blocking solution (Tris-buffered saline with 1 % Tween-20 (TBST) 
and 10 % Marvel) for 1-2 hours on a rotary mixer. The membrane was washed three 
times in 10 ml TBST for 5 minutes each, before 10 ml of primary antibody in antibody 
buffer (TBST and 5 % Marvel) was added to the membrane. After a further hour on the 
rotary mixer the membrane was washed as before and 10 ml secondary antibody in 
antibody buffer was added to the membrane and incubated on a rotary mixer for 1 hour. 
The membrane was washed as before and covered in chemiluminescent reagent for 5 
minutes before being developed on film.
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2.3 Program Information for Data Produced and/or Analysed In Silico
2.3.1 In Silico Analysis of Ligand Binding to PXR
Autodock (version 3.0.5; La Jolla, USA; Morris et al., 1998) was used to predict the 
interaction of ligands with the nuclear receptor, PXR. The crystal structure of PXR was 
obtained from the RCSB protein data bank (www.rcsb.org/pdb/index) (Watkins et al., 
2001) and docked to ligands with the following parameters:
Genetic Algorithm Parameters: 150 GA runs, 100 pop size, 1000000 energy evaluations, 
100000 max generations.
Local Search Parameters: LS runs 500, 3000 max iterations.
2.3.2 Molecular Pathway Modelling
Cell Designer (v.3.5.1; http://ceUdesigner.org) was used for aU pathway modeUing, which 
was simulated by Jarnac (v.2.26b). Jarnac is an interactive language for numerical analysis 
with features that aUow the simulation of ceUular models. It forms part of the systems 
biology workbench (SBW; v.2.6; http://sys-bio.org/research/sbwIntro.htm) for CeU 
Designer.
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2.4 Statistical Analysis of Data
Where results are an average of several biological repeats, the mean and standard error of 
the mean (SEM) are used. The number of biological repeats is given in the figure 
legends. Results from dosing studies are given as fold induction above control to allow 
inter-experiment comparison and expression analysis results are given as a percentage of 
the Hver expression levels. Statistical significance of results was calculated using the most 
suitable statistical measurement for each experiment (for details see figure legends) using 
GraphPad Prism software (version 5; San Diego, USA).
Principal component analysis was performed using the Multivariate Statistical Package 
(MVSP version 3.1; Kovach Computing Systems). Correlation analysis was calculated 
using a Spearman rank correlation (GraphPad Prism).
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3 Drug Transporter Expression in Human-derived Cell Lines
3.1 Introduction
In vitro cultured cell lines are regularly used to assess ADME and toxicology 
characteristics of compounds prior to pre-cHnical in vivo experimentation. As predictive 
tools however, they are not always accurate due to a number of factors, centred on 
differences between both the absolute and relative expression of proteins in the model 
systems compared to in vivo tissue. A better understanding of the expression levels and 
biological functionality of genes and gene products in in vitro cell culture systems is 
important for ADME and toxicology studies, one of the key gene groups being drug 
transporters as they dictate the disposition of compound within a cell.
Cell lines derived from a range of tissues are used in ADME and toxicology studies, for 
example Caco2 cells are used to estimate the permeability of a compound across the gut 
wall (Artursson and Karlsson, 1991) and Hep G2 cells are used to assess hepatotoxicity 
(Chen et al., 1997; Xu et al., 2003; Hassen et al., 2007). HEK cells are used to determine 
if a compound is a substrate for ABCG2 (Kevin Jones, personal communication) and 
therefore can be used to model biliary efflux as well as drug resistance in tumour cells, 
which over express ABCG2 (Turner et al., 2006). Huh7 cells have been used with 
reporter gene technology to assess the regulatory mechanisms of CYP3A4 (El-Sankary et 
al., 2001; Wang et al., 2006).
In this chapter, the mRNA transcript level of 12 human drug transporter genes (Table 
3-1) was quantified using quantitative-RT-PCR in Huh7, HepG2, HEK and Caco2 as a 
first step in resolving the differences in transporter expression between these cell lines. 
Over-expression of individual transporters is a common method for examining the 
characteristics of potential substrates towards single drug transporters, but at present it 
has not been determined if such an over-expression approach alters the expression level 
of other drug transporters in the system. To examine this, the expression levels of the 
same 12 transporters were also measured in HEK cells stably transfected with ABCG2 
and Huh7 cells transiendy transfected with SLCOIBI. All transcript level measurements 
were compared to levels from human liver samples to allow comment on potential in vitro 
— in vivo correlations to be made.
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Transporter m R N A H u m an  CeU Culture System s Studied
Efflux Influx Liver-derived Kidney-derived Colon-derived
ABCBl
ABCB4
ABCCl
ABCC2
ABCC3
ABCC4
ABCG2
SLCOIBI
SLC02B1
SLC01B3
SLClOAl
SLC22A1
Huh7 cells 
HepG2 cells
HEK cells Caco2 cells
Table 3-1 Human drug transporter genes detected in human-derived cell lines.
The transcript level for a number o f efflux and influx drug transporter, known to be important in 
ADMET processes (FDA guidance to industry, 2006), were measured in human-derived in vitro 
cell systems. The expression level in human liver was also measured and used as a comparison.
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3.2 Basal Expression of Drug Transporters in Human-Derived Cell Lines
In theory cell lines derived from liver carcinoma such as Huh7 and HepG2 should be 
more similar to liver than non-liver ceU lines such as HEK or Caco2 ceUs, which are 
derived from kidney and colon respectively, and hence represent more reaUstic models 
for the in vivo situation. Therefore transporter expression mRNA level was measured in 
aU four ceU lines in order to estabUsh if this was true.
3.2.1 Efflux Drug Transporter Transcript Levels in Human-Derived CeU Lines
Expression of the apical drug efflux proteins ABCBl and 4 (Figure 3-1), ABCC2 and 
ABCG2 (Figure 3-2) and the basolateral drug efflux transporters ABCCl, 3 and 4 (Figure 
3-3) was found to vary in the human derived ceU Unes compared to the level in human 
Hver. In most cases the Uver-derived ceU Unes have closer expression levels of 
transporter transcript compared to Uver than the kidney- or intestinal- derived ceU Unes. 
For example, transcript levels of ABCBl and ABCG2 are closer to Uver expression levels 
in HepG2 and Huh7 ceUs than in HEK or Caco2 ceUs. A lack of statistical data for 
HEK ceUs Umits conclusions, but the expression of drug transporters in HEK ceUs is 
very different to human Uver.
GeneraUy, if one ceU line over-expresses a transporter, aU ceU Unes over-express it relative 
to Uver and this is also true for transporters that are relatively under-expressed. The 
notable exception to this rule is ABCBl, which is over expressed in HepG2 ceUs relative 
to Uver, but in the other ceUs its expression level is lower relative to Uver. Likewise 
ABCC2 faUs outside of this generalisation as it is not expressed at significandy different 
levels in Huh7, Hep G2 or Caco2 ceUs compared to Uver.
Compared to the basolateral efflux transporters, ABCCl, 3 and 4, the apical efflux 
transporter expression shows greater simUarity to Uver with the greatest change being 
only approximately 3 times that of Uver expression. In contrast, ABCCl and 4 are 
expressed at 5-10 times the amount in Uver in Huh7 and HepG2 ceUs and up to 15 fold 
higher in the case of ABCC4 expression in Caco2 ceUs. ABCC3 does not share this 
pattern of high transporter expression with ABCCl and 4; it is expressed at only 2-5 % 
of the Uver expression level in the cultured ceUs. In general, the apical drug efflux 
transporters that are under expressed relative to Uver, for example ABCBl and 4, do not 
faU to such low levels.
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Figure 3-1 Expression of the apical drug efflux transporters ABCBl and ABCB4 in 
human-derived in  vitro  cell lines compared to human liver.
The mRNA expression level o f ABCBl (A) and ABCB4 (B) was quantified by RT-PCR in Huh? 
and HepG2 ( 1), HEK  ( ) and Caco2 (■ ) cells and compared to the level in human Uver (■ ).
Absolute expression levels were measured by comparing the signal from samples to human 
genomic DNA standards o f known concentration. Expression levels are normaUsed to GAPDH 
and expressed as a percentage of human liver expression. Results were analysed by one sample t 
test and show where expression in cell Unes is significantly different to Uver (** = p < 0.05, *** = 
p < 0.01; n=3 except for HEK cells where n = 1; error bars = SEM; where no error bars are 
observed they are contained within the Umits of the data point; ND = not detected).
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Figure 3-2 Expression o f the apical drug efflux transporters ABCC2 and ABCG2 in 
human-derived In vitro cell lines compared to human Uver.
The mRNA expression level o f ABCC2 (A) and ABCG2 (B) was quantified by RT-PCR in Huh7 
and HepG2 ( ), HEK  ( ) and Caco2 (■ ) cells and compared to the level in human liver (■ ).
Absolute expression levels were measured by comparing the signal from samples to human 
genomic DNA standards o f known concentration. Expression levels are normalised to GAPDH 
and expressed as a percentage of human liver expression Results were analysed by one sample t 
test and show where expression in cell lines is significantly different to liver (* = p < 0.1; n=3 
except for HEK cells where n = 1; error bars = SEM).
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Figure 3-3 Expression o f the basolateral drug efflux transporters ABCCl, ABCC3 and 
ABCC4 in human-derived in  vitro cell lines compared to human liver.
The mRNA expression level o f ABCCl (A), ABCC3 (B; max. y-axis = 150 %, split between 10 
and 75 %) and ABCC4 (C) was quantified by RT-PCR in Huh7 and HepG2 ( ), HEK ( ) and 
Caco2 ( ! )  cells and compared to the level in human liver (■ ). Absolute expression levels were 
measured by comparing the signal from samples to human genomic DNA standards o f known 
concentration. Expression levels are normalised to GAPDH and expressed as a percentage of 
human liver expression. Results were analysed by one sample t test and show where expression 
in cell lines is significantly different to liver (* = p < 0.1; ** = p < 0.05, *** = p < 0.01, **** = p 
< 0.001, n=3 except for HEK  cells where n = 1; error bars = SEM).
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3.2.2 Principal Component Analysis of Drug Efflux Transporter Expression
Principal component analysis (PGA) is a multivariate statistical tool, which can be used to 
reduce the dimensionality of data sets and hence ascertain both the most conserved and 
variable factors within a data set. It is important to note that, unlike alternate 
multivariate analysis methods such as hierarchical cluster analysis (HCA), PGA is 
relatively unbiased, and wül only separate groups if sufficient variation is present to drive 
this; by comparison HGA produces clusters even when the statistical and/or biological 
relevance of these clusters is dubious, which can result in erroneous conclusions being 
made.
Data from the PGA is separated along multiple axes; together, the axes make up 100 % 
total variation between samples, each accounting for a certain percentage of the total 
variation. In turn each axis is made up of variation from each transporter and this is 
expressed as a percentage of the individual axis. Ultimately PGA separates the cell 
culture groups based on transporter expression and this leads to clustering of groups that 
have similar expression of transporters that, as a rule, vary through the whole data set. 
Performing PGA on the expression data above (Figure 3-1, Figure 3-2 and Figure 3-3) 
can hence be used to identify the important facts; first, the overall similarity of a cell line 
to the in vivo tissue; and second, the drug transporter or transporters that drive the 
differences between cell lines and in vivo tissue.
PGA of the drug efflux transporters shows clustering of the cell line samples away from 
human liver (Figure 3-4). The principal components driving the majority of this variance 
(axis 1) that cause this clustering were identified as members of the ABGG family, 
especially ABGG3. The next most variable set of transporters (axis 2) was identified as 
being members of the ABGB and ABGG families, especially ABGB4. Within the analysis 
the greatest variation within a group was seen with the in vivo tissue, which underlies the 
inter-individual variability previously reported for the expression of drug transporters and 
metabolic enzymes (Ingelman-Sundberg, 2005).
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Axis 1 (52.9 % of total variation) Axis 2 (24.8 % of total variation)
Transporter Percentage contribution 
to axis variation
Transporter Percentage contribution to 
axis variation
ABCC3 64.3 ABCB4 50.9
ABCC2 25.5 ABCBl 22.4
ABCCl 10.2 ABCC2 20.4
ABCCl 6.3
Figure 3-4 Principal component analysis of drug efflux transporter expression.
PCA was performed on the expression of drug efflux transporters in human liver (^ )  and 
human-derived cell lines (Huh7, V ;  HepG2, ■ ; HEK, ♦ ;  Caco2, • ) .  The percentage that each 
transporter contributes to axis variation is shown in the table. Separation o f cell lines from liver 
on axis 1 (52.9% total variation) is due mostly to variation in the expression of ABCC3 with 
contributions from ABCC2 and 1. Separation on axis 2 (24.8% total variation) is due mostly to 
variation in expression of ABCB4 with contributions from ABCBl, ABCC2 and 3. Data is 
normalised to GAPDH expression.
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As a large variability was observed between the human liver samples, expression data 
from these samples was excluded from a second PCA in order to focus on the cell 
culture samples (Figure 3-5). Samples from the same cell line form distinct clusters based 
on separation along axis 1 and 2. ABCBl and ABCC2 contribute the most variation to 
axis 1, with a smaller contribution from ABCCl. On axis 2, these three transporters
ABCC3 and 4 and ABCG2.
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ABCC2 38.7 ABCBl 23.8
ABCCl 14.0 ABCCl 17.7
ABCC4 9.9
ABCG2 7.2
ABCC3 5.6
Figure 3-5 Principal component analysis of drug efflux transporter expression (excluding 
Uver expression data).
PCA was performed on the expression o f efflux transporters in human-derived cell lines (Huh7, 
HepG2, T; HEK, ■ ; Caco2, ♦ ) .  The percentage that each transporter contributes to axis 
variation is shown in the table. Separation of cell lines along axis 1 (63.3 % total variation) is due 
mostly to variation in the expression o f ABCBl and ABCC2 with a smaller contribution from 
ABCCl. Separation along axis 2 (27.4 % total variation) is due mostly to variation in expression 
o f ABCC2 and ABCBl with a smaller contribution from ABCCl, 3, 4 and ABCG2. Samples 
within circles are all from the same cell type. Data is normalised to GAPDH expression.
93
Variance in a PGA can be due to differences in expression between samples of the same 
type (intra-sample variance) as well as between different types of samples e.g. liver and 
Huh7 cells (inter-sample variance). Samples of cells that have been cultured in the same 
way and are taken from cells of the same passage number should not have a large 
amount of intra-sample variation but samples taken from different humans may vary in 
the expression of drug transporters, as in the case of the liver samples taken from three 
different people. Comparing the PCA that included the data from liver samples and the 
PCA that excluded them highlights where the variation in expression between liver 
samples (intra-liver variation) is responsible for driving separation.
From the raw expression data, ABCC2 appeared to vary very little and yet it is an 
important source of variation in both PCA’s (Figure 3-4 and Figure 3-5). When liver is 
included in the analysis, this can be accounted for by intra-liver variation and inter­
sample variation. When liver is excluded, the appearance of ABCC2 as a driving force of 
variation between cell culture systems must be due only to the difference between 
expression in HEK cells compared to the other cell lines, thus representing a tissue- 
specific difference.
ABCC3 and ABCB4 are both identified as variable transporters in the PCA with the liver 
samples but are very minor contributors to variance once liver data is excluded. 
Therefore, either intra-liver variation of these transporters is high or the difference 
between liver samples and all cell culture samples is high. Looking back at the raw data 
for ABCB4 (Figure 3-1) and ABCC3 (Figure 3-3) it is likely both these reasons play a role 
in the difference between the PCA’s as both sets of liver show high standard error and 
both differ from aU ceU culture samples. Cell line samples express similar levels of both 
these transporters so it is not unsurprising that once the liver data is removed from the 
analysis ABCB4 and ABCC3 no longer figure as drivers of the variation.
In the same way that ABCC3 and ABCB4 only drive separation when the liver data is 
included, ABCBl only becomes a major contributor to variation once it is removed. 
Therefore ABCBl expression varies between cell culture types, with one or more cell 
lines under-expressing ABCBl and one or more over-expressing it. Again this is 
confirmed by looking back at the raw data for ABCBl (Figure 3-1).
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3.2.3 Influx Drug Transporter Transcript Levels in Human-Derived Cell Lines
The expression levels of the human influx transporters, SLCOIBI, 1B3 and 2B1 (Figure 
3-6) are aU under-expressed relative to human liver levels. However, as with efflux drug 
transporter expression, influx drug transporter expression is more similar to human liver 
expression in Huh7 and HepG2 cells compared to HEK or Caco2 cells.
SLCOIBI and 1B3 are Hver specific transporters so it is worthy of note that they are only 
expressed in Huh7 and HepG2 ceUs. This is important as one would not expect to find 
them in the non-Hver ceU lines, but equally because their expression demonstrates that 
both the human Hver ceH Hnes retain Hver-specific markers. HEK ceUs don’t express any 
of the SLCO’s whereas Caco2 ceUs only expressed SLC02B1. SLClOAl and SLC22A1 
were both expressed at less than 0.5% of human Hver levels in Caco2 and Huh7 ceUs but 
transcript was absent in HEK and HepG2 ceUs (data not shown).
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Figure 3-6 Expression of the influx drug transporters SLCOIBI, SLC01B3 and SLC02B1 
in human-derived in  vitro cell Unes compared to human Uver.
The mRNA expression level of SLCOIBI (A), SLC01B3 (B) and SLC02B1 (C) was quantified 
by RT-PCR in Huh7 and HepG2 ( ), HEK ( ) and Caco2 ( ■ ) cells and compared to the level 
in human liver (■ ). Absolute expression levels were measured by comparing the signal from 
samples to human genomic DNA standards of known concentration. Expression levels are 
normalised to GAPDH and expressed as a percentage of human liver expression. Results were 
analysed by one sample t test and show where expression in cell lines is significantly different to 
liver (** = p < 0.05, **** = p < 0.001, n=3 except for HEK cells where n = 1; error bars = 
SEM; where no error bars are observed they are contained within the limits o f the data point; all 
y-axis split from 20 — 70 %; N D  = not detected).
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3.2.3.1 Principal Component Analysis of Influx Drug Transporter Expression
PCA of the influx drug transporters again shows clustering of the cell line samples away 
from human liver (Figure 3-7). The principal component of this variance (axis 1) was 
identified as SLC02B1 with smaller contributions from SLCOIBI and 1B3. Variance 
along axis 2 was mostly due to differences in SLC01B3 expression with smaller 
contributions from SLCOIBI and 2B1. It should be noted that with so few data points 
there is a risk that the data is being biased more than it would be with more data points.
As with the efflux transporter PCA, the liver data was excluded a further influx 
transporter PCA because the initial PCA shows obvious intra-liver variability in the 
expression of SLC02B1, which may be masking variability within cell culture groups. 
Removal of the liver data results in clustering of the cell culture groups (Figure 3-8) 
based on separation along axis 1 and 2. Differences in SLC02B1 expression still 
contribute the most variation to axis 1 indicating that both intra-liver variation and inter­
sample variation in expression of this transporter are high. On axis 2 expression of aU 
the influx transporters contribute to separation with SLCOIBI being the most variable, 
however axis 2 contributes only very slightly to the total variation and just separates a 
single HepG2 sample from the others.
SLCOIBI expression contributed very little to the PCA including the liver sample data 
(Figure 3-7), therefore intra-liver sample variation in SLCOIBI expression is low but its 
expression varies between the cell culture groups as it becomes a component of the 
second PCA (Figure 3-8). This is mainly driven by the fact that SLCOIBI is expressed 
in Huh7 and HepG2 cells but is absent in HEK and Caco2 cells. Unlike SLCOIBI, 
SLC01B3 is more important in the PCA with liver data (Figure 3-7) than without (Figure 
3-8), meaning that intra-liver variability in SLC01B3 expression is high but variation 
between cell culture samples is low. This can be confirmed by looking at the raw data 
(Figure 3-6).
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Figure 3-7 Principal component analysis of influx drug transporter expression.
PCA was performed on the expression of influx transporters in human liver (^ )  and human- 
derived cell lines (Hub?, T; HepG2, ■ ; HEK, ♦ ;  Caco2, • ) .  The percentage that each 
transporter contributes to axis variation is shown in the table. Separation o f cell lines from liver 
on axis 1 (97.8% total variation) is due mostly to variation in the expression o f SLC02B1 with 
minor contributions from SLC01B3 and IB l. Separation on axis 2 (1.2% total variation) is due 
mostly to variation in expression o f SLC01B3 with minor contributions from SLC02B1 and 
IB l. Data is normalised to GAPDH expression.
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Figure 3-8 Principal component analysis of influx drug transporter expression (excluding 
Hver data).
PCA was performed on the expression of influx transporters human-derived cell lines (Huh7, 
HepG2, ; HEK, ■ ; Caco2, ♦ ) .  The percentage that each transporter contributes to axis 
variation is shown in the table. Separation of cell lines on axis 1 (94.5 % total variation) is due 
mostly to variation in the expression o f SLC02B1 with a minor contribution SLCOIBI. 
Separation on axis 2 (3.7 % total variation) is due mostly to variation in expression o f SLCOIBI 
with minor contributions from SLC02B1 and 1B3. Samples within circles are all from the same 
cell type. Data is normalised to GAPDH expression.
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3.2.3.2 OATPIBI Protein Level in Huh? Cells
Measurement at the RNA level is advantageous as it is more amenable to high specificity, 
high throughput analysis. However, a potential limitation is that expression at the 
transcript level may not reflect protein (or indeed activity); therefore, to compliment the 
RNA analysis protein level measurements should be made where suitable antibodies 
exist.
At the RNA level, SLCOIBI expression was previously show to be very low in Huh? 
cells compared to expression in liver (Figure 3-6), and this was confirmed at the protein 
level (Figure 3-9). Ten micrograms of protein from the membrane and cytosolic 
fractions of human liver and Huh? cells were separated via SDS-PAGE and transferred 
to PVDF membrane. OATPIBI was detected in the membrane fractions of liver and 
Huh? cells, with more OATPIBI being detected in the liver membrane sample than in 
Huh? membrane. By comparison, no immunoreactive band was visible in either Huh? 
or human liver cytosolic fractions.
Marker Huh? membrane Liver membrane
90kDa
Huh? cytosol Liver cytosol
Figure 3-9 OATPIBI protein expression in Huh? cell membrane and liver membrane.
Protein was extracted from human liver and Hub? cells and separated by ultracentrifugation into 
cytosolic and membrane fractions. Ten micrograms of protein from each fraction was separated 
by SDS-PAGE and transferred to a PVDF membrane. Immunodetection o f OATPIBI gave a 
band corresponding to OATPIBI at approximately 90kDa (arrow).
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3.3 Drug Transporter Expression in Transfected Cell Lines
Cell lines that have been transfected with an expression plasmid for individual drug 
transport proteins can be useful in assessing two main areas of a compounds ADME 
profile: First, such systems can be used to look at compound disposition through a 
particular transporter, for example HEK cells transfected with ABCG2 are used to 
elucidate whether a compound is a substrate for ABCG2 (Kevin Jones, personal 
communication); second, they can be useful in making cell lines more V» vivo-\ik.€. For 
example, Huh? cells express low levels of SLCOIBI compared to human Hver (Figure 
3-6 A and Figure 3-9); therefore transfection of an SLCOIBI expression plasmid into 
the cells wiU ensure that response to compounds is not Hmited by reduced ceUular access.
MDCKII ceUs are often transfected with human transporters as they are a polarised ceU 
line and can be used to study the vectorial transport of drugs. However as the ceU Hne is 
derived from dog kidney cells, the basal expression of transporters could not be 
measured with human probes and primers. However the level of ABCBl in MDCKII 
ceUs transfected with the human version of the gene was found to be over-expressed 
several hundred fold compared to wild type (data not shown).
The mRNA levels of transporters in HEK ceUs stably transfected with ABCG2 and 
Huh? ceUs transiently transfected with pTriExl.l-SLCOIBI were measured by 
quantitative RT-PGR in order to observe the effect of the transfections on basal 
expression of other transporters.
3.3.1 Transporter Expression in HEK Cells Transfected with ABCG2
HEK ceUs transfected with ABCG2 have higher expression of ABCG2 compared to the 
wild type but the transfection also appears to affect the expression of other transporters 
(Figure 3-10), with ABCBl and ABCC2 being relatively overexpressed while the 
basolateral efflux transporters, ABCCl, 3 and 4, remaining relatively unchanged by the 
transfection. Neither ABCB4 nor the SLC transporters were expressed in HEK wild 
type or HEK-ABCG2 cells.
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Figure 3-10 The change in efflux transporter expression in HEK cells transfected with 
ABCG2.
The mRNA expression level of each transporter was quantified by RT-PCR in wild type HEK 
cells and H EK  cells transiently transfected with ABCG2. Absolute expression levels were 
measured by comparing the signal from samples to human genomic DNA standards o f known 
concentration. Expression levels are normalised to GAPDH and the expression in HEK- 
ABCG2 cells is represented as a percentage o f expression in wild type HEK cells (expression in 
wild type cells = 0%; the y - axis is split from 500 to 12000 %; ND = not detected).
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3.3.2 Transient Transfection of an SLCOIBI Clone in Huh? Cells
In order to transiently transfect SLCOIBI into Huh? cells, the gene was cloned into an 
expression plasmid, pTriExl.l, and subsequently transfected into Huh? cells.
3.3.2.1 Cloning of SLCOIBI
SLCOIBI cDNA was produced from adult human liver total RNA (Stratagene) using 
specific primers (1691R and 2246R, table 2-3). As the SLCOIBI cDNA is 
approximately 2.2kb in length it was cloned as three fragments, which were amplified 
with a high fidelity enzyme using the following primer pairs; 120F + 1691R, 120F + 
2246R and 1580F + 2246R. The PCR products were separated on a 1% agarose gel 
(Figure 3-11); each resulted in the correctly sized band (120F + 1691R (1) = 1.55kb, 
120F + 2246R (2) = 2.1kb and 1580F + 2246R (3) = 0.65kb).
M 1 2  3
Figure 3-11 Precipitated SLCOIBI PCR products.
PCR was performed with the following SLCOIBI primer pairs: 1 = 120F + 1691R, 2 = 120F + 
2246R, 3 = 1580F + 2246R. The products were separated on a 1% agarose gel. The correct 
weight bands are seen in each lane (1 = 1.55kb, 2 = 2.1kb and 3 = 0.65kb). M = molecular 
weight markers (values are size of bands in kilobases).
The PCR product from 120F + 2246R (Figure 3-11, lane 2) was digested and ligated into 
pTriExl.l (for vector maps see appendix 9.2). The vector and insert were transformed 
into DH5a E. coli cells and plasmid DNA was prepared using the Qiagen Miniprep kit. 
The DNA was digested with four different sets of enzymes — BamHI and Xhol; EcoRI 
and Hind III; Xhol and Xbal; Xbal and Pstl. All gave the expected digest bands (Figure
3-12).
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Figure 3-12 Restriction digest of the Qiagen mini-preparation taken from SLCOIBI.
A mini-preparation o f DNA from DH5 a  cells transformed with pTriExl.l-SLCOIBI was 
digested with BamHI + Xhol (1 = 5.4kb and 1.8kb), EcoRI + H indlll (2 = 5.7kb, 879b and 
659b), Xhol + Xbal (3 = 4.8kb and 2.4kb) and Xbal + Pstl (4 = 5.4kb and 1.8kb). The digests 
were separated on a 1% agarose gel. M = molecular weight marker (values are size o f bands in 
kilobases).
To ensure no mutations had been incorporated during PCR the plasmid was confirmed 
by sequencing (data not shown).
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3.3.2.2 Transporter Expression in Huh7 Cells Transfected with SLCOIBI
Huh7 cells transiently transfected with pTriExl.l-SLCOIBI have significantly higher 
expression of SLCOIBI mRNA compared to the wild type (Figure 3-13). Surprisingly, 
the over-expression of SLCOIBI affects the expression of other transporters, with 
SLC02B1 expression being significantly lowered by the transfection of SLCOIBI in 
Huh7 cells. Indeed, the expression of the majority of transporters appears affected to 
some extent by this over-expression; for example ABCB4 and ABCCl levels are reduced 
while SLC22A1 levels are increased. However, expression of ABCC2, 3 and 4 and 
ABCG2 are altered very little by the transfection.
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Figure 3-13 The change in transporter expression in Huh? cells transfected with 
pTriExl.l-SLCO lBl compared to wild type.
The mRNA expression level of each transporter was quantified by RT-PCR in wild type Huh7 
cells and Huh7 cells transiently transfected with pTriExl.l-SLC O lB l. Absolute expression 
levels were measured by comparing the signal from samples to human genomic DNA standards 
of known concentration. Expression levels are normalised to GAPDH and the expression in 
Huh7 SLCOIBI cells is represented as a percentage of expression in wild t}pe Huh7 cells 
(expression in wild type cells = 0%). Results were analysed by two-way ANOVA with 
Bonferonni post hoc test to show where expression in Huh7 cells transfected with SLCOIBI 
was significantly different to wild type cells (** = p < 0.01, *** = p < 0.001; n=3; error bars = 
SEM; where no error bars are observed they are contained within the limits o f the data point). 
The y - axis is split from 200 to 7500 %.
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At the RNA level, ABCC3 expression was not affected by transfection of Huh7 cells 
with pTriExl.l-SLCOlBl (Figure 3-13) and this was confirmed at the protein level by a 
Western blot of wild type Huh7 versus Huh7 transfected with SLCOIBI. Ten 
micrograms of total protein from the transfected Huh7 cells and wild type Huh7 cells 
were separated via SDS-PAGE and transferred to PVDF membrane. Similar amounts of 
ABCC3 were detected in both samples of Huh7 cells by immunodetection (Figure 3-14).
M M
WT +1B1
Figure 3-14 ABCC3 protein expression is not altered when Huh? cells are transfected 
with pTriExl.l-SLCO lBl.
Protein was extracted from wild type Huh? cells (WT) and cells that had been transfected with 
pTriExl.l-SLCOlBl (+1B1). Ten micrograms o f protein from each sample was separated by 
SDS-PAGE and transferred to a PVDF membrane. ABCC3 was detected by western blotting 
with a specific antibody. M = molecular weight marker; the arrow highlights the molecular weight 
band corresponding to ABCC3 (170 KDa).
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3.4 Discussion
Cell lines that have been derived from tumour tissue are useful in several stages of 
ADME and toxicology testing of new drugs, as they are not only easy to work with but 
provide a relatively stable and uniform preparation in which to assess the action of new 
drugs over a long time period. However, results from cell lines are not always predictive 
of the effects of drugs in vivo and this may, in part, be due to the differences in expression 
of a number of key ADME genes. Within this group of genes, transporters play an 
important role in compound access to cells and how long a compound or its metabolites 
remain in the cell. These factors wiU affect a compounds metabolism and its effects on 
the transcriptome.
3.4.1 RNA, Protein and Function
It is worth remembering that although assessing mRNA levels is a quick way of 
quantitatively measuring the expression of a large number of transporters in a number of 
different samples, mRNA expression does not always equal expression of protein level 
due to a number of factors including post-transcriptional modifications to RNA (Day 
and Tuite, 1998; Modrek and Lee, 2002) and degradation of protein (Ciechanover et al,, 
2000). In the case of integral membrane proteins, the cellular machinery for targeting 
and inserting proteins into the lipid bilayer must be functional and in cell lines this may 
not be the case, especially in unpolarised cell culture models of polarised ceU types such 
as hepatocytes. For example, Huh7 ceUs express ABCC2 mRNA at a similar level to 
human liver but when Huh7 ceUs are dosed with the fluorescent ABCC2 substrate 
carboxydichlorofluroscein (CDF), the fluorescence remains within the ceU (Samantha 
Forster, personal communication) indicating that ABCC2 is not functional in these ceUs. 
However other work has found that for some transporters such as ABCBl, mRNA 
levels in MDCKII ceUs could be used to predict the functional activity of efflux better 
than protein levels as quantitatively measuring the expression of membrane proteins is 
technicaUy chaUenging and not precise (Taipalensuu et al., 2004).
Care should always be taken when using mRNA levels to assess the differences between 
ceU Hnes and liver. The relevance of transcript levels on protein level and more 
importandy on functional transport activity should be assessed for each gene, which 
makes extrapolation difficult between ceU lines and in vivo tissue. IdeaUy more work
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should be performed to assess not only transporter protein levels but also functional 
activity in cell lines used for ADME or toxicology work. Quantitatively measuring the 
expression of protein is notoriously difficult especially with integral membrane proteins 
but the development of better and cheaper antibodies for the drug transporters makes 
this kind of work more possible. However, until this work is completed transporter 
mRNA levels should be used as a guide to expression and function.
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3.4.2 Expression of Drug Transporters in Cell Lines Compared to Liver
3.4.2.1 Expression of Efflux Drug Transporters in Cell Lines Compared to Liver
In this study, the basal expression level of a number of efflux and influx drug 
transporters was found to differ greatly between Huh7, HepG2, HEK and Caco2 cells 
when compared to the expression in Hver. In general, transporter expression was more 
similar to Hver expression in the Hver-derived ceU Hnes Huh7 and HepG2 than in the 
kidney or intestinal derived ceU Hnes, HEK and Caco2, respectively.
This study also identified some potentiaUy important differences between the expression 
of apical and basolateral efflux transporters in the ceU Hnes, which may impact upon the 
utiHty of these Hnes to model both processes simultaneously. In general the expression 
of the apical efflux transporters is closer to that of human Hver than the expression of 
basolateral transporters. The reasons for this are unclear although it is Hkely that the 
regulation of apical and basolateral transporters differs at a number of levels including 
transcriptional and translational regulation as weU as in the way different transporters are 
targeted to different parts of the membrane. The results shown here hint that a 
transcriptional mechanism affects mRNA expression of the transporters and that this is 
affected in the ceU Hnes causing extreme under- or over-expression of basolateral 
transporters. However the mechanism controUing this is unHkely to be simple as ABCCl 
and 4 are over expressed while ABCC3 is expressed at only 2-7 % of Hver levels.
3.4.2.2 Expression of Influx Drug Transporters in Cell Lines Compared to Liver
AH of the influx drug transporters tested, SLCOIBI, 1B3, 2B1, SLClOAl and SLC22A1, 
were significantly under expressed in aU ceU Hnes relative to the Hver expression level. 
The Hver specific transporters, SLCOIBI and 1B3 were only expressed in the Hver- 
derived ceU Hnes indicating that although these ceUs differ from hepatocytes in many 
ways, they retain some Hver-specific markers. However SLClOAl, which is also a Hver- 
specific transporter (Hagenbuch and Dawson, 2004), was detected at low levels in Caco2 
ceUs. A recent paper that compared levels of a number or transporter transcripts in 
Caco2 ceUs to human jejunum levels saw no SLClOAl transcript in either group of 
samples (HHgendorf et al., 2007). One possible reason for this erroneous result may be
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that SLClOAl is a very similar transporter to SLC10A2, which encodes an intestinal 
transporter and there may have been cross reactivity of the TaqMan probes and primers 
between the two transcripts.
In the case of SLCOIBI, low mRNA levels compared to liver were confirmed at the 
protein level too. This apparent lack of influx transporters in cell lines could be a major 
problem for their use in ADME studies involving hydrophilic drugs, which rely on influx 
transporters to get into cells. The absence of a drug influx transporter in a cell line that is 
present in the in vivo tissue could lead to ‘false negative’ results for compounds unable to 
get into cells in vitro. For example HepG2 cells may express low levels of metabolic 
enzymes but if hydrophilic compounds can’t get into the ceU then drug metabolism can’t 
occur. Once the compound is dosed in humans expressing a full range of transporters, 
drug metabolism may occur potentially reducing the efficacy of the compound. 
Alternatively reactive metabolites may be produced, which would increase the risk of 
cellular toxicity.
3.4.2.3 Future Directions
This work concentrated on the expression of transporters in liver, but it would have been 
interesting to see how expression levels in the cell lines compared to expression in kidney 
and jejunum tissue. Previous studies have shown that expression of drug transporters in 
Caco2 cells correlates very well with levels in human jejunum (Taipalensuu et al., 2001; 
Hilgendorf et al., 2007), while levels in HEK cells should in theory correlate better with 
levels in kidney tissue. It would also be useful to ascertain the basal expression of 
transporters in the dog kidney cell line, MDCKII, as the presence of dog transporters is 
known to interfere in the vectorial transport of drugs across these cells when they are 
transfected with human transporters (Bartholome et al., 2007).
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3.4.3 The Effect of Transfecting Transporters into Cell Lines
One possible way to increase the cellular access of a hydrophilic compound to one of the 
cell lines tested, would be to transfect cells with an influx transporter. The same can be 
done with efflux transporters to investigate the substrate specificity of a particular 
transporter. MDCKII cells are often transfected with human influx and efflux 
transporters to study vectorial transport across polarised cells (Bartholome et al., 2007). 
This study has shown that transfection of ABCBl into MDCKII cells, ABCG2 into 
HEK cells and SLCOIBI into Huh7 cells, increases the mRNA expression of the 
transfected transporter.
However in the cell lines tested, transfection of a particular transporter affects the 
expression of other transporters already expressed in the cell. In HEK cells, the over 
expression of ABCG2 caused an increase in the expression of the other apical 
transporters, ABCBl and ABCC2. At the same time the expression of basolateral 
transporters was increased only slightly in the transfected cells compared to the mock 
transfectants. It is possible that some unknown mechanism exists to regulate apical 
transporters at a transcriptional level that does not affect the basolateral transporters. 
While the basal level of endogenous dog transporters was not measured in MDCKII 
cells, it would be interesting to see if they are altered as this is a cell line regularly 
transfected with human transporters and changes in dog transporters could alter results 
(Bartholome et al., 2007). Also unlike HEK cells, MDCKII cells polarise so any 
mechanism that controls the expression of apical/basolateral transporters may be more 
apparent.
A number of transporters were affected by the over expression of SLCOIBI in Huh7 
cells although there is no apparent pattern in the up or down regulation of different 
transporters. Interestingly SLC22A1 levels appear to be up-regulated while SLC02B1 
levels are significantly down regulated; the reasons behind this are unclear. ABCC3 
mRNA was not affected by the transfection and this was confirmed at the protein level 
indicating that for this gene, RNA levels are indicative of protein expression.
The net result of changes to transporter expression following transfection is ultimately to 
make extrapolation more complex, as transfecting a transporter doesn’t necessarily 
increase its levels to the same as in vivo and it appears to affect the expression of other
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transporters. As changes at the mRNA level are not always indicative of protein and 
functional levels, a small increase in one transporter such as ABCBl could match a larger 
increase in another such as ABCG2. This could potentially affect the results given by 
assays using such cell lines. Many drugs are transported by ABCBl, ABCC2 and ABCG2 
(Litman et al., 2000) and the assay using HEK cells transfected with ABCG2 to test new 
compounds for being ABCG2 substrates (Kevin Jones, personal communication) could 
potentially overestimate the role of ABCG2 in efflux.
Alterations in gene expression caused by a change to another gene in this way have been 
seen before in in vivo studies. For example altering the level of a transporter in mice has 
been shown to effect the expression of cytochrome P450’s (Schuetz et al., 2000) and 
other transporters (Kuroda et al., 2004). The reasons for this remain speculative but it 
may be that altering the level of a transporter changes the intracellular availability of 
extracellular components, which may alter gene expression via interactions with 
regulatory factors. It has also been seen in animal models that when a transporter is 
absent others are upregulated to compensate for the loss, for example Abcc2 is absent in 
EHBR rats (Buchler et al., 1996) but Abcc3 is induced to avoid a toxic build up of bile 
acids and bilirubin in the cell (Keppler and Konig, 2000).
The transfection of SLCOIBI into Huh7 cells may improve compound access to 
hydrophilic SLCOIBI substrates but as it affects levels of other transporters it is unlikely 
to make Huh7 cells more like hepatocytes. However in assays where cellular access may 
be problematic, the ability to compare results from cells transfected with an influx 
transporter with wild type cells may help predict ADME and/or toxicology 
characteristics of a compound.
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3.4.4 Summary
In summary, the expression of drug transporters differs in cell lines compared to liver 
with liver-derived cell lines being more representative of hepatocytes than cell lines 
derived from extra-hepatic tissue, although even these cells show significant variation 
from the in vivo tissue. The relative expression of basolateral and apical transporters in 
cell lines differs due to an unknown mechanism and this extends to basolaterl influx 
transporters, all of which are down regulated in cell lines compared to liver. Access of 
hydrophilic compounds to cells may be difficult in the absence of the correct 
transporters with implications for ADME and toxicology work carried out in them.
Transfection of transporters into cell lines increases levels of the transfected transporter 
but also affects the transcript levels of other transporters. In the case of HEK cells, the 
expression of apical transporters was affected more than that of basolateral transporters. 
Again the mechanism behind this is unclear. The transfection of uptake transporters into 
cell lines may improve cellular access to hydrophilic drugs and this will be investigated in 
the next chapter.
In conclusion, variable expression of drug transporters at the mRNA level in cell Hnes 
compared to liver means they should be used only with differences in transporter 
expression taken into account in hepatic drug transport studies especially in cases where 
compound access is likely to be an issue.
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4 Compound Access to Cell Lines
4.1 Introduction
The previous chapter identified a large discrepancy between the expression of drug transporter 
transcript in human-derived cell lines compared to the expression levels found in samples of 
human liver. This was especially true of the influx transporters SLCOIBI, 1B3 and 2B1 as 
well as SLC22A1 and SLClOAl indicating that compound access may be reduced in cell lines 
relative to that observed in vivo.
Low compound access to cells due to the lack of an influx drug transporter would result in 
false negative results in assays looking at, for example, the metabolism of drugs because if 
compound can not get into cells it cannot be metabolised even though this would occur in the 
‘real’ situation with drug transporters present. Assays measuring hepatotoxicity would likewise 
be affected, for if compound can’t get into the cell line being used, it can’t cause toxicity.
Previous experiments in this laboratory to measure the ability of a number of compounds to 
induce expression of the drug metabolising enzyme CYP3A4, found that the HMG CoA 
reductase inhibitors, simvastatin and lovastatin were potent inducers while pravastatin, a 
structurally similar compound, was the least potent compound tested (El-Sankary et al., 2001). 
The experiment used HepG2 cells and while simvastatin and lovastatin are lipophilic 
compounds, pravastatin is hydrophilic and doesn’t cross cell membranes without the help of 
an active transporter, namely OATPIBI. It was therefore hypothesised that the lack of 
induction of CYP3A4 by pravastatin was not due to a lack of inductive ability but rather that 
the compound could not access cells i.e. it was a false negative result.
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4.1.1 The HMG CoA Reductase Inhibitors
The HMG CoA reductase inhibitors, or ‘Statins’ as they are more commonly known, are a 
class of drugs used to treat hypercholestremia in order to prevent incidences of cardiovascular 
disease. They reduce de novo cholesterol synthesis by inhibiting HMG-CoA reductase (Figure
4-1), the rate limiting enzyme in the cholesterol biosynthesis pathway (Dietschy and Wilson, 
1970a; Dietschy and Wilson, 1970b; Dietschy and Wilson, 1970c). Each compound in the 
statin class contains a mevalonic acid moiety that inhibits product formation by the reductase 
(Alberts et al., 1980).
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Figure 4-1 The cholesterol biosynthesis pathway.
The HMG-CoA reductase inhibitors or ‘statins’ inhibit HMG-CoA reductase, which is responsible for 
the conversion of HMG-CoA to mevalonic acid. Products in the cholesterol synthesis pathway are 
given in black with the enzymes that catalyse each reaction in blue. ‘STATINS’ indicates where the 
HMG CoA reducatse inhibitors have their effect on reducing the de novo synthesis of cholesterol.
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Most cholesterol synthesis occurs in the liver and it must therefore be transported to other 
tissues where it is vital in forming functional plasma membranes. In the circulation cholesterol 
forms part of lipoprotein complexes, which can be separated by their density as high (HDL), 
intermediate (IDL), low (LDL) or very low (VLDL) density lipoproteins. Newly synthesised 
cholesterol is incorporated into VLDL particles for release into the circulation where it is 
transformed to LDL and IDL particles for transport to other tissues. HDL particles are 
thought to bring cholesterol back into the liver from the circulation and it is therefore 
described as ‘good cholesterol’ because it reduces the amount in the systemic circulation 
whereas LDL or ‘bad cholesterol’ increases levels of cholesterol in the blood (Linsel-Nitschke 
and Tall, 2005).
A reduction in cholesterol synthesis by the HMG CoA reuctase inhibitors, leads to an 
upregulation of LDL receptors on hepatocytes, which increases the uptake of LDL and thus 
cholesterol from the systemic circulation. The combined effect of reducing de novo synthesis 
and the upregulation of LDL receptors leads to a typical reduction in LDL cholesterol of 20- 
35% (Linsel-Nitschke and TaU, 2005) although rosuvastatin, the most recently marketed 
compound in the statin class, reduces LDL by 63 % (Olsson et al., 2001). Lipid lowering 
contributes to the stability of atherosclerotic plaques in blood vessels, possibly by reducing 
plaque size or by modifying the lipid composition of the plaque, or a combination of both. 
Plaque rupture is a major cause of cardiovascular disease (Linsel-Nitschke and TaU, 2005) so 
by stabilising atherosclerotic plaques statins reduce cardiovascular disease by around 30-35% 
(Lennernas and Fager, 1997).
The chemical structure of each HMG CoA reductase inhibitor can be split into three main 
areas (Figure 4-2); first, aU the compounds include an analogue of HMG CoA, which is the 
substrate for the reductase they inhibit; second, the HMG CoA-like group is attached 
covalently to a hydrophobic ring structure, involved in the binding of the drug to the 
reductase; and finally, side groups affect the solubility and lipophilicity of the compound. 
Simvastatin, lovastatin and pravastatin, which are all fungal-derived compounds (Alberts et al., 
1980; Endo, 1992), share very similar structures although the hydroxyl groups make 
pravastatin more hydrophilic than simvastatin or lovastatin (Table 4-1; Figure 4-2). 
Fluvastatin, pitavastatin, cerivastatin, atorvastatin and rosuvastatin are synthetically derived 
compounds and again share structural similarities, for example they all contain a fluoride side 
group (Figure 4-2).
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Simvastatin and lovastatin are administered as inactive lactone prodrugs, which are hydrolysed 
to P-hydroxyacids after absorption (Corsini et al,, 1995) by esterases and paraoxonases 
(BiUecke et al., 2000) whereas the other statins are administered in the active P-hydroxyacid 
form. Pravastatin differs from the other statins in pharmacokinetic properties due in part to 
its greater hydrophilicity (Table 4-1). For example pravastatin does not undergo metabolism 
by cytochrome P450’s (Everett et al., 1991; Fujino et al., 2004) and a larger proportion of 
pravastatin (20 %) is eliminated in the urine than the other statins (5-13 %) (Lennernas and 
Fager, 1997). As 34 % of an oral dose of pravastatin is excreted in the bile as unchanged drug 
(Everett et al., 1991), enterohepatic recirculation is thought to play a role in its disposition 
(Komai et al., 1992).
HMG Co A Reducatse Inhibitor LogDyo
Simvastatin (acid) 4.4 (1.88)
Lovastatin (acid) 3.91 (1.51)
Pravastatin -0.47
Fluvastatin 1.75
Atorvastatin 1.53
Cerivastatin 2.32
Pitavastatin * 1.5
Rosuvastatin ** -0.25 to -0.5 (LogDy.s)
Table 4-1 Lipophilicity of the HMG CoA reductase inhibitors.
The partition coefficients (LogD) of each statin at pH 7.0 are shown (except rosuvastatin where LogD 
was calculated at pH 7.5). Values are taken from (Ishigami et al., 2001) except * (Hitano et al., 2005) 
and ** (Holdgate et al., 2003).
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4.1.1.1 Uptake of the HMG CoA Reductase Inhibitors
The HMG CoA reductase inhibitors are all relatively selective for the liver, their target organ, 
as most de novo synthesis of cholesterol occurs here. The lipophilic statins such as simvastatin 
and lovastatin, can passively diffuse into ceUs and are selective for hepatocytes due to efficient 
‘first pass’ uptake. The hydrophilic statins such as pravastatin and rosuvastatin are substrates 
for transporter proteins. OATPIBI transports pravastatin into hepatocytes, and as OATPIBI 
is only expressed in hepatocytes (Nakai et al., 2001), distribution of the drug is limited to the 
liver and this transport is rate limiting in disposition of pravastatin (Yamazaki et al., 1997). 
Rosuvasatin is taken up into cells by a number of transporters including OATPIBI, 
OATP1B3, OATP2B1, OATP1A2 and NTCP (Ho et al., 2006) and so is mainly but not solely 
targeted to the liver.
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4.1.2 Compound Access of the HMG CoA Reductase Inhibitors
To assess if the lack of influx transporter expression in transformed cell lines such as Huh7 
and HepG2 was causing the previously observed lack of CYP3A4 induction by pravastatin (El- 
Sankary et al., 2001), reporter gene technology was used to examine the potential mechanisms 
underlying the observed differences between pravastatin and simvastatin/lovastatin. Initially, 
Huh7 cells were exposed to the HMG-CoA reductase inhibitors to investigate any statin- 
mediated induction of CYP3A4 expression by these compounds, using a CYP3A4-SEAP 
reporter gene construct. Next, computer-based modelling was used to examine the ability of 
all three statins to bind into the ligand-binding pocket of PXR. To examine if the level of 
OATPIBI in Huh7 cells, previously shown to be relatively low compared to liver (section 
3.23), impacts upon pravastatin activation of CYP3A4 by limiting access of pravastatin to cells, 
experiments were undertaken using the SLCOIBI expression plasmid to increase levels of 
OATPIBI.
The expression of many other ADME genes are also under the control of PXR, including both 
phase I and II metabolic enzymes and drug transporters such as ABCBl and ABCC2. As 
increasing evidence suggests that target gene activation may be ligand specific, it is therefore 
important to ascertain if pravastatin is negative for CYP3A4 transcriptional activation alone, or 
for more PXR target genes. Therefore reporter genes containing the promoter regions of 
human ABCBl and rat Abcc2 were used to assess the ability of the HMG CoA reductase 
inhibitors to activate different genes under the control of the same transcription factor.
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4.2 CYP3A4 Induction by the HMG-CoA Reductase Inhibitors
Huh7 cells transfected with the CYP3A4-SEAP reporter gene were dosed with lOpM 
simvastatin, lovastatin or pravastatin, 50 pM rifampicin as a positive control and 0.1% DMSO 
as a vehicle control for 48 hours. The medium was removed from ceUs and the concentration 
of secreted alkaline phosphatase (SEAP) was measured to give the induction of CYP3A4 by 
each of the drugs (Figure 4-3). Induction was observed when cells were dosed with the 
positive control, rifampicin, as well as simvastatin and lovastatin but not with pravastatin.
ns
Figure 4-3 Induction of CYP3A4 in Huh7 cells by Rifampicin, Simvastatin and Lovastatin but 
not Pravastatin.
Huh7 cells were transfected with the CYP3A4 reporter gene and a PXR expression plasmid before 
being exposed to 0.1% DMSO (vehicle control), 50pM rifampicin or 10 pM lovastatin, simvastatin or 
pravastatin. The level o f induction was assessed by measuring the luminescence from the reporter gene 
product. Data was adjusted for background luminescence and expressed as fold induction over the 
control. Results were analysed by one-way ANOVA with Bonferroni post-hoc test and show where 
activation of the CYP3A4 promoter in response to drug treatment is significandy different to the 
DMSO control (** = p < 0.05, *** = p < 0.01, ns = not significant; n=6; error bars = SEM, where no 
error bars are observed they are contained within the limits o f the data point).
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4.2.1 Dose Response of CYP3A4 Induction
To further examine the induction profile of the CYP3A4 reporter gene by these drugs, and to 
ensure that lack of induction by pravastatin was not dose-related, Huh7 cells transfected with 
the CYP3A4-SEAP reporter gene were dosed with 0.01 — 30 pM rifampicin, simvastatin or 
pravastatin. Induction of CYP3A4 was measured by assessing the concentration of SEAP 
(Figure 4-4). CYP3A4 induction by rifampicin had an ECgg of 0.96 pM + /-  0.15 pM , in line 
with previous findings (Lehmann et al., 1998), whereas for simvastatin the EC 5 0  was calculated 
to be 4.75 pM + /-  0.79 pM. The maximal induction for simvastatin is higher than that of 
rifampicin indicating that simvastatin is a more potent inducer of CYP3A4 at the same dose. 
Pravastatin did not induce CYP3A4 even at high doses. This data can be used to calculate the 
inductive ability (lA) of rifampicin and simvastatin (Table 4-2) by dividing the I^ ,^^  (measured 
as specific chemical effect, SCE) by the ECgg. SCE takes the dose of compound into account 
and is measured using Equation 4-1 (El-Sankary et al., 2001).
Imax * drug concentration
Specific Chemical Effect (SCE) =
EC5 0  + drug concentration
Equation 4-1 Specific Chemical Effect
Concentration 
of drug at I ^
Im. (SCE) EC5 0 Inductive Ability 
(lA)
Rifampicin 50 pM 15.17 0.96 15.83
Simvastatin 50 pM 26.82 4.75 5.65
Table 4-2 Kinetic values for the induction of the CYP3A4 reporter gene by rifampicin and 
simvastatin.
Imax and EC5 0  were derived from the dose response curves of each dmg and used to calculate the 
CYP3A4 inductive ability of rifampicin and simvastatin.
The media was checked for the presence of lactate dehydrogenase (LDH), a marker of cell 
death. No significant increase in LDH was seen when cells were dosed with drug compared to 
control (data not shown).
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Figure 4-4 D ose response of 
CYP3A4 induction by (A) 
rifampicin, (B) simvastatin 
and (C) pravastatin.
Huh7 cells were transfected with 
the CYP3A4 reporter gene and a 
PXR expression plasmid before 
being exposed to 0.1% DMSO 
(vehicle control), 0.01 -  30 pM 
rifampicin, simvastatin or 
pravastatin. The level of
induction was assessed by 
measuring the luminescence 
from the reporter gene product. 
Data was adjusted for
background luminescence,
expressed as fold induction over 
the control and fitted using non­
linear regression analysis (n=3; 
error bars = SEM; where no 
error bars are observed they are 
contained within the limits o f the 
data point.). The EC 50 was 
calculated to be 0.96 pM + /-  
0.15 pM and 4.75 pM + /-  0.79 
pM for rifampicin and 
simvastatin, respectively. An 
EC50 could not be calculated for 
pravastatin.
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4.2.2 RNA Interference of SLCOIBI Expression
Pravastatin is taken up into cells by OATPIBI (Nakai et ak, 2001), therefore to demonstrate 
that SLCOIBI was not important in the simvastatin-mediated activation of CYP3A4 gene 
expression, siRNA was utilized to reduce expression levels of SLCOIBI. Huh7 ceUs were 
plated with 1 nM SLCOIBI siRNA or 1 nM control siRNA and transfection reagent followed 
by transfection with the PXR expression plasmid and the CYP3A4-SEAP reporter gene 
construct 24 hours later. CeUs were dosed with 0.1 % DMSO, 50 pM rifampicin, 10 pM 
simvastatin or 10 pM pravastatin. SLCOIBI was knocked down at the mRNA level by 80% 
compared to cells transfected with control siRNA (Figure 4-5).
Ü  100
Figure 4-5 Expression of SLCOIBI mRNA in Huh? cells treated with control or SLCOIBI 
siRNA.
Huh? cells were plated in 96 well plates with either control siRNA or SLCOIBI siRNA and the 
transfection reagent, lipofectamine RNAMAX. The extent o f knockdown was measured by 
quantitative measurement of SLCOIBI transcript levels by RT-PCR. Results are expressed as a 
percentage o f the level of SLCOIBI transcript in the control cells. Data was analysed by one sample t- 
test (**** = p<0.0001; n=10, error bars = SEM).
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Induction of CYP3A4 was measured by assessing the concentration of SEAP in ceil medium 
after 48 hours of dosing (Figure 4-6). Although significant induction was observed with 
rifampicin and simvastatin over the vehicle control, no change in induction of CYP3A4 by 
rifampicin, simvastatin or pravastatin was observed following reduction of SLCOIBI 
expression. Therefore, reduction of SLCOIBI expression by siRNA can be used to 
demonstrate that the activation of CYP3A4 gene expression by rifampicin and simvastatin is 
independent on SLCOIBI expression.
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Figure 4-6 Induction o f CYP3A4 when SLCOIBI was ‘knocked down’ by RNAi.
SLCOIBI was knocked down by 1 nM SLCOIBI siRNA in Huh7 cells, which were then transfected 
with the PXR expression plasmid and the CYP3A4 reporter gene. Cells were exposed to 0.1% DMSO 
(vehicle control), 50 pM rifampicin or 10 pM simvastatin or pravastatin. The level o f induction was 
assessed by measuring the luminescence from the reporter gene product. Data was adjusted for 
background luminescence and expressed as fold induction over the control. Results were analysed for 
significant induction over the DMSO control by one-way ANOVA with Newman-Keuls post-hoc test 
(** = p<0.01, *** = p<0.001; black = control siRNA, grey = SLCOIBI siRNA; ns = not significant; 
n=4). A two-way ANOVA was performed with Bonferroni post hoc test to evaluate the difference 
between induction in cells where SLCOIBI was knocked down compared to control; there was no 
significant difference (ns) in activation of the CYP3A4 promoter (n=4; error bars = SEM; where no 
error bars are observed they are contained within the limits of the data point).
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4.2.3 In Silico Analysis of Ligand Binding to PXR
A possible alternate explanation for the observed lack of activation of the CYP3A4 promoter 
by pravastatin may be that it is unable to bind and activate PXR; therefore, in silico modelling 
was used to examine if pravastatin was liable to act as a ligand for PXR. Using Autodock 
(v.3.0.5) each of the three statins was docked into the ligand-binding domain (LBD) of PXR, 
tiie crystal structure of which was obtained from the RCSB protein data bank 
(www.rcsb.org/pdb/index) (Watkins et al., 2001). To account for potential changes in protein 
conformation upon ligand binding, this procedure was undertaken against the crystal structure 
with rifampicin docked, as opposed to the receptor alone. From this analysis. Autodock 
identified the 150 most favourable conformations for each statin binding to PXR, and Figure 
4-7 shows histographs of the frequency of predicted binding energies for each compound 
examined.
The most frequent binding energies for the statins are -11 kj for pravastatin and lovastatin and 
-9.5 kJ for simvastatin. According to the law of Gibbs free energy (Equation 4-2) this makes it 
likely that pravastatin would be as good a ligand for PXR as simvastatin and lovastatin, as the 
more negative the binding energy, the higher the binding constant.
AG^-RTlnKo
Equation 4-2 Gibbs Free Energy
Where AG = Gibbs free energy (kJ), R = gas constant, T  = temperature and Kd is the binding 
constant.
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Figure 4-7 Frequency o f binding energies o f (A) pravastatin, (B) lovastatin and (C) simvastatin 
bound to PXR.
Autodock 3.0.5 was used to find the 150 most favourable binding conformations o f the HMG-CoA 
reductase inhibitors, pravastatin (A), lovastatin (B) and simvastatin (C), to the ligand binding domain of 
PXR. The frequency o f each binding energy is shown for each of the most energetically favourable 150 
conformations. Autodock search parameters: 150 G A runs, 100 pop size, 1000000 energy evaluations, 
100000 max generations, LS runs 500 and 3000 max iterations.
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To further examine the putative binding of pravastatin in to the PXR ligand binding pocket, 
the potential hydrogen bonds formed between ligand and receptor were examined for the 
most energetically favourable conformation. Figure 4-8 shows an in silico model of the ligand- 
binding domain (LBD) of PXR, derived from the crystal structure, with the prototypical PXR 
agonist rifampicin docked (Chrencik et al., 2005). Figure 2A shows the orientation of the most 
energetically favourable pravastatin conformation over-laid on this model, and figure 2B 
highlights important amino acid residues (Ser^ '^ ,^ Gln^ ®^  and His'^ )^ predicted to form hydrogen 
bonds with pravastatin in its docked conformation. These amino acids have previously been 
shown experimentally, through mutagenesis experiments, to be important for hydrogen 
bonding of substrates to the LBD of PXR (Watkins et al., 2001; Chrencik et al., 2005). For all 
three of these amino acids it can be seen that potential electrostatic interactions are possible, 
with the distance between each amino acid and pravastatin being approximately 2Â.
A B
Figure 4-8 The most favourable energy conformation of pravastatin (yellow) superimposed on 
rifampicin (red) binding to the ligand binding domain o f PXR (blue).
The most energetically favourable binding position o f pravastatin found in the Autodock analysis was 
overlayed on the crystal structure of the PXR ligand binding domain bound to its prototypical 
substrate, rifampicin (A). A closer view of the binding indicates that pravastatin is capable o f forming 
hydrogen bonds with amino acids (Ser247, His407 and Gln285) in the LBD of PXR (B).
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4.2.4 Transport of Phenol Red
Literature suggests that rat Slcolal, which transports pravastatin into rat hepatocytes (Hsiang 
et ai., 1999), also transports phenol red, a common component of cell culture medium 
(Schwab et al., 2001). It was therefore important to ascertain that SLCOIBI transport of 
phenol red into human hepatocytes was not inhibiting the uptake of pravastatin through 
competition for the transporter. Any competition could result in a decrease in the intracellular 
concentration of pravastatin, effectively reducing the exposed dose. To examine this, the 
induction of CYP3A4 was repeated using phenol red free medium. There was no discernable 
change between activation of the CYP3A4 promoter by any of the tested agents when phenol 
red was absent from the culture medium; both rifampicin and simvastatin were still seen to be 
potent activators of CYP3A4, whereas pravastatin failed to cause PXR-mediated activation of 
the CYP3A4 promoter (Figure 4-9 compared to Figure 4-3), confirming that phenol red in the 
medium was not preventing compound access through competition for uptake transporters.
Figure 4-9 Induction of CYP3A4 in Huh? cells when phenol red was omitted from the 
medium.
Huh? cells were transfected with the CYP3A4 reporter gene and PXR before being exposed to 0.1% 
DMSO (vehicle control), SOpM rifampicin or 10 pM simvastatin or pravastatin in DMEM without 
phenol red. The level o f induction was assessed by measuring the luminescence from the reporter gene 
product. Data was adjusted for background luminescence and expressed as fold induction over the 
control. Results were analysed by one-way ANOVA with Bonferroni post-hoc test and show where 
activation of the CYP3A4 promoter in response to drug treatment is signiticandy different to the 
DMSO control (*** = p < 0.01, ns = not significant; n=6; error bars = SEM; where no error bars are 
observed they are contained within the limits o f the data point).
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4.2.5 The Effect of Over-expression of SLCOIBI on CYP3A4 Induction by 
Pravastatin
Results from the previous chapter showed that the expression level of many uptake 
transporters is significantly reduced in cell lines derived from hepatocytes. In order to examine 
if this was a limiting factor for compound uptake increased expression of SLCOIBI was 
achieved through the co-transfection of a SLCOlBl-pTriExl.l expression plasmid into Huh? 
cells with the PXR expression plasmid and the CYP3A4-pSEAP construct. Cells were dosed 
with 0.1 % DMSO, 50 [xM rifampicin, 10 pM simvastatin or 10 pM pravastatin. The 
expression level of SLCOIBI mRNA was quantitatively measured using RT-PCR in mock- 
transfected cells and transfected cells and compared to expression in human hver (Figure 
4-10).
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Figure 4-10 Expression o f SLCOIBI mRNA in Huh? cells transfected with empty pT riExl.l or 
pTriExl.l-SLCO lBl.
The expression o f SLCOIBI mRNA was quantified using RT-PCR in Huh? cells transfected with 
pTriExl.l or pTriExl.l-SLC O lB l. Data is normalised to levels o f GAPDH and expressed as a 
percentage of the expression of SLCOIBI in the mock-transfected cells. (n=3; error bars = SEM).
Induction of CYP3A4 was measured by assessing the concentration of SEAP in cell medium 
after 48 hours of dosing (Figure 4-11). Again, induction was significant when cells were 
treated with rifampicin, simvastatin and lovastatin compared to vehicle control and no change 
in induction of CYP3A4 by rifampicin, simvastatin or pravastatin was observed following
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over-expression of SLCOIBI. However there was a small but significant increase in the 
activation of the CYP3A4 promoter by lovastatin when SLCOIBI expression was increased. 
Therefore, increasing SLCOIBI expression by transient transfection can be used to 
demonstrate that the activation of the CYP3A4 promoter by pravastatin is not dependent on 
SLCOIBI expression but it does affect activation by lovastatin. As the addition of a third 
plasmid in to the co-transfection may have adversely affected cell viability this was examined 
through examination of the level of lactate dehydrogenase (LDH) in the cell culture medium as 
a measure of cell death. No difference in LDH levels was observed between control cells and 
the cells transfected with the SLCOIBI over-expression plasmid (data not shown).
* * * pTriExI .1 
pTriEx1.1-SLCG1B1
Rifampicin Simvastatin Lovastatin Pravastatin
Figure 4-11 Induction o f CYP3A4 when SLCOIBI was over expressed in Huh? cells.
pTriExl.l-SLCOIBI or empty pTriExl.l (vector control) was transfected into Huh? cells with the 
PXR expression plasmid and the CYP3A4-SEAP reporter gene construct. Cells were dosed with 0.1 % 
DMSO (vehicle control), 50 pM rifampicin or 10 pM simvastatin, lovastatin or pravastatin for 48 
hours. The level o f induction was assessed by measuring the luminescence from the reporter gene 
product. Data was adjusted for background luminescence and expressed as fold induction over the 
control. Results were analysed for significant induction over the DMSO control by one-way ANOVA 
with Newman-Keuls post-hoc test (*** = p<0.001; black = pTriExl.l control, grey = pTriExl.l 
SLCOIBI transfectants; ns = not significant; n=6). A two-way ANOVA was performed with 
Bonferroni post hoc test to evaluate the difference between induction in cells with increased SLCOIBI 
levels compared to control in activation of the CYP3A4 promoter (* = p<0.05; ns = not significant; 
n=6; error bars = SEM; where no error bars are observed they are contained within the limits o f the 
data point). Figure is representative o f at least three independent measurements.
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4.3 Activation of the ABCBl Promoter by the HMG-CoA Reductase Inhibitors
To assess whether the previously observed results extended beyond the proto-typical PXR 
target gene, CYP3A4 activation of other PXR target genes was examined. The ABCBl-pSEAP 
plasmid, which was cloned within the laboratory by Fadheela Salman, was transfected into 
Huh7 cells with the PXR expression plasmid and either the SLCO1B1 -pTriExl. 1 expression 
plasmid or empty pTriExl.l. Cells were dosed with 50 pM rifampicin or 10 pM simvastatin, 
lovastatin or pravastatin for 48 hours. The medium was removed from the cells and SEAP 
activity was measured to give induction of ABCBl over the DMSO control for each 
compound (Figure 4-12). Significant induction over vehicle control was observed when cells 
were dosed with rifampicin, simvastatatin and lovastatin but not pravastatin, consistent with 
this being a PXR-target gene effect, and not limited to CYP3A4 alone. No significant 
difference in induction was observed when the SLCOIBI expression plasmid was transfected 
into cells compared to the vector control.
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Figure 4-12 Induction o f ABCBl in Huh? cells by the HMG-CoA reductase inhibitors when 
cells were transfected with SLCOIBI compared to control.
Huh? cells were transfected with the ABCBl reporter gene, a PXR expression plasmid and either the 
SLCOIBI expression plasmid or empty vector (pTriExl.l). Cells were dosed with 0.1 % DMSO 
(vehicle control), 50 pM rifampicin or 10 pM simvastatin, lovastatin or pravastatin. The level of 
induction was assessed by measuring the luminescence from the reporter gene product. Data was 
adjusted for background luminescence and expressed as fold induction over control. Results were 
analysed for signiticant induction over the control by one-way ANOVA with Newman-Keuls post-hoc 
test (* = p<0.05, ** = p<0.01, *** = p<0.001; black = empty vector control, grey = cells tranfected 
with SLCOIBI; n=4; ns = not signiticant). A two-way ANOVA was performed with Bonferroni post 
hoc test to evaluate the difference between induction in cells transfected with SLCOIBI compared to 
control; there was no signiticant difference (ns) in induction (n=4; error bars = SEM; where no error 
bars are observed they are contained within the limits o f the data point). Figure is representative o f at 
least two independent measurements.
133
4.4 Activation of the Abcc2 Promoter by the HMG-CoA Reductase Inhibitors
Abcc2-pSEAP, which was cloned in this laboratory by Ana Sousa-Marcelino, was transfected 
into Huh? cells with the PXR expression plasmid and either the SLCOlBl-pTriExI.l 
expression plasmid or empty pTriExl.l, with the experimental rationale as described 
previously. Cells were dosed with 50 pM rifampicin or 10 pM simvastatin, lovastatin or 
pravastatin for 48 hours. The medium was removed from the cells and SEAP activity was 
measured to give induction of Abcc2 over the DMSO control for each compound (Figure 
4-13). Induction was observed when cells were dosed with rifampicin, simvastatin and 
pravastatin, confirming this gene to be a PXR target gene. Interestingly, pravastatin once again 
failed to cause activation in the basal cell state but a significant increase in Abcc2 promoter 
activation was observed when SLCOIBI had been transfected into the cells.
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Figure 4-13 Induction of Abcc2 in Huh? cells by the HMG-CoA reductase inhibitors when  
cells were transfected with SLCOIBI compared to control.
Huh? cells were transfected with a reporter gene containing the rat Abcc2 promotor region, as well as a 
PXR expression plasmid and either the SLCOIBI expression plasmid or empty vector (pTriExl.l). 
CeUs were dosed with 0.1 % DMSO (vehicle control), 50 pM rifampicin or 10 pM simvastatin, 
lovastatin or pravastatin. The level of induction was assessed by measuring the luminescence from the 
reporter gene product. Data was adjusted for background luminescence and expressed as fold 
induction over control. Results were analysed for significant induction over the control by one-way 
ANOVA with Newman-Keuls post-hoc test (* = p<0.05, ** = p<0.01, *** = p<0.001; black = empty 
vector control, grey = ceUs tranfected with SLCOIBI; n=4; ns = not significant). A two-way ANOVA 
was performed with Bonferroni post hoc test to evaluate the difference between induction in ceUs 
transfected with SLCOIBI compared to control (** = p<0.01; n=4; error bars = SEM; where no error 
bars are observed they are contained within the limits o f the data point).
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4.5 Discussion
Results from the previous chapter highlighted the fact that the expression of drug influx 
transporters was very low in cell lines compared to liver and it was hypothesised that this may 
limit hydrophilic compound access to cells. Previous work in this laboratory indicated that, in 
HepG2 cells transfected with a CYP3A4 reporter gene, simvastatin and lovastatin were potent 
activators of CYP3A4 transcription via activation of PXR. However, the structurally and 
pharmacologically similar compound pravastatin, was negative in the assay (El-Sankary et al.,
2001). Therefore, the work in this chapter set out to test the hypothesis that a low level of 
OATPIBI in HepG2 and Huh7, limits access of pravastatin to the cells resulting in a lack of 
activation of PXR mediated transcription.
4.5.1 CYP3A4 Induction by Simvastatin and Lovastatin
Simvastatin and lovastatin were found to be inducers of CYP3A4 when a reporter gene 
construct containing the XREM promoter region of CYP3A4 was transfected into Huh? cells. 
At 10 [jlM  simvastatin and lovastatin induced CYP3A4 to a greater extent than 50 pM of 
rifampicin. This mirrors the result previously found when the same construct was transfected 
into HepG2 cells (El-Sankary et al., 2001), showing this to be a robust effect across two 
human hepatocyte-derived ceU lines.
The induction of CYP3A4 gene expression by simvastatin was shown to be dose dependent, 
with an EC5 0  of nearly 5 pM, whereas rifampicin induced CYP3A4 with an EC5 0  of nearly 1 
pM, similar to previous studies (Lehmann et al., 1998), indicating rifampicin is a more potent 
inducer of CYP3A4 than the statins. This was confirmed by calculating the inductive ability of 
rifampicin and simvastatin, which was three times higher for rifampicin than simvastatin.
The induction of CYP3A4 by simvastatin was found to be independent of SLCOIBI after 
siRNA was used to knockdown its expression by 80 % of control levels. CYP3A4 induction 
by rifampicin was also unaffected by SLCOIBI knockdown, which considering it is a substrate 
for OATPIBI (Vavricka et al., 2002) is sUghdy surprising. However rifampicin is a substrate 
for a number of influx transporters (Vavricka et al., 2002) and its uptake is unlikely to be 
limiting to its intracellular activity. Therefore even with reduced levels of OATPIBI, 
rifampicin may stiU get into cells at sufficient quantities to cause induction. It would have been 
interesting to see if SLCOIBI knockdown affected rifampicin mediated CYP3A4 induction at
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lower doses of rifampicin, as the maximum non-toxic dose of the drug was used in studies. 
Alternatively, although the RNAi reduced RNA levels of SLCOIBI, it may not have reduced 
OATPIBI protein expression sufficiently to cause a biological effect, as occurred with the 
glutamate transporter, GluRl, which continues to be detected in cell membranes for over 2 
days after RNA production had ceased (Horikawa and Nawa, 1998). However as the turnover 
rate of OATPIBI appears not to have been measured this point remains speculative.
Previous work has found simvastatin to have a much lower EC 5 0  (El-Sankary et al., 2001) that 
indicated that it should be as potent an inducer of CYP3A4 as rifampicin is, whereas the work 
in this study found a higher ECgg. This may be due to sHght differences in the experimental 
technique, for example the current study used Huh? cells whereas previous work was carried 
out in HepG2 cells. However the current study predicts the in vivo effect of these drugs on 
CYP3A4 better than the previous work, as neither simvastatin nor lovastatin cause CYP3A4 
induction in vivo, whereas rifampicin remains a potent inducer of the enzyme in man (Yew,
2002). The lack of simvastatin and lovastatin induction in vivo is due to differences in the dose 
given in man as well as the potency of the drugs as inducers. Rifampicin is dosed at 600 mg 
per day in man and is a more potent inducer of CYP3A4 with an EC5 0  of around 1 pM. 
Simvastatin and lovastatin are prescribed at a maximum dose of 80 mg per day and were 
calculated in this work to have a higher ECgg. Therefore rifampicin will reach intracellular 
concentrations capable of inducing CYP3A4 but the statins do not. Again the difference in 
inductive ability calculated in this work supports this conclusion.
Caution must be utilised in the prescription of rifampicin during polypharmacy as it can alter 
the pharmacokinetics of co-administered CYP3A4 substrates (LeBel et al., 1998). This is an 
increasing problem as rifampicin is used to treat tuberculosis (TB), which is often found in 
patients with HIV who are also treated with protease inhibitors e.g. ritonavir, some of which 
are CYP3A4 substrates (Barry et al., 1997). Increased levels of CYP3A4 caused by rifampicin- 
mediated increases in gene expression would increase the clearance of CYP3A4 substrates 
such as the protease inhibitors resulting in a possible loss of efficacy. While the statins may 
not be at risk of causing potentially harmful drug interactions due to CYP3A4 they are 
concentrated into the liver either by the effects of first pass extraction or due to specific 
uptake systems. Therefore they do present a potential problem with regards to hepatotoxicity 
and rare incidences of this have been recorded (Davidson et al., 1997). New drugs are usually
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screened for their ability to induce CYP3A4 and such activity may be missed for hydrophilic 
compounds if assays are carried out in cells such as Huh7 or HepG2.
4.5.2 CYP3A4 Induction by Pravastatin
Pravastatin did not cause CYP3A4 induction even at higher doses and this could be due to a 
number of reasons other than cellular access due to a lack of OATPIBI and these were first 
discounted. First, pravastatin was predicted to bind to PXR with a similar affinity to 
simvastatin and lovastatin and in a similar conformation to rifampicin. It was also predicted to 
hydrogen bond to amino acids in the LBD of PXR that have previously been shown to be 
important in PXR activation (Watkins et al., 2001; Chrencik et al., 2005).
Second, cellular access of compounds can be inhibited by competition between compounds 
for one transporter. In rats pravastatin is a substrate for Oatplal (Hsiang et al., 1999), which 
also transports phenol red (Schwab et al., 2001), a pH indicator in cell medium. In theory 
phenol red could be limiting pravastatin influx into cells but this was discounted by removing 
phenol red from the medium with no concurrent increase in pravastatin mediated CYP3A4 
induction.
After these issues had been discounted, Huh7 cells transiendy transfected with the SLCOIBI 
expression plasmid from the previous chapter were also transfected with the CYP3A4 reporter 
gene construct and the PXR expression plasmid before being dosed with the statins. No 
significant change in pravastatin-mediated induction was observed in the SLCOIBI 
transfected cells compared to the mock transfectants indicating that pravastatin does not affect 
CYP3A4 expression. While the increase at transcript level was not confirmed at the protein 
level, the increased effect of lovastatin on the CYP3A4 reporter gene following transfection of 
SLCOIBI would support an increase in uptake activity.
However lovastatin induction of CYP3A4 increased approximately 2 fold in the cells 
transfected with SLCOIBI compared to the mock-transfected cells. This is probably because 
lovastatin is an OATPIBI substrate (Neuvonen et al., 2006) but due to its lipophilic nature, 
allowing passive diffusion, OATPIBI-mediated cellular access of lovastatin is of minor 
importance. When SLCOIBI is transfected into cells, protein levels of OATPIBI may be 
increased above normal cellular levels increasing the amount of lovastatin in cells so increasing 
its effect on CYP3A4. Simvastatin is more lipophilic than lovastatin so the increase in
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OATPIBI has less effect on its intracellular activity. It would have been interesting to dose 
cells where SLCOIBI has been knocked down by siRNA with lovastatin to see if this reduces 
the effect of the compound on CYP3A4, however if passive diffusion predominates then 
knockdown may not be subtle enough to pick up on a minor transport route.
A small, but non-significant increase in rifampicin induction of CYP3A4 is also observed when 
SLCOIBI is transfected into cells. Again this is probably due to it being a substrate for 
OATPIBI so slightly more compound gets into cells. However OATPIBI alone doesn’t 
affect the ability of rifampicin to induce CYP3A4 as it is a very potent activator of PXR and 
can get into cells by other transport systems.
4.5.3 ABCBl and Abcc2 Induction by the Statins
PXR is also known to control the expression of several other genes involved in the disposition 
of drugs (Schuetz et al., 2001). Therefore using two reporter gene constructs previously 
cloned by members of this laboratory containing the promoter regions of human ABCBl and 
rat Abcc2, the effects of statins on the other ADME genes that are PXR targets were assessed.
Simvastatin and lovastatin both induced ABCBl to a greater extent than rifampicin but 
pravastatin showed no inductive ability. However the general level of ABCBl induction was 
low, for example rifampicin only increased ABCBl expression by approximately 2.5 fold. As 
the doses used for each compound were significantly higher than the EC50 observed for 
CYP3A4 gene expression it is unlikely that this is purely a dose-dependent effect, although this 
cannot be discounted. One possible alternate explanation is that the promoter region cloned 
into the reporter gene construct contained only a region of the distal enhancer of the ABCBl 
promoter; full induction may require other regulatory regions such as the proximal promoter 
to be present too. The over expression of SLCOIBI made no significant change to the level 
of induction of ABCBl by any of the compounds tested.
Rifampicin and simvastatin caused small but significant inductions of Abcc2 and this was not 
significandy enhanced by SLCOIBI over expression. Surprisingly, lovastatin caused no 
induction of Abcc2 and the reasons for this are unclear. It could be that the dose was not high 
enough or due to differential gene regulation by the different drugs. Pravastatin caused a 
significant induction of Abcc2 only when SLCOIBI was transfected into cells, presumably 
because more pravastatin can get into to the cells and activate transcription of the promoter.
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As pravastatin didn’t affect CYP3A4 or ABCBl induction this result also supports a theory of 
differential gene regulation.
4.5.4 Differential Gene Regulation
A number of possible explanations exist to rationalise the apparently contradictory results that 
pravastatin can induce Abcc2 but not ABCBl or CYP3A4, while lovastatin can induce 
CYP3A4 and ABCBl but not Abcc2. First, it is possible that different compounds bind to 
PXR and attract different co-activators, which results in differential gene expression. 
Alternatively, the statins may bind and activate different nuclear receptors, which cause 
activation of transcription of a different set of genes to PXR. However it may be that 
incomplete promoter regions of ABCBl and Abcc2 were cloned into the reporter gene so the 
results obtained in this work are misleading. Further work would be needed to ascertain which 
explanation is more likely, but potential explanations wiU be discussed below in the light of 
currently available literature evidence.
4.5.4.1 Can a Nuclear Receptor Induce Different Genes when bound by Different 
Ligands?
The lactone forms of simvastatin and lovastatin are metabolised by CYP3A4 (Prueksaritanont 
et al., 1997; Jacobsen et al., 1999) to produce active drugs, while the lactone forms of the drugs 
are substrates of ABCBl (Sakaeda et al., 2002; Chen et al., 2005) and both forms are substrates 
of ABCC2 (Chen et al., 2005). It therefore makes sense that the cell acts to increase the 
clearance of these compounds by increasing the expression of the three genes. However, 
pravastatin is not metabolised by CYP3A4 and it is not a good substrate of ABCBl so 
increasing levels of these genes in response to pravastatin would not increase clearance of the 
compound from cells. As pravastatin is a substrate for ABCC2 in rats (Yamazaki et al., 1997) 
and humans (Sasaki et al., 2002), increasing ABCC2 levels in response to pravastatin would 
increase the rate of efflux across the canalicular membrane of hepatocytes.
It is possible that when different substrates bind to PXR they induce slightly different changes 
in conformation, which attracts a different set of coactivators. This would change the 
complex of proteins able to induce transcription of genes and might, in theory, alter the genes 
that can be transcribed. There is limited evidence for this hypothesis in mouse studies where 
mice were treated with a number of different nuclear receptor activators and the effects on
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Slco expression were quantified at the mRNA level (Cheng et al., 2005). Three different 
rodent PXR activators, PCN, spironolactone and dexamethasone had differential effects on 
the expression of a number of Slco’s, for example PCN induced Slcola4 expression, whereas 
spironolactone treatment resulted in only slight induction and dexamethasone had no effect. 
AH three compounds were shown to induce Cyp3al 1 levels to a similar degree indicating the 
doses were effective at mediated PXR activation of the enzyme. PCN also showed differential 
expression to the other treatments in the case of Slcola6 and Slcolb2, while spironolactone 
caused a down regulation of Slco4al, which was not caused by the other compounds. 
Dexamethasone caused induction of Cyp2bl0 and again none of the other PXR activators had 
this effect. However, this data must be interpreted with some caution as these compounds are 
known to activate more than one nuclear receptor, for example dexamethasone activates both 
PXR and GRa, meaning that the differential effects observed may be due to differential 
receptor activation as opposed to differential activation of a single receptor. Recent work 
within this laboratory using PCN and LCA also demonstrated differential effects on gene 
expression, although once more it is problematic to definitively exclude the possibility of PXR- 
independent effects (Ian Bailey, personal communication).
4.S.4.2 Could Different Nuclear Receptors be Involved?
Another explanation for observed differential activation of transcription of target genes by 
statins is that they may bind and activate different nuclear receptors. It is well known for 
example that PXR and CAR share substrate specificity but activate the transcription of distinct 
gene sets (Moore et al., 2000; Magüch et al., 2002). CAR is known to bind to the ER6 element 
in the CYP3A4 promoter (Xie et al., 2000) and has also been implicated in the regulation of 
ABCBl (Burk et al., 2005).
Basal expression of PXR in Huh7 cells is low (Phillips et al., 2005), hence the need for 
transfection of a PXR over-expression plasmid into these cells with the reporter gene 
constructs. However, other transcription factors such as GR, RXRa, HNF3a, HNF4a and 
SPl are all expressed in Huh7 cells to differing levels (Phillips et ak, 2005), and it is therefore 
possible that simvastatin, lovastatin or pravastatin activate transcription of different 
transcription factors and thereby have different effects on the reporter genes.
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Cerivastatin, simvastatin, fluvastatin and atorvastatin were all shown to be activators of CAR 
as well as PXR in reporter gene studies (Kobayashi et al., 2005), whereas pravastatin had no 
affinity towards this nuclear receptor. The study reported the use of an SLCOIBI expression 
plasmid had no effect on pravastatins action through CAR but the data was not included in the 
paper (Kobayashi et al., 2005). Another study showed that pravastatin had no effect on 
CYP2B6 or CYP3A4 levels in primary cultures of human hepatocytes indicating once more 
that pravastatin was unlikely to be an activator of PXR or CAR for these genes (Kocarek et al., 
2002).
PXR and CAR are therefore unlikely to mediate the transcriptional regulation of Abcc2 by 
pravastatin unless the hypothesis of differential gene regulation by the same nuclear receptor in 
response to different drugs could be proven. However other transcription factors are involved 
in the regulation of Abcc2 and it is possible that pravastatin mediates its effects through one of 
these factors. For example the transcription factor Nrf2 (nuclear factor-erythroid 2 p45- 
related factor 2) has been shown to regulate Abcc2 transcription in mouse liver and in HepG2 
cells in response to treatment with the Nr£2 activator BHA (butylated hydroxyanisole) 
(VoUrath et al., 2006). Interestingly Abcc2 is likely to form part of a co-ordinately regulated 
network of genes controlled by Nr£2 as GSTs and an enzyme involved in glutathione 
synthesis, glutamate-cysteine ligase catalytic subunit (GCLC), have also been shown to be 
regulated by Nrf2 (VoUrath et al., 2006). It is possible that pravastatin could activate 
transcription through an alternative transcription factor such as Nrf2 or through an as yet 
unidentified mechanism.
4.S.4.3 Promoter Regions used in Reporter Genes
The promoter regions used in the reporter gene constructs consist of either the distal enhancer 
elements (ABCBl) or the proximal promoter region (Abcc2) of the genes studied. In aU these 
cases it is probable that response elements for nuclear receptors exist in both the proximal and 
distal regulatory regions and that maximal activation of transcription may only occur when aU 
the response elements are present. For example the CYP3A4 XREM region contains a DR3 
site (Goodwin et al., 1999) and 200bp of the proximal promoter containing an ER6 site 
(KUewer et al., 1998; Lehmann et al., 1998), both of which PXR can bind to with RXRa. 
However other response elements found in regions not contained in the promoter construct 
may be essential for activation via some complexes.
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Whereas the CYP3A4 XREM construct has been extensively studied, both by this laboratory 
and others, the ABCBl and Abcc2 reporter genes are relatively new and hence have not been 
subject to the same level of validation. Therefore the low activation of the reporter gene may 
be due to the promoter region not containing aU the response elements necessary for a 
maximal response leading to complex results. Further work should be carried out to establish 
if different regions of the promoter have similar effects on expression.
4.5.5 Summary
In summary, the lack of drug influx transporter expression in cell lines derived from human 
tumour tissue, such as Huh7, can result in reduced compound access and lack of biological 
effect. This was exemplified by pravastatin, which only caused activation of the Abcc2 
promoter reporter gene when its influx transporter, SLCOIBI, was transfected into cells. 
However pravastatin had no effect on the CYP3A4 and ABCBl reporter genes while 
simvastatin and lovastatin activated CYP3A4 transcription and simvastatin activated ABCBl 
transcription, suggesting the statin class of drugs causes differential gene activation either 
though different nuclear receptors or by activating PXR to transcribe different target genes 
depending on the ligand.
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5 Drug Transporter Expression and Regulation in Rat Hepatocytes
5.1 Introduction
The previous chapters concentrated on the expression of human drug transporters and 
showed that the level of transporter expression in human cell lines derived from tumour 
tissue differed significandy from the level in human liver at the mRNA level; this 
alteration was seen both in terms of absolute- and relative-expression, and generally 
produced a decrease in the expression of influx transporter number and an increase in 
efflux transporters. Such differences could cause a problem when such cells are dosed 
with hydrophilic compounds, as very low expression of influx transporters may prevent 
compound access, potentially producing experimental anomalies. The ‘gold standard’ for 
in vitro liver cell models is human primary hepatocytes cultured in sandwich formation, 
between two layers of coUagen, as this produces polarised cells with similar functions to 
hepatocytes in vivo, such as a functioning biliary canalicular network (LeCluyse et ak, 
1994).
However, fresh human liver is difficult to obtain and cryopreserved human hepatocytes 
are expensive and often have differential expression of proteins relative to fresh cells. 
Therefore primary rat hepatocytes provide a good substitute, as they are easily obtained 
and cheap to use. Sandwich cultured rat hepatocytes have been used to predict the 
biliary efflux of drugs (Liu et al., 1999) and have recently been shown to be applicable to 
measuring the biliary disposition of both drugs and their metabolites (Turncliff et al., 
2006). However, it is well known that the expression of phase I and II enzymes changes 
with the length of time hepatocytes are cultured for (Wiikening and Bader, 2003) and by 
the method used to culture the cells (Tuschl and Mueller, 2006). Establishing when a 
particular set of transporters reaches the most ‘liver-like’ level could help to determine 
when cells should be dosed during ADME studies to be most accurate. Also, better 
understanding of the differences between monolayer-cultured and sandwich-cultured 
hepatocytes would establish which system of culture should be used for which assay and 
help to interpret results between the two.
Using rat hepatocytes to test drugs destined for human use may potentially cause 
problems, as protein expression and function are not equal between species. Therefore a
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comparison of the expression levels of human and rodent orthologues for the studied 
drug transporters was undertaken to aid the extrapolation of ADME and toxicology data 
from pre-clinical to clinical species. Samples from both Sprague-Dawley and Hans- 
Wistar rats were used in this assessment to determine any differences in expression 
between these commonly used rat breeds and the hepatocytes produced from them.
In light of the results from the reporter gene studies in the previous chapter, an 
assessment was made in the second part of this chapter as to how drug transporter 
expression in rat hepatocytes is affected by nuclear receptor agonists. Drug transporter 
proteins are involved in the disposition of both endogenous compounds and xenobiotics 
within the body, and contribute to setting the pharmacokinetic parameters of individual 
chemicals in the same way as DME’s. The regulation of DME’s by nuclear receptors has 
been fairly well characterised, for example CYP3A4 is regulated via the nuclear receptor 
PXR (Kliewer et al., 1998) and SULTlAl is regulated via the glucocorticoid receptor 
(Duanmu et al., 2001). Several recent studies have found a number of transporters to 
also be under the control of nuclear receptors such as PXR, FXR and PPARa (Geick et 
al., 2001; Kast et al., 2002; Moffit et al., 2006; Hirai et al., 2007). This would imply a 
system of coordinate regulation of both DME’s and transporters (Synold et al., 2001; 
Plant, 2004). To increase the understanding of how the regulation of drug transporter 
gene expression may impact upon drug disposition, and indeed if this co-ordinates with 
the regulation of DME expression, the regulation of drugs transporters were examined 
by exposing hepatocytes to a number of nuclear receptor agonists.
5.1.1 Culture Conditions for Primary Rat Hepatocytes
Several studies have shown that the culture conditions for hepatocyte culture effect the 
expression of metabolic enzymes (LeCluyse et al., 1999) including GSTs (LeCluyse et al., 
2000) and SULTs (Slaus et ak, 2001), as well as transporters (Luttringer et al., 2002; 
Turncliff et al., 2006). Studies have shown that rat hepatocytes cultured in Williams E 
medium rather than DMEM express a more extensive network of büe canaliculi 
(Chandra et al., 2001; Turncliff et ak, 2006), whereas low levels of dexamethasone (30 
nM) are required for the formation of functioning büe canaliculi (Yamada et al., 1980) 
and cause an increase in CYP activity, which would otherwise faU away during culture 
(LeCluyse et al., 1996). A matrigel overlay, which is composed of 60 % laminin, 30 % 
type IV coUagen and 3 % heparin sulphate proteoglycan (Kleinman et ak, 1982), has also
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been reported to improve the formation of bile canaliculi and expression of a number of 
transport proteins in rat hepatocytes (Turncliff et al., 2006).
Therefore, cells were cultured on a layer of type I collagen in 6 well Biocoat ™ plates in 
Williams E medium supplemented with 30 nM dexamethasone. Other medium 
supplements included antibiotics, L-Glutamine, HEPES and 10 % foetal calf serum 
(PCS), although PCS was added only during the initial stages of cell culture to aid 
attachment of cells to cell culture plates (Williams et al., 1977), as hepatocytes that are 
sandwich cultured in medium containing serum have been shown to deteriorate and lose 
büe canalicular structures (Hewitt et al., 2007). Matrigel was overlaid on sandwich- 
cultured ceUs after they had attached to the bottom layer of coUagen, whUe monolayer- 
cultured ceUs were left without an overlay.
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5.2 Expression o f Drug Transporters in Rat Hepatocytes
A number of studies have quantified the expression of drug transporters in primary rat 
hepatocytes; however this is usually done at one time point or only up until cells express 
functioning bile canalicular networks (Luttringer et al., 2002), which usually occurs after 
four days in culture. In the first part of this study the RNA level of 10 transporter genes 
(Table 5-1) was measured in rat hepatocytes cultured either as a monolayer or in 
sandwich culture over a week. Transcript levels were compared to those in rat Hver in 
order to understand how culturing hepatocytes effects transporter expression over time. 
In addition, expression of Abcc2 and Abcc3 protein was confirmed in the same samples 
to increase the biological relevance of the measurements.
Transporter mRNA
Efflux Influx
Abcbl Slcolal
Abcb4 Slcola4
Abed Slcolb2
Abcc2
Abcc3
Abcc4
Abcg2
Table 5-1 Rat drug transporter genes detected in primary cultures o f rat hepatocytes and 
rat liver.
The transcript level for a number of efflux and influx drug transporter, known to be important in 
ADMET processes (FDA guidance to industry, 2006), were measured in primary cultures of rat 
hepatocytes. The expression level in rat Hver was also measured and used as a comparison.
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5.2.1 Drug Efflux Transporter Transcript Expression in Rat Hepatocytes
The RNA level of the apical drug efflux transporters Abcbl and Abcb4 (Figure 5-1), 
Abcc2 and Abcg2 (Figure 5-2) and the basolateral drug efflux transporters Abccl, 3 and 
4 (Figure 5-3), changed over 7 days in both monolayer and sandwich cultures. Two 
general conclusions can be made regarding the data; first, transporter levels reach a peak 
after 4 days in culture; and second, sandwich-cultured hepatocytes have more similar and 
more stable levels of drug efflux transporters than monolayer-cultured cells when 
compared to expression in rat liver. The latter point can be observed as statistically 
significant differences in expression more often occurring between monolayer-cultured 
samples and liver than between sandwich-cultured samples and liver (Figure 5-1, Figure 
5-2 and Figure 5-3).
There are, of course, exceptions to these general rules; Abcbl expression (Figure 5-1) 
does not peak at 4 days post culture in monolayer-cultured samples, instead levels of 
Abcbl reach a very high peak earlier in the culture period and then the general trend is a 
reduction in expression. Abcb4 expression (Figure 5-1) peaks at 4 days post-plating but 
is higher in sandwich-cultured samples than monolayer-cultured samples relative to liver. 
Abcc2 expression (Figure 5-2) peaks early in monolayer-cultured samples and then falls 
so it is closer to liver expression on day 4 than the sandwich cultured samples, but the 
latter show more consistent expression of Abcc2. Abcc3 and 4 (Figure 5-3) show very 
similar profiles with peaks appearing earlier than 4 days, though sandwich-cultured 
samples remain closer to liver expression levels.
148
Liver
Monolayer 
Sandwich Culture
(0 25000001
2000000-
> 1500000-
0: 1000000-
& 500000-
iS! r T T 1
Days post culture
800-1 *** Liver
Monolayer 
Sandwich Culture
Q.
600-
0)
^ 400-
o 200-0)
Fc
8
a! r T
Days post culture
Figure 5-1 Expression o f the apical efflux transporters Abcbl (A) and Abcb4 (B) in 
monolayer ( 1) and sandwich ( T )  cultures o f rat bepatocytes over 7 days.
Rat bepatocytes were cultured for 7 days (where cells were plated on day 0) in either monolayer 
( i) or sandwich culture ( T )  conformation. Samples o f cells were taken each day for analysis by 
RT-PCR of the expression o f Abcbl (A) and Abcb4 (B). Data is expressed as a percentage o f the
level in rat liver (100%,------) and was analysed by 2-way ANOVA with Bonferroni post hoc test
and show where expression in bepatocytes is significantly different to liver expression (*** = p < 
0.001; n=3 RNA isolations from the same liver: error bars = SEM; where no error bars are 
observed they are contained within the limits o f the data point).
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Figure 5-2 Expression of the apical efflux transporters Abcc2 (A) and Abcg2 (B) in 
monolayer (1 )  and sandwich ( T )  cultures o f rat bepatocytes over 7 days.
Rat bepatocytes were cultured for 7 days (where ceils were plated on day 0) in either monolayer 
( '1) or sandwich culture ( T )  conformation. Samples o f cells were taken each day for analysis by 
RT-PCR of the expression of Abcc2 (A) and Abcg2 (B). Data is expressed as a percentage o f the
level in rat liver (100%,------) and was analysed by 2-way ANOVA with Bonferroni post hoc test
and show where expression in bepatocytes is significantly different to liver expression (** = p < 
0.01; *** = p < 0.001; n=3 RNA isolations from the same Liver; error bars = SEM; where no 
error bars are observed they are contained within the limits o f the data point).
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Figure 5-3 Expression o f the basolateral efflux transporters A b ed  (A), Abcc3 (B) and 
Abcc4 (C) monolayer (1 )  and sandwich (T) cultures o f rat bepatocytes over 7 days.
Rat bepatocytes were cultured for 7 days (where cells were plated on day 0) in either monolayer 
( or sandwich culture ( T )  conformation. Samples o f cells were taken each day for analysis by 
RT-PCR of the expression o f Abccl (A), Abcc3 (B) and Abcc4 (C). Data is expressed as a
percentage of the level in rat liver (100%, ------) and was analysed by 2-way ANOVA with
Bonferroni post hoc test and show where expression in bepatocytes is significantly different to 
liver expression (* = p< 0.05, ** = p < 0.01, *** = p < 0.001; n=3 RNA isolations from the 
same hver; error bars = SEM; where no error bars are observed they are contained within the 
limits o f the data point).
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5.2.1.1 Correlation of Drug Efflux Transporter Expression in Rat Liver with 
Monolayer-cultured and Sandwich-cultured Hepatocytes
A further statistical analysis was performed on the data to produce a correlation between 
rat liver expression levels and either monolayer-cultured or sandwich-cultured 
hepatocytes (Figure 5-4). The correlation analysis was performed on the relative 
expression data from hepatocytes cultured for 4 days; however, Abcbl levels were 
excluded as it was found that the very high expression levels resulted in the introduction 
of an unacceptable bias in the data. As postulated, expression of efflux transporters in 
sandwich cultured hepatocytes showed a stronger correlation with expression in liver, 
compared to the correlation between liver expression levels and those in monolayer- 
cultured hepatocytes; spearman rank correlations were calculated as of 0.89 and 0.37 
respectively (Figure 5-4).
The correlation analysis highlighted Abcc2 as it falls outside the 95 % confidence limits 
of the line of best fit within the sandwich-cultured hepatocyte to liver correlation. The 
raw data for Abcc2 expression confirms that after four days of culture Abcc2 expression 
is significantly different to rat liver expression in sandwich-cultured hepatocytes. 
Removing Abcc2 from the correlation improves the Spearman rank correlation from 
0.89 to 0.90 for the sandwich-cultured to liver correlation, and 0.37 to 0.50 for the 
monolayer-cultured to liver correlation (Figure 5-5). It is perhaps not entirely acceptable 
to trim the data series in this way but it does identify those transporters that contribute to 
differences between the liver and cell line expression levels and shows an otherwise 
strong correlation between the data sets.
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Figure 5-4 Correlation o f the relative expression o f drug efflux transporters in rat liver and 
monolayer-cultured (A) or sandwich-cultured (B) hepatocytes.
Correlation of the relative expression o f drug efflux transporters between Hans-Wistar liver and 
monolayer-cultured hepatocytes (A; spearman rank correlation = 0.37), and sandwich-cultured 
hepatocytes (B; spearman rank correlation = 0.89, significant correlation p < 0.05). Results were 
also analysed by linear regression to give lines of best fit. Statistical significance was calculated by 
one-tailed t-test (n=3 RNA isolations from the same liver; error bars = SEM; where no error bars 
are observed they are contained within the limits o f the data point. The grey dotted line refers to 
the 95 % confidence limits o f the linear regression.
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Figure 5-5 Correlation of the relative expression of drug efûux transporters in rat liver and 
monolayer-cultured (A) or sandwich-cultured (B) hepatocytes where Abcc2 was removed 
from the analysis.
Correlation of the relative expression o f drug efflux transporters between Hans-Wistar liver and 
monolayer-cultured hepatocytes where Abcc2 had been removed from the analysis. The 
spearman rank correlation improves to 0.50 for monolayer-cultured hepatocytes and liver (A) and 
0.90 for sandwich-cultured hepatocytes and liver (B; significant correlation p < 0.05). Results 
were also analysed by linear regression to give lines o f best fit. Statistical significance was 
calculated by one-tailed t-test (n=3 RNA isolations from the same liver; error bars = SEM; where 
no error bars are observed they are contained within the limits o f the data point. The grey dotted 
line refers to the 95 % confidence limits o f the linear regression.
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5.2.2 Drug Efflux Transporter Protein Expression in Rat Hepatocytes
Total protein was extracted from both monolayer-cultured and sandwich-cultured cells 
grown for up to 6 days post culture, separated using SDS-PAGE and transferred to a 
PVDF membrane. Immunodetection of Abcc2 (Figure 5-6 A) and Abcc3 (Figure 5-6 B 
and C) protein confirmed the expression pattern seen in the RNA results; Abcc2 RNA 
and protein expression are higher in both sets of cultured hepatocytes than liver on days 
3, 4 and 5 and expression in sandwich cultured cells is higher than in monolayer-cultured 
cells. RNA and protein expression of Abcc3 are both higher in monolayer-cultured cells 
than sandwich-cultured hepatocytes and Hver, which express very Httle Abcc3 protein.
M Liver ML 3 ML 4 ML 5 SC 3 SC 4 SC 5
B
M MLl ML 2 ML3 ML 4 ML 5 ML6 Liver
c
M SCI SC2 SC3 SC4 SC5 SC6 Liver
Figure 5-6 Protein expression o f Abcc2 (A) and Abcc3 (B and C) in rat hepatocytes 
cultured over 6 days.
Protein was extracted from hepatocytes grown in either monolayer (ML; A and B) or sandwich 
culture (SC; A and C) conformation for up to 6 days (Abcc2 = days 3-5, Abcc3 = 1—6, where 
cells were plated on day 0) and from a sample o f rat Hver. Ten micrograms of protein from each 
sample was separated by SDS-PAGF and transferred to a PVDF membrane. Abcc2 (A) and 
Abcc3 (B and C) were detected with specific antibodies. M = molecular weight marker, arrows 
highlight molecular weight band corresponding to Abcc2 or Abcc3 (approximately 170 KDa).
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5.2.3 Drug Efflux Transporter Activity in Rat Hepatocytes
Although monolayer-cultured hepatocytes express Abcc2 RNA (Figure 5-2) and protein 
(Figure 5-6), the cells are not polarised, i.e. there is no differentiation in the cell 
membrane to apical and basolateral parts. As drug transporters tend to be localised 
specifically on one membrane within a polarised hepatocyte it is therefore not clear if 
production of a drug transporter in a non-polarised cell would result in correct 
transporter function or not. To examine this the ability of Abcc2 to transport substrates 
was tested in hepatocytes cultured for 4 days.
On each day of a five-day culture period hepatocytes were exposed to 
carboxydichlorofluroscein diacetate (CDFDA), which is hydrolysed by intracellular 
esterases to produce CDF, a fluorescent substrate of Abcc2. After 30 minutes 
incubation at 37 °C a fluorescent image was take of the cells through a FITC filter (485 
nm) with an Axiovert 100 microscope to assess where the CDF had accumulated in the 
cells.
After 24 hours in culture, both monolayer-cultured and sandwich-cultured hepatocytes 
appear the same with CDF remaining within the cells (Figure 5-7 A and B). After 4 days 
in culture, the fluorescence from CDF still remained within the monolayer-cultured cells 
(Figure 5-7 C), whereas in sandwich-cultured hepatocytes CDF has been effluxed via 
Abcc2, collecting in the büe canaliculi surrounding the hepatocytes (Figure 5-7 D).
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Figure 5-7 Efflux of CDF via Abcc2 in monolayer- (A and C) and sandwich-cultured (B 
and D) hepatocytes.
Monolayer cultured (A and C) or sandwich cultured (B and D) rat hepatocytes were cultured for 
one (A and B) or four days (C and D) after plating (on day 0) and dosed with 10 pM CDFDA 
and incubated at 37 °C for 30 minutes. Fluorescent images were taken using an Axiovert 100 
microscope with the integral digital camera at lOx magnification through a FITC filter (485 nm). 
Cells were exposed to fluorescence for 2 seconds before the image was taken.
157
5.2.4 Influx Transporter Expression in Rat Hepatocytes
The RNA levels of Slcolal, la4 and lb2 also change over 7 days in both monolayer- 
cultured and sandwich-cultured hepatocytes compared to rat liver (Figure 5-8). 
Expression levels of the influx transporters in monolayer-cultured hepatocytes are 
significantly lower than in rat liver and remain constant over the culture period. 
However, in sandwich-cultured hepatocytes expression of Slcolal and la4 reaches a 
peak after 4 days in culture, equating to approximately 100 % of liver expression, 
although these are sharp peaks and expression is generally depressed. In contrast, 
Slcolb2 levels remain significantly lower in sandwich-cultured cells compared to liver.
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Figure 5-8 Expression o f Slcolal (A), Slcola4 (B) and Slcolb2 (C) in monolayer (1 )  and 
sandwich (T) cultures of rat hepatocytes over 7 days.
Rat hepatocytes were cultured for 7 days (where cells were plated on day 0) in either monolayer 
( ') or sandwich culture ( T )  conformation. Samples o f cells were taken each day for analysis by 
RT-PCR of the expression of Slcolal (A), Slcla4 (B) and Slcolb2 (C). Data is expressed as a
percentage o f the level in rat liver (100%, ------) and was analysed by 2-way ANOVA with
Bonferroni post hoc test and show where expression in hepatocytes is significandy different to 
liver expression (* = p< 0.05; ** = p < 0.01; *** — p < 0.001; n=3 RNA isolations from the 
same liver; error bars = SEM; where no error bars are observed they are contained within the 
limits of the data point).
159
5.2.5 Drug Efflux Transporter Expression: Rat to Human Extrapolation
Rat primary hepatocytes are easily obtained and relatively cheap to prepare compared to 
obtaining fresh, or buying expensive cryopreserved, human hepatocytes. However, data 
produced from in vitro studies using rat hepatocytes must be interpreted with an 
understanding of how expression of key transporters compares to levels in human liver. 
Therefore, the transcript levels of transporters in rat liver and cultured hepatocytes were 
compared to human liver levels of the orthologue transporter. Based on the findings of 
the previous work in this section, hepatocytes were cultured to 4 days post plating before 
samples were taken.
To identify human-rat orthologues, a BLAST analysis of each transporter amino acid 
sequence in rat and human was performed to establish percentage identity and similarity 
between species. The rat drug efflux transporters each had a single protein in humans 
with at least 75 % identical amino acid sequence and 85 % similar amino acids (Table 
5-2), and these were thus designated as the orthologue. No other combinations of efflux 
transporters between rat and human had significant identity to suggest they were 
orthologues, but parallels were seen as would be expected for members of the same 
family or subfamily (not shown).
Although the rat and human influx transporters that have been investigated from the 
Slco/Oatp family are all expressed in liver and are responsible for drug uptake into 
hepatocytes, the BLAST analysis showed low identity between the amino acid sequences, 
only reaching a maximum of 65% for OATP1B3 versus Oatplb2 (Table 5-3). Even in 
this case, a clear orthologue cannot be identified as oatplb2 also shares 62% identity with 
OATPIBI. This supports previous conclusions that the rat and human OATP’s can be 
identified as members of the same family but that no single orthologue exists in the same 
way as for the ABC family, although the evolutionary explanation for this is not clear 
(Ogura et al., 2000; Hagenbuch and Meier, 2003). Such divergence appears to be 
reflected at the functional level, with influx transporters from the same family also 
appearing to have different functions in different species; for example OATPIBI 
transports pravastatin into human hepatocytes (Nakai et al., 2001), whereas in rat 
hepatocytes Oatplal takes up pravastatin (Tokui et al., 1999). Therefore, expression 
levels of SLCO/OATP influx transporter were not compared between human and rat
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samples as there is no clear evidence as to which human transporters should be 
compared to which rat transporters.
Protein Ref. Seq. accession Identity (%) Similarity (%)
(HUMAN/Rat) number
ABCBl NP_000918.2 81 90
Abcbl NP_036755.2
ABCB4 NP_000434.1 91 95
Abcb4 NP_036822.1
ABCCl NP_004987.2 87 93
Abccl NP_071617.2
ABCC2 NP_000383.1 77 88
Abcc2 NP_036965.1
ABCC3 NP_003777.2 79 88
Abcc3 NP_542148.1
ABCC4 NP_005836.1 86 93
Abcc4 NP_596902.1
ABCG2 NP_004818.2 81 89
Abcg2 NP_852046.1
Table 5-2 Homology of rat and human drug efflux transporters.
A BLASTp alignment was performed between the amino acid sequences of each rat and human 
efflux transporter to give the percentage of the sequences that are identical between species and 
the percentage of the sequences that are made up of similar amino acids.
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Identity /  similarity between rat and human OATP’s (%)
Rat
Human
Oatplal
(NP_058807.1)
Oatpla4
(NP_571981.1)
Oatplb2
(NP_1138338.1)
OATPIBI
(NP_006437.2)
4 2 / 6 0 4 3 / 6 2 6 2 / 7 8
OATP1B3
(NP_062818.1)
4 3 / 6 2 4 4 / 6 2 6 5 / 8 0
OATP2B1
(NP_009187.1)
3 1 / 5 2 2 9 / 4 9 3 1 / 5 0
Table 5-3 Homology of rat and human drug OATP transporters.
A BLASTp alignment was performed between the amino acid sequences of each rat and human 
OATP transporter to give the percentage of the sequences that are identical between species and 
the percentage of the sequences that are made up of similar amino acids.
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5.2.5.1 Expression of Drug Efflux Transporter Transcript Levels in Rat Samples
Compared to Human Liver
The RNA level of the apical transporters Abcbl and Abcb4 (Figure 5-9), Abcc2 and 
Abcg2 (Figure 5-10) and the basolateral Abcc family members 1, 3 and 4 (Figure 5-11) 
were examined in liver samples from two different breeds of rat, Hans-Wistar and 
Sprague-Dawley, as well as hepatocytes cultured for four days. Only monolayer-cultured 
hepatocytes were available for Sprague-Dawley, while samples from both monolayer- and 
sandwich-cultured hepatocytes were taken from Hans-Wistar. Data is expressed as a 
percentage of the level of the orthologous transporter in human liver and statistical 
significance is shown between human liver and aU samples (in black), and between rat 
liver and hepatocytes from the same breed (light grey for Sprague-Dawley and dark grey 
for Hans-Wistar).
General statements can be made regarding the expression data comparing the rat samples 
to human liver; first, expression levels of each transporter are not significantly different 
between samples of liver RNA from the two rat breeds (statistical data not included on 
graph). Second, the expression of each transporter is not significantly different when 
comparing rat liver to human liver. The only exception to this is Abcc3, which is much 
more highly expressed in human liver than rat (Figure 5-11). Third, expression of 
transporters is not significantly different when comparing sandwich cultured rat 
hepatocytes to human liver. Again the only exception is Abcc3; the sandwich-cultured 
cells have similar levels of Abcc3 to the rat liver and therefore they have significantly 
lower expression of Abcc3 compared to human Hver expression. Finally, the data shows 
that expression levels of transporters are closer between rat Hver and sandwich-cultured 
ceUs than between rat Hver and monolayer-cultured ceUs. The only exception to this 
point is Abcc2 thereby confirming the data in section 5.2.1.
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Figure 5-9 Expression o f the apical efflux transporters Abcbl and Abcb4 in rat liver and 
hepatocytes compared to human liver.
The mRNA expression level of Abcbl (A; y-axis split from 200 to 1000% and 4000 to 30000%), 
and Abcb4 (B) was quantified by quantitative RT-PCR in rat liver and cultured hepatocytes; = 
Sprague-Dawley; = Hans-Wistar (ML = monolayer, SC = sandwich culture), and compared to 
the level o f ABCBl and ABCB4 in human liver (■ ). Data is expressed as a percentage o f human 
liver expression and was analysed by one-way ANOVA with bonferroni post hoc test. 
Significant difference in expression is shown between human liver and all samples (■ )  and 
between samples from the same rat breed ( = Sprague-Dawley; * = Hans-Wistar) (ns = not
significant, *** = p<0.001; n=3; error bars = SEM; where no error bars are observed they are 
contained within the limits of the data point).
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Figure 5-10 Expression of the apical efflux transporters Abcc2 and Abcg2 in rat liver and 
hepatocytes compared to human Hver.
The mRNA expression level o f Abcc2 (A), and Abcg2 (B; y-axis split from 250-500 %) was 
quantified by quantitative RT-PCR in rat liver and cultured hepatocytes; = Sprague-Dawley;
I = Hans-Wistar (ML = monolayer, SC = sandwich culture), and compared to the level of 
ABCC2 and ABCG2 in human liver (■ ). Data is expressed as a percentage of human liver 
expression and was analysed by one-way ANOVA with bonferroni post hoc test. Significant 
difference in expression is shown between human liver and all samples ( ■ ) and between samples 
from the same rat breed ( = Sprague-Dawley; I = Hans-Wistar) (ns = not significant, * = p <
0.05; ** = p < 0.01; n=3; error bars = SEM; where no error bars are observed they are contained 
within the limits of the data point).
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Figure 5-11 Expression of 
the basolateral efflux 
transporters Abccl, Abcc3 
and Abcc4 in rat liver and 
hepatocytes compared to 
human liver.
The mRNA expression level 
o f Abccl (A), Abcc3 (B; y- 
axis split 40-75 %) and 
Abcc4 (C; y-axis split 500- 
1000 %) was quantified by 
quantitative RT-PCR in rat 
liver and cultured 
hepatocytes; = Sprague- 
Dawley; ! = Hans-Wistar 
(ML - monolayer, SC - 
sandwich culture), and 
compared to the level of 
ABCCl, ABCC3 and 
ABCC4 in human liver (■ ). 
Data is expressed as a 
percentage o f human liver 
expression and was analysed 
by one-way ANOVA with 
bonferroni post hoc test. 
Significant difference in 
expression is shown between 
human liver and all samples 
( ■ ) and between samples 
from the same rat breed (
= Sprague-Dawley; 1 =
Hans-Wistar) (ns = not 
significant, * = p<0.05, ** = 
p<0.01 *** = p<0.001; n=3; 
error bars = SEM; where no 
error bars are observed they 
are contained within the 
limits o f the data point).
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5.2.S.2 Principal Component Analysis of Rat Efflux Transporter Expression
Following the observation that drug transporter levels varied between rat/human 
hepatocyte preparations, it was necessary to examine this data to see which transporters 
varied the most between preparations, and hence could have a significant effect on drug 
disposition. The data was analysed to find the principal components of variation within 
the data set i.e. the drug efflux transporter or transporters that contribute to the variation 
between the different hepatocytes and liver samples.
Analysis of the entire data set reveals that the variability between the expression of efflux 
transporters in rat Hver and hepatocytes is driven mainly due to variabiHty in expression 
of Abcbl in Hans-Wistar monolayer-cultured ceUs. When Abcbl is included in a PGA 
(Figure 5-12), only one transporter contributes to the variation of each axis; separation of 
groups along axis 1 is due only to differences in Abcbl expression between the Hver and 
hepatocyte samples, and accounts for 99.4 % of the total variation of the PGA. Variation 
in Abcc4 expression accounts for separation of groups along axis 2 and is responsible for 
only 0.5 % of the total variation. The remaining axes contribute only 0.1 % to total 
variation and no single axis contributes more than 0.05 % (data not shown).
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Figure 5-12 Principal component analysis of rat efflux transporter expression.
PCA was performed on the expression of efflux transporters in rat liver (Sprague-Dawley, T  and 
Hans-Wistar, ♦ )  and hepatocytes cultured for 4 days post-plating (ML=monolayer-cultured, ■ 
and • ;  SC=sandwich cultured, ) and compared to human liver, A.. Separation along axis 1 
(99.4 % total variation) is due to Abcbl expression in Hans-Wistar hepatocyte monolayer 
cultures. Separation along axis 2 (0.5 % total variation) is due to expression of Abcc4 in Sprague- 
Dawley hepatocytes.
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As Abcbl expression is very high in aU samples compared to the other transporters it is 
possible that this is masking other important variances between samples. With Abcbl 
removed from the analysis, the expression of more than one drug transporter contributes 
to the separation along each axis (Table 5-4). Expression of Abcc4, Abcg2 and Abccl 
are identified as contributing the most to the variation between rat liver samples and 
hepatocyte samples.
Axis 1 (90.5 %) Axis 2 (4.7 %) Axis 3 (3.4 %)
Transporter and 
Contribution to axis 
variation (%)
Transporter and 
Contribution to axis 
variation (%)
Transporter and 
Contribution to axis 
variation (%)
Abcc4 82.8 Abcg2 82.8 Abccl 100
Abcg2 17.2 Abcc4 17.2
Table 5-4 Contribution of each axis to the PCA-derived separation of samples based on 
efflux transporter expression in rat liver and hepatocytes.
Principal component analysis (PCA) separates groups along axes, which together make up 100 % 
of the total variation between groups. The components of axis 1, 2 and 3 are shown for the PCA 
analysis of rat efflux transporter expression in rat liver and hepatocytes. Several dmg transporters 
contribute to the variation along each axis and the contribution of each transporter is given. The 
remaining total variation is expressed on several more axes but none of these accounts for more 
than 1 % of total variation (not shown).
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The PCA analysis causes clustering of the SC hepatocyte samples with the liver samples 
while MLC samples are separated from liver samples along axis 1 and 2 (Figure 5-13A). 
This separation is driven by differential expression of Abcc4 between rat liver and 
hepatocytes from Sprague-Dawley rats, and Abcg2 between rat liver and hepatocytes 
from Hans-Wistar rats: This is confirmed by the raw data (Figure 5-10 and Figure 5-11). 
Separation along the third axis is also shown as it contributes a similar amount of 
variation to axis 2 (Table 5-4 and Figure 5-13B). Abccl is the only contributor to 
separation along this axis and causes clustering of the two MLC hepatocyte groups away 
from rat liver, while SC hepatocyte samples cluster with the liver samples. The remaining 
axes contribute to less than 1 % of total variability, and hence are probably of little 
biological significance (data not shown). In conclusion, the PCA shows that monolayer- 
cultured samples cluster away from liver samples irrespective of rat breed, while the 
Hans-Wistar sandwich cultures cluster with the rat and human liver samples (Figure 5-12 
and Figure 5-13).
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Figure 5-13 Principal component analysis of rat efflux transporter expression (where 
Abcbl bas been removed from the analysis).
PCA was performed on the expression o f efflux transporters (minus Abcbl) in rat liver (Sprague- 
Dawley, T  and Hans-Wistar, ♦ )  and hepatocytes cultured for 4 days post-plating 
(ML=monolayer-cultured, ■ and •  : SC= sandwich cultured, ) and compared to human liver, 
^ . Separation along axis 1 (A; 90.2% total variation) is due to Abcc4. Separation along axis 2 
(A; 4.8% total variation) is due to expression o f Abcg2. Separation along axis 3 (B; 3.5% total 
variation) is due to Abccl expression in both Hans-Wistar (monolayer-cultured) and Sprague- 
Dawley hepatocytes.
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5.3 Induction of Efflux Drug Transporters by Nuclear Receptor 
Agonists
In order to study the effect of nuclear receptor agonists on drug transporter expression, 
cells were dosed with one of three compounds: dexamethasone, a glucocorticoid receptor 
(GR) and PXR agonist (Huss and Kasper, 2000; Pascussi et al., 2001); cyproterone 
acetate (CPA), a PXR agonist (Jones et al., 2000); and Wy-14,643, a PPAR a  agonist 
(Peters et al., 1997). The dose was set at 50 pM for each compound, as previous studies 
have shown this to be the maximal dose that does not cause toxicity in primary rat 
hepatocytes (Kate Plant, personal communication). It should be noted that at this 
concentration dexamethasone can act directly as a PXR agonist, while lower doses would 
only activate GR, which in turn has an indirect affect on PXR targets by increasing levels 
of PXR itself (Huss and Kasper, 2000).
5.3.1 Induction of Efflux Drug Transporters by Nuclear Receptor Agonists
Hepatocytes were dosed for 96 hours during which time samples of the cells were taken 
at 12, 24, 48, 72 and 96 hours. Transcript level of the apical efflux transporters Abcbl 
and 4 (Figure 1-16), Abcc2 and Abcg2 (Figure 1-17) and the basolateral efflux 
transporters Abccl, 3 and 4 (Figure 1-18) was measured by quantitative-RT-PCR. Fold 
induction over a DMSO control (0.1%) was calculated for each drug and time point.
No overall pattern in the activation of expression of the apical efflux transporters was 
observed; Expression of Abcbl is not significantly affected by any of the compounds 
tested in either monolayer or sandwich cultured cells, while Abcb4 expression is induced 
by dexamethasone in both monolayer cultured and sandwich-cultured hepatocytes 
(Figure 1-16). Abcc2 is induced by dexamethasone and CPA in the monolayer-cultured 
cells but this is absent in the sandwich cultured cells (Figure 1-17 A). Abcg2 presents a 
unique case in the efflux drug transporters tested, as it is the only transporter to have its 
transcript levels induced by Wy-14,643, while treatment of the cells with CPA resulted in 
a similar induction profile of Abcg2 as Wy-14,643 (Figure 1-17 B).
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Figure 5-14 Fold induction of the apical efflux transporters Abcbl (A) and Abcb4 (B) in 
response to dosing o f monolayer and sandwich cultures o f rat bepatocytes with 
dexamethasone, CPA and Wy-14,643.
Primary rat hepatocytes were cultured in either monolayer or sandwich culture as indicated and 
exposed to 50 pM dexamethasone (•), CPA ( ) or Wy-14,643 ( ) (or a 0.1% DMSO control) 
for 0, 24, 48, 72 or 96 hours. Transcript levels of Abcbl (A) or Abcb4 (B) were measured by 
quantitative RT-PCR against rat genomic DNA standards and results were expressed as fold 
induction over DMSO control. Results were analysed by 2-way ANOVA with Bonferroni post 
hoc test to determine which drugs gave a significantly different response compared to the control 
(* = p<0.05, *** = p<0.001; n=3 RNA isolations from the same liver; error bars = SEM; where 
no error bars are observed they are contained within the limits of the data point).
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Figure 5-15 Fold induction o f the apical efflux transporters Abcc2 (A) and Abcg2 (B) in 
response to dosing of monolayer and sandwich cultures o f rat bepatocytes with 
dexamethasone, CPA and Wy-14,643.
Primary rat bepatocytes were cultured in either monolayer or sandwich culture as indicated and 
exposed to 50 pM dexamethasone (•), CPA ( ') or Wy-14,643 ( ) (or a 0.1% DMSO control) 
for 0, 24, 48, 72 or 96 hours. Transcript levels o f Abcc2 (A) or Abcg2 (B) were measured by 
quantitative RT-PGR against rat genomic DNA standards and results were expressed as fold 
induction over DMSO control (n=3). Results were analysed by 2-way ANOVA with Bonferroni 
post hoc test to determine which drugs gave a significandy different response compared to the 
control (* = p<0.05, ** = p<0.001, *** = p<0.001; n=3 RNA isolations from the same liver; 
error bars = SEM; where no error bars are observed they are contained within the limits o f the 
data point).
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Whereas the apical efflux drug transporters showed no pattern in their response to the 
compounds tested, the basolateral efflux drug transporters, A bed, 3 and 4, have almost 
identical inductive profiles. First, all three transporters are induced in sandwich cultured 
bepatocytes by CPA at 48 and 72 hours; second, a significant, but much smaller 
induction, is also observed for all three transporters in monolayer-cultured bepatocytes 
treated with CPA for 48 hours (Figure 1-18).
However, there are some differences in how these three transporters respond to drug 
treatment; Abcc3, and to a lesser extent, Abed transcript expression, are induced by 
dexamethasone as well as CPA at 48 hours dosing (Figure 1-18 A and B). A response to 
dexamethasone exposure is also observed at 96 hours for Abcc3 in both monolayer and 
sandwich cultured bepatocytes, which is not seen with either of the other transporters 
(Figure 1-18 B).
Whereas the response to CPA by A bed and 3 results in a maximal induction of 
approximately 12-fold over control, the response by Abcc4 is much higher with a 
maximal induction of approximately 65-fold over control (Figure 1-18 C). Although this 
point is associated with high error, even the lowest point of the error bar would still give 
a much higher induction of Abcc4 the A bed or 3 by CPA.
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Figure 5-16 Fold induction of the basolateral efflux transporters A b ed  (A), Abcc3 (B) and 
Abcc4 (C) in response to dosing of monolayer and sandwich cultures o f rat bepatocytes 
with dexamethasone, CPA and Wy-14,643.
Primary rat bepatocytes were cultured in either monolayer or sandwich culture as indicated and 
exposed to 50 pM dexamethasone (• ) , CPA ( ) or Wy-14,643 ( ') (or a 0.1% DMSO control) 
for 0, 24, 48, 72 or 96 hours. Transcript levels o f A bed  (A), Abcc3 (B) and Abcc4 (C) were 
measured by quantitative RT-PGR against rat genomic DNA standards and results expressed as 
fold induction over DMSO control (n=3). Results were analysed by 2-way ANOVA with 
Bonferroni post hoc test to determine which drugs gave a significantly different response 
compared to the control (* = p<0.05, ** = p<0.001, *** = p<0.001; n=3 RNA isolations from 
the same liver; error bars = SEM; where no error bars are observed they are contained within the 
limits o f the data point).
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5.3.2 Induction of Influx Drug Transporters by Nuclear Receptor Agonists
Transcript levels of the influx transporters, Slcolal, la4 and lb2 were also measured in 
bepatocytes exposed to dexamethasone, CPA or Wy-14,643. Influx transporters from 
the Slcola family showed a similar response to drug treatment, whereas Slcolb2 had a 
distinct profile of induction. Expression of both Slcolal and la4 was induced by 
dexamethasone in monolayer cultured cells at 72 and 96 hours, a response that is missing 
for both transporters in sandwich cultures; instead, a much smaller, but still significant, 
increase in expression of these transporters is elicited by dexamethasone earlier in the 
time course (Figure 1-19 A and B). No induction of Slcolb2 in response to treatment 
with dexamethasone is observed in either the monolayer or sandwich cultured 
bepatocytes (Figure 1-19 C).
In MLC cells Slcolal expression is induced by Wy-14,643 at 96 hours and shows a 
significant early response at 12 hours, while Slcola4 expression is induced by CPA at 72 
and 96 hours. Apart from a small induction by CPA of Slcola4 at 96 hours, none of 
these responses are seen in sandwich-cultured cells (Figure 1-19 A and B).
Slcolb2 expression is significantly induced after 96 hours treatment with CPA although 
this response starts at 72 hours of dosing; this occurs only in the sandwich-cultured 
bepatocytes (Figure 1-19 C). Such an induction resulting from CPA treatment is missing 
for the other two influx drug transporters tested (Figure 1-19 A and B). In monolayer- 
cultured bepatocytes, Slcolb2 expression is induced after 12 hours exposure to Wy- 
14,643 at a similar level as the early response of Slcolal to the same treatment (Figure 1- 
19 A and C).
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Figure 5-17 Fold induction of the influx drug transporters Slcolal (A), Slcola4 (B) Slcolb2 
(C) in response to dosing o f monolayer and sandwich cultures o f rat bepatocytes with 
dexamethasone, CPA and Wy-14,643.
Primary rat bepatocytes were cultured in either monolayer or sandwich culture as indicated and 
exposed to 50 pM dexamethasone (•), CPA ( ) or Wy-14,643 ( ) (or a 0.1% DMSO control) 
for 0, 24, 48, 72 or 96 hours. Transcript levels o f Slcolal (A), Slcola4 (B; y-axes differ, MLC 
max. y = 600 fold, SC max. y = 100 fold) Slcolb2 (C) were measured by quantitative RT-PCR 
against rat genomic DNA standards and results expressed as fold induction over DMSO control 
(n=3). Results were analysed by 2-way ANOVA with Bonferroni post hoc test to determine 
which drugs gave a significantly different response compared to the control (* = p<0.05, ** = 
p<0.001, *** = p<0.001; n=3 RNA isolations from the same liver; error bars = SEM; where no 
error bars are observed they are contained within the limits o f the data point).
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5.4 D iscussion
The results from chapters 3 and 4 identified that cell lines derived from human tumour 
tissue express different levels of transporters, especially influx transporters, and this may 
affect results from assays where compound needs to access bepatocytes to have an effect, 
be metabolised or be excreted via the büe. Whereas human bepatocytes are the ‘gold 
standard’ of in vitro hepatocyte assays, they are impractical for many steps in drug 
discovery, and are often replaced by primary rat bepatocytes for ease of use. This study 
examined the expression of drug transporters in rat bepatocytes over a week in a 
monolayer or sandwich culture and how levels after 4 days of culture compared to 
expression in human liver. The effect of nuclear receptor agonists was also measured in 
rat bepatocytes by dosing them with compounds known to activate PXR, GR or PPARa.
5.4.1 The Effect of Culture Time on Drug Transporter Expression
As cells adapt to culture the proteins they express change, both in absolute and relative 
terms. In the case of the efflux transporters, expression is generally higher than liver 
over a week in culture, while influx transporters are generally expressed at lower levels 
compared to rat liver. Interestingly, this is a similar pattern to that seen in the human 
derived cell lines where the influx transporters are expressed at much lower levels than in 
the liver. This might suggest that influx transporters do not adapt well to cell culture, 
although the reasons for this are unclear.
One aim of this study was to ascertain on which day cells should be used for assays 
involving drug transport, such as predicting biliary efflux of compounds. Transporter 
RNA expression levels were used to provide a general overview of expression, showing a 
correlation between A bed, 3 and 4, Abcg2 and Abcb4 between SC bepatocytes cultured 
for 4 days and rat liver showed a strong correlation with an R^  value of 0.90. Slcolal and 
la4 levels, which are generally low compared to hver, recover to ‘liver like’ levels after 4 
days in sandwich culture. These observations were extended to protein expression levels, 
as well as a functional activity assay for Abcc2, establishing that after four days in culture, 
the RNA levels peak, Abcc2 is expressed at the protein level and is functional in 
polarised sandwich-cultured (SC) cells.
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It would be useful to carry out studies with bepatocytes for longer periods than 4 days of 
culture to assess the effect of chronic exposure to drugs but further work would be 
needed to determine if this was viable from a drug transport point of view. These results 
suggest that expression of efflux transporters is similar to Hver at the end of the 7 day 
culture period but levels of influx transporters may be much lower, which would be a 
problem if hydrophiHc compounds were being tested, as they may not be able to access 
cells. Studies in human bepatocytes have described the fact that cells exhibit alterations 
in structure after a few days in culture, indicating that they are probably exposed to stress 
factors (GuiUouzo et al., 1993). This could explain why levels of transporters tend to fall 
rapidly by the end of the culture period.
It has also been reported that CYPs and phase II DMEs are expressed at variable levels 
over culture time. A study in SC human bepatocytes showed variable expression of a 
number of DMEs over a week in culture (Wilkening and Bader, 2003); CYPlAl and 
CYP1A2 tended to increase steadily over the week, while CYP2C9, CYP2D6 and 
UGT1A6 expression peaked after four days of culture, in a similar fashion to 
transporters in this study. The expression of CYP2B6, CYP2E1, CYP3A4, CYP3A7, 
GSTMl and SULTlAl tended to faU initially and then recover after 5 days of culture. 
Similar patters have been noted in other studies, especially regarding the widely studied 
CYP3A4 (George et al., 1997; Kern et al., 1997; LeCluyse, 2001). Therefore, the 
expression of a range of ADME relevant genes including DMEs and transporters vary 
over time in culture but in most cases expression has recovered after four days of culture.
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5.4.2 The Effect of Culture Conditions on Drug Transporter Expression
Almost aU the transporter genes that were measured in this study showed expression 
levels closer to liver expression in sandwich cultured (SC) bepatocytes compared to the 
monolayer cultured (MLC) cells, probably due to the fact that SC bepatocytes are 
polarised and form a büe canalicular network (BCN) and so are a better representation of 
liver. The correlation between transporter expression in SC cells and liver was better 
than between MLC ceUs and liver, and this was mirrored at the protein level for the two 
transporters studied. Abcc3 protein was present at significant levels in MLC bepatocytes 
but not in SC ceUs or liver, which mirrors the RNA data. Most importantly transporters 
appear to be functional in the SC ceUs, demonstrated in this study by the ability of Abcc2 
to efflux CDF into the BCN whüe other studies have shown Abcbl and Abcg2 to be 
functional with sirmlar specific fluorescent dyes (Hopwood et al., 2006). MLC 
bepatocytes express very low levels of influx transporter transcript, whüe SC ceUs recover 
‘liver-like’ levels of Slcolal and Slcola4 after 4 days in culture. These transporters have 
also been shown to be functional in SC bepatocytes (Annaert et al., 2001; Hoffmaster et 
al., 2004). However Slcolb2 levels remain low, which may limit ceUular access to some 
drugs.
A study completed in rat bepatocytes and concentrating on the effects of dexamethasone 
on ceüs, also measured the transcript level of some of the transporters quantified in this 
study (Luttringer et al., 2002). Whereas the results may not be directly comparable, as 
MLC ceUs were not treated with dexamethasone as in this study, it is notable that simüar 
results were seen; for example, the influx transporters were down regulated over time in 
MLC ceüs but recovered in SC bepatocytes after 4 days of culture. In contrast, Abcblb 
was highly upregulated in MLC ceüs but was much closer to liver levels in the SC 
bepatocytes (Luttringer et al., 2002). A comparison between this work and the earlier 
study is therefore favourable, however as Luttringer’s study only looked at ceüs cultured 
over 4 days it is difficult to say if the correlation would continue over the extended 
culture period used in this study.
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5.4.2.1 The Effects of ‘Cholestasis’ on Sandwich-Cultured CeUs
The BCN of SC bepatocytes are an enclosed network, with no exit route for excreted 
compounds as would be seen in the liver in vivo. It is hence feasible that after four days 
in culture cells are starting to accumulate sufficient levels of bile acids that could 
influence transporter expression via activation of nuclear receptors such as FXR and 
PXR, an in vivo defence mechanism against cholestasis. This may help to explain why 
two transporters, Abcb4 and Abcc2, were expressed in MLC bepatocytes at levels closer 
to liver than in SC cells on at least day 4 of the culture period. Increased expression of 
Abcc2 transcript in SC cells relative to MLC bepatocytes and liver was confirmed at the 
protein level.
Both Abcb4 and Abcc2 are expressed on the canalicular membrane, transport across 
which is only likely to be functional in the SC cells; Abcb4 effluxes PC across the 
cancalicular membrane to protect ceU membranes from the detergent properties of büe 
and Abcc2 exports the büe acids themselves, whüe the other apical efflux transporters 
studied in this work, Abcbl and Abcg2, have a less important role in büiary efflux of 
endogenous compounds. Therefore, Abcb4 and Abcc2 may have been upregulated in 
SC bepatocytes to try and reduce the level of büe acids in ceüs.
However, it would be expected that during cholestasis, basolateral efflux transporters, 
such as Abcc3, would also be upregulated to increase the clearance of büe acids from the 
ceüs (Schuetz et al., 2001). This does not occur suggesting other unknown mechanisms 
may play a role in the basal expression of the transporters in ceü culture systems. Also a 
continuation of the Abcb4 and Abcc2 upregulation may be expected and again the 
reasons this does not happen are unclear. Interestingly, SlclOal, the major büe acid 
uptake transporter in bepatocytes has been shown to be down regulated in SC ceüs, and 
it was speculated that this was to prevent büe acid accumulation in ceüs whüe the Slco’s 
recovered to Hver levels as a ‘back up’ system for compound clearance when SlclOal was 
compromised (Luttringer et al., 2002). Whüe a recovery of Slco’s was shown in this 
study, supporting such a hypothesis, levels of SlclOal were not measured in rat 
bepatocytes and hence a fuU comparison cannot be made.
If cholestasis is affecting the expression of transporters in SC bepatocytes, it could 
potentiaUy affect results from this system. One way to prevent ceüs from becoming
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‘cholestatic’ would be to wash them with a calcium free buffer before every media 
change, as a lack of calcium opens the tight junctions that hold the BCN together. 
Excess büe acids would then be washed away before calcium is added back in and the 
BCN aUowed to reform. An initial study investigating this, suggested incomplete BCN 
reformation so more work would be required to optimise this (data not shown). 
However, in theory, this technique could lengthen the time ceüs could be cultured for.
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5.4.3 Extrapolating Data to Man
While it is essential to know the level of drug transporter expression in SC and MLC 
bepatocytes compared to rat liver, the ultimate aim of ADME studies using rat 
bepatocytes wiU be to extrapolate the data to man in order to predict the disposition, 
metabolism and/or toxicity of a compound in humans. In the current study this 
question was addressed, and expression levels of orthologue shown not to vary 
significantly between human and rat liver. As SC bepatocytes are a better representation 
of rat liver than MLC, it is a logical conclusion that they are a better representation of 
human Hver than MLC cells too.
The only case of an orthologue transporter pair that didn’t correlate well between human 
and rat was Abcc3; rats express much lower levels of Abcc3 compared to humans and 
whereas Abcc3 expression in SC bepatocytes is not significantly different to expression in 
rat liver, they both significantly differ compared to human liver expression. In terms of 
the effect this may have on extrapolating data between species, low expression of Abcc3 
in rats may lead to underestimations of the efflux of substrate via Abcc3 and may in fact 
lead to the role of biliary efflux being over estimated, as some compounds are likely to be 
substrates for both transporters due to the fact that Abcc3 and Abcc2 have similar 
substrate specificities. In fact during cholestasis Abcc3 along with Abcc4 act as 
‘overflow’ transporters for Abcc2 substrates to reduce cellular toxicity due to bile acid 
accumulation (Dormer and Keppler, 2001).
The lack of a single comparison between rat and human drug influx transporters also 
presents a problem in extrapolation between species. The BLASTp data suggests that 
Oatplb2 is possibly the rat orthologue of both OATPIBI and OATP1B3 but substrate 
specificities are different, for examples OATPIBI transports pravastatin in man but the 
pravastatin influx transporter in rat bepatocytes is the more distantly related Oatplal. 
This suggests that members of the same family such as Gatplb2 and OATPIBI may 
have different functions in different species. Generally, however, it is thought that if a 
compound is a substrate for a human OATP, it will be a substrate of one of the rat 
Oatp’s. Expression levels of two of the three rat Oatp’s reached similar levels to liver 
expression indicating substrate access to rat bepatocytes may not be a problem if assays 
are performed before influx transporter expression falls.
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5.4.4 Induction of Drug Transporters by Nuclear Receptor Agonists
In the previous chapter, reporter gene assays were used to investigate compound access 
to human-derived cells but as two of the reporter gene constructs used promoter regions 
from transporters, it formed the start of an investigation of how drug transporters are 
regulated. However, producing reporter genes is a lengthy process and as discussed in 
the previous chapter, gene expression often relies on regions of promoters both distal 
and proximal to the transcription start site, which may not all be present in a generated 
reporter gene construct. CeU lines derived from human tumour tissue also differ in the 
expression of important ADME genes and do not always express functional proteins. 
Therefore any change seen using reporter gene technology may not be an accurate 
prediction for the functional level.
In this section, MLC and SC rat bepatocytes were dosed with compounds known to 
activate nuclear receptors; CPA was chosen as it is known to activate rodent PXR, 
dexamethasone activates both the GR and PXR, while Wy-14,643 was chosen to activate 
PPARa dependent transcription.
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5.4.4.1 Regulation of Transcription by PXR, GR and PPAR
The results from the reporter gene study carried out in the previous chapter confirmed 
literature data that PXR is probably involved in the regulation of at least some 
transporter genes. To investigate the role of PXR, GR and PPAR in drug transporter 
transcription, rat bepatocytes were dosed with agonists of the nuclear receptors. The 
response for each gene or gene family, and any implications on drug disposition are 
discussed below.
S.4.4.2 Abcbl
No significant induction of Abcbl was observed in either MLC or SC rat bepatocytes 
exposed to any of the compounds tested. However, there is a small, 4-fold increase in 
Abcbl expression after SC cells were exposed to CPA for up to 48 hours. A similar level 
of induction was seen in Huh7 cells transfected with the ABCBl reporter gene and 
exposed to the statins in the previous chapter and a study involving human bepatocytes 
dosed with rifampicin, a human activator of PXR, only saw 2-fold induction of ABCBl 
(Jigorel et al., 2006) confirming low levels of induction in bepatocytes by PXR agonists.
As Abcbl is a well-known PXR target gene (Demeule et al., 1999; Geick et al., 2001) 
such low induction may appear surprising; however it has been shown in rodents that 
expression of Abcbl is higher in intestine than liver (Brady et al., 2002) and is more 
inducible in the intestine than in the liver (Jin et al., 2006). The ability of the body to 
increase Abcbl expression in the intestine makes sense as this protects the body against 
exposure to xenobiotic compounds, whereas metabolic enzymes are present in greater 
quantities in bepatocytes than intestinal enterocytes and so can clear a compound by 
oxidation and/or conjugation more effectively in the former tissue. In most cases, 
conjugated xenobiotics are substrates for a wider range of transporters than parent drug 
so inducing Abcbl becomes less useful to clearing potentially toxic compounds from the 
body, as it does not transport conjugates.
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5.4.4.3 Abcb4
Current evidence supports the theory that PPARa has a regulatory role in Abcb4 
expression (Chawla et al., 2001; Kok et al., 2003), which would make sense as PPARa is 
involved in the regulation of lipid pathways and PC is the endogenous ligand of Abcb4. 
The fibrate class of drugs, which are known to act through PPARa, also cause induction 
of Abcb4 (Chianale et al., 1996). However, only a small amount of Abcb4 induction was 
seen when MLC ceUs were treated with the PPARa agonist, Wy-14,643, with no 
significant activation being observed in SC hepatocyts. Abcb4 expression levels in both 
SC and MLC bepatocytes responded to dexamethasone treatment, which would be 
indicative of a possible role for PXR or GR in the regulation of this gene. Other studies 
have seen induction of Abcb4 after rats were treated with dexamethasone (Salphati and 
Benet, 1998), agreeing with the current data. Whether such activation is mediated via 
PXR of GR is not clear, with literature data being equivocal. For example a recent study 
found that atorvastatin, which is a PXR ligand, caused Abcb4 induction in mice (Wagner 
et al., 2005), whereas others reject a role for PXR (Teng and Piquette-Müler, 2005). This 
data may be further complicated by the finding that statins have also been linked with 
PPAR mediated transcriptional activation (Landrier et al., 2004). It is likely that the 
Abcb4 induction caused by dexamethasone is not via PXR, but rather GR, but the actual 
mechanism is unclear and requires further work to clarify.
5.4.4.4 Abcg2
This study provides evidence that Abcg2 is regulated by PPARa agonist in bepatocytes. 
Studies into the transcriptional regulation of Abcg2 have so far been limited; however 
very recent work supports our conclusion as it found that drug activation of PPARa is 
likely to play a role in increasing Abcg2 expression in mouse liver (Hirai et al., 2007). 
They found a 3-fold induction of Abcg2 in mouse liver in response to treatment with 
Wy-14,643 and another PPARa agonist GW7647. Induction in the present study was at 
least 10-fold higher than Hirai et al. found, but this could have been due to species or 
tissue differences, or due to a difference between the in vivo and in vitro experiments. 
Another recent study, this time using monocyte-derived dendritic cells, found ABCG2 to 
be under the control of PPARy (Szatmari et al., 2006). However, due to the restricted 
expression profile of PPARy, with negligible expression in the liver, this is unlikely to be
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of biological significance in bepatocytes, and therefore the current work and the study by 
Hirai et al. supports the idea that Abcg2 is regulated by activation of PPARa in the liver.
Interestingly, SC bepatocytes dosed with CPA, a PXR agonist in rodents, also show 
increased Abcg2 expression to a similar level to that seen when cells were exposed to 
Wy-14,643, while dexamethasone has no significant effect. A recent study investigated 
the RNA level of CYP’s and phase II enzymes, as well as a number of transporters, in 
patients treated with carbamazepine, an antiepileptic drug known to activate PXR 
(Oscarson et al., 2006). One of the elevated genes when compared to control patients 
was ABCG2, indicating activation of PXR may lead to increased levels of ABCG2 
mRNA. PXR and ABCG2 mRNA levels were shown to correlate in human intestine 
(Albermann et al., 2005), whüe exposure of human bepatocytes to rifampicin, a human 
PXR activator, resulted in increased ABCG2 expression (Jigorel et al., 2006). It is 
therefore possible that Abcg2 is regulated by both PXR and PPARa.
Induction of ABCG2 by PXR and PPAR agonist may represent the requirement of this 
transporter to transport different substrate groups; for example xenobiotics are more 
likely to stimulate PXR to increase ABCG2 levels and thereby increase compound 
clearance whüe lipids may activate PPAR to increase transcription of lipid transporters. 
ABCG2 is closely related to Hpid transporters also in the ABCG famüy and may share 
common regulatory mechanism although no evidence exists that ABCG2 is itself a lipid 
transporter. Alternatively PXR activation may be more important in non-rodent species 
such as humans where PPAR plays much less of a role in transcriptional activation than 
in rats. Therefore both PXR and PPAR would be able to induce Abcg2/ ABCG2 in vitro 
but the physiological relevance of the two pathways may differ in vivo.
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S.4.4.5 The Abcc Family
The response of members of the Abcc family to dexamethasone, CPA and Wy-14,643 is 
differentially regulated in SC and MLC bepatocytes; for example Abcc2 is not 
significantly affected by any of the compounds in SC bepatocytes but is induced by CPA 
and dexamethasone in MLC cells, while the basolateral Abcc’s are induced by CPA 
and/or dexamethasone in SC cells but any response is either reduced or absent in MLC 
cells. Abcc2 is known to be induced by dexamethasone in rats (Courtois et al., 1999; 
Gerk and Vore, 2002), however both these studies compared induction of Abcc2 in rat 
with induction in MLC rat bepatocytes and so whüe the lack of induction in SC ceüs is 
surprising it may be due to the experimental conditions. In the case of the other Abcc 
transporters, the lack of response in MLC ceüs to any of the drugs may indicate a need 
for the ceüs to be polarised for these transporters to be fuUy functional and properly 
regulated, although this would need further work to prove.
A bed, Abcc3 and Abcc4 are aU induced foUowing treatment of SC bepatocytes with 
CPA indicating a role for PXR mediated activation of these genes. However 
dexamethasone did not cause any significant induction of Abcc4 expression and only 
low-level induction of Abccl, whüe Abcc3 is induced by dexamethasone to a simüar level 
as by CPA. The reason for this is unclear but may support a theory of differential gene 
regulation by PXR where different compounds activate the nuclear receptor to increase 
levels of different groups of genes. Abcc4 is also induced to a much higher level by CPA 
than either Abccl or 3, suggesting that bepatocytes are capable of increasing levels of this 
transporter more in response to external stimuU. Abcc3 and 4 are known to be induced 
during cholestasis (Schuetz et al., 2001) as this reduces the accumulation of büe acids in 
the ceü. Likewise during exposure to xenobiotics that activate PXR, increasing levels of 
Abcc3 and 4 would increase the clearance of drug or metaboHtes by effluxing them into 
the blood for processing by the kidneys and excretion in urine. Why Abcc4 should be 
induced to a higher level than Abcc3, and whether the increase is mirrored at the protein 
level, remains unclear.
Less is known regarding Abccl induction although this work puts forward an argument 
that the basolateral Abcc’s share a common regulatory pathway so it would foHow that 
Abccl be induced in response to similar stimuH and in order to reduce the levels of 
potentiaUy toxic substances within the ceU just as Abcc3 or 4 have been found to do. In
189
MLC human hepatocytes the PXR activator rifampicin caused a slight increase in ABCC2 
levels but failed to induce ABCCl or 3 (Nishimura et al., 2006). This may be a species 
difference or due to cells being cultured in monolayer and not in sandwich culture.
The ‘co-ordinated’ response by the basolateral efflux transporters to CPA may form part 
of the bigger network of proteins regulated at a transcriptional level by the ligand 
activation of PXR. Both phase I and II DME’s are induced by PXR and this increases 
the metabolism of compounds entering hepatocytes and so clears them more quickly. 
During cholestasis there is evidence that the enzymes that are induced lead to a change in 
the relative amounts of different conjugates thereby creating better substrates for 
basolateral efflux transporters and increasing bile acid efflux into the blood. Other 
nuclear receptors contribute to this complex regulatory system, for example CAR has 
been implicated with regulating Abcc4 expression (Assem et al., 2004; Wagner et al., 
2005) and Nrf2 with Abcc2 expression (Jigorel et al., 2006); it is likely that more 
interactions remain to be discovered by further work in this area.
S.4.4.6 The Slco Family
As might be expected for close family members, Slcolal and la4 appear to share a 
common regulatory pathway, distinct from Slclb2 regulation. For example, 
dexamethasone induces levels of Slcolal and la4 mRNA in both MLC and SC 
hepatocytes but has no effect on Slclb2 levels, whereas CPA induces Slcolb2 levels in 
SC ceUs but has no effect on Slcolal and only a tiny effect on Slcola4 levels. 
Interestingly Wy-14,643 appears to have an early effect on Slco levels but as this is 
restricted to MLC hepatocytes, it would require further investigation to fuUy understand 
the biological relevance of this. Others have also noted induction of influx transporters 
in rats and humans in response to activation of nuclear receptors (Jung et al., 2002). One 
possible reason why a cell would increase influx transporter expression is that as weU as 
increasing the amount of drug in the cell, it would also increase the amount of drug 
available for metabolism thereby clearing unmetabolised compound more quickly by 
increasing its hydrophilicity.
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5.4.5 Summary
In conclusion, sandwich cultured rat hepatocytes after 4 days of culture provide the best 
in vitro model of hepatocytes in vivo on the basis that drug transporter mRNA levels and 
in the case of those tested, protein and activity levels, are most like rat and human liver. 
Such a system could be used to measure the biliary efflux of compounds to gain a better 
understanding of how dmgs and/or their metabolites are excreted from the body. This 
may allow better predictions of efficacy and toxicity to be made for new compounds, for 
example, if a compound is excreted into the bile, cholestasis may increase intracellular 
levels of drug leading to a higher risk of toxicity. Only through a better understanding of 
drug transporter levels in in vitro cellular assays can we aim to make robust 
pharmacokinetic and toxicological predictions for new compounds.
The regulation of drug transporter expression is complex and is likely to occur by a 
number of different mechanisms including drug activation of nuclear receptors and 
activation by endogenous species, for example during cholestasis. The in vitro dosing of 
rat hepatocytes with PXR, GR or PPAR activators showed several links between the 
nuclear receptors and increased drug transporter expression, including induction of 
Abcg2 by the PPARa agonist Wy-14,643, which has not been reported in hepatocytes 
before. This work supports the theory that some transporters are regulated by the 
nuclear receptor PXR, which also regulates the expression of a number of phase I and 
phase II DME’s. Therefore PXR is of vital importance in the coordinate regulation of 
these important ADME genes in response to drugs; influx transporters are induced to 
increase the uptake of compound into hepatocytes, DME’s are induced to increase 
metabolism of this compound and finally efflux transporters are induced to increase the 
rate of the metabolites and/or parent drug effluxed into the büe for biliary excretion, or 
blood for urinary excretion.
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6 In vitro Measurement and in silica M odelling o f Transport 
Processes Involving ABCC2
6.1 Introduction
The previous chapters in this thesis have concentrated on the expression of drug 
transporter genes at the transcript level and whereas it is useful to ascertain the overall 
transporter expression profile in a cell, as this may suggest the potential disposition of 
chemicals through these transporters, it does not take into account important factors 
such as transporter functionality and substrate specificity. The biliary efflux of drugs and 
metabolites affects compound distribution and excretion, for example most metabolites 
effluxed into the bile will be excreted from the body in the faeces. However if parent 
drug is effluxed into the büe it may be reabsorbed from the GI tract via enterohepatic 
reabsorption. In addition, inhibition of büe salt efflux by xenobiotics competing for 
transport can result in adverse drug events leading to cholestatic symptoms as büe acids 
accumulate in the ceüs. Therefore understanding the efflux pathways of compounds 
from hepatocytes is important in both ADME and toxicity testing of new compounds.
Abcc2 was chosen in order to characterise drug transport at the functional level by using 
carboxydichlorofluroscein diacetate (CDFDA), a compound that is hydrolysed once it 
has passively diffused into ceüs to form carboxydichlorofluroscein (CDF), a fluorescent 
substrate of Abcc2. It would also be advantageous to be able to model drug transport 
processes using an in silico computer model, as this would increase the number of 
variables that could be tested on Abcc2 efflux. Therefore a simple molecular model was 
designed in order to simulate CDFDA and CDF disposition in SC rat hepatocytes.
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6.1.1 In vitro Measurements of Büiary Excretion
Sandwich cultured hepatocytes have previously been used to assess the biliary excretion 
and hepatotoxic potential of drugs involved in bile acid efflux (Kostrubsky et al., 2003). 
Patented technology to measure biliary excretion known as B-CLEAR (European Patent 
1163517) is available from Qualyst and involves dosing SC hepatocytes with compounds 
of interest for a certain time period, following which cells are washed in buffer either 
containing calcium or with calcium removed. When SC hepatocytes are deprived of 
calcium the BCN is dismpted so releasing the contents of the BCN into the buffer. The 
difference between the amount of drug in the cells and BCN, compared to the cells alone 
is the amount of drug effluxed into the BCN. This is called the biliary excretion index 
(BEI) and allows predictions of compound excretion into the büe.
6.1.1.1 Carboxydichlorofluroscein Efflux via Abcc2
The majority of studies into biliary excretion from hepatocytes now use the B-CLEAR 
technology from Qualyst, however the patent required for this was not feasible during 
the current work and B-CLEAR doesn’t aUow transport via a specific transporter to be 
measured, which makes the system sub-optimal for determining precise 
quantitative/kinetic data for a single transporter. Therefore an in vitro assay which had 
previously been estabHshed by AstraZeneca to measure compound efflux via Abcc2 in 
sandwich cultured rat hepatocytes (Hopwood et al., 2006) was adapted for use in this 
work.
In the Abcc2 efflux assay SC hepatocytes are dosed with CDFDA, which passively 
diffuses into ceüs and is hydrolysed by intraceüular esterases to CDF, a fluorescent 
substrate of Abcc2. As sandwich cultured rat hepatocytes form contained büe canaHcular 
structures (section 5.2.3), CDF fluorescence is concentrated in a smaU area between ceüs 
from where it can be easüy visualised and measured (Figure 6-1). Although CDF is also 
effluxed via the basolateral transporter Abcc3 (Zamek-Gliszczynski et al., 2003), the ceüs 
are washed prior to analysis so any CDF effluxed from ceüs via this route wül be 
removed before fluorescence is measured. This assay was used to assess functional 
transport via Abcc2 in SC rat hepatocytes and the molecular pathway was used as the 
basis of a simple in silico model of drug transport processes within hepatocytes.
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Figure 6-1 The cellular disposition and excretion o f CDFDA and CDF from an 
hepatocyte.
CDFDA passively diffuses across the sinusoidal membrane o f hepatocytes and is rapidly 
hydrolysed by intracellular esterases to form CDF. Abcc2 actively transports CDF across the 
canalicular membrane o f hepatocytes into canalicular structures surrounding hepatocytes.
6.1.2 In Silico Modelling
In vitro studies to assess biliary efflux have their place in identifying compounds that wül 
be excreted into the büe or which have the potential to cause hepatotoxicity via 
interactions with transporters. However such assays are costly, labour intensive, not very 
high throughput and rely on the use of rat or human hver. The supply of human hver 
can be sporadic, whhe the current move to reduce animal testing provides impetus to 
find alternatives. Therefore whüe in vitro assays are required in the first instant to identify 
substrates for büiary excretion, a move towards in silico modeUing of such data would be 
advantageous as it aUows ‘what if?’ questions to be posed and answered without vast 
amounts of in vitro work, thus potentiaUy producing an initial screen aUowing the 
refinement of later in vitro analysis. It is estimated that 1 5  % of drug development 
budgets W Ü 1 be spent on simulating data using in silico models in the next 5 - 1 0  years 
(Rostami-Hodjegan and Tucker, 2 0 0 7 ) ,  with the expectation that the produced systems 
wiU aUow savings in both time and money. The FDA has also indicated that the use of in 
silico data provides ‘valuable insight into optimising study design’ (FDA, draft advice to 
industry, 2 0 0 6 ) .
Another advantage of a model is the abihty to assess the importance of ‘missing data’; 
simulations are made up of what is known, with the difference between the observed and 
expected simulations being predictive of the amount of ‘missing’ biological information
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in the system. The use of such information can therefore be important in understanding 
the interaction networks of complex biological systems, thus ensuring better prediction 
of compound action/fate in the future. An example of a model being used in this way 
was the recent simulation of compound flux through MDCKII cells transfected with 
human transporters, which identified dog Abcc4 as having a role in the vectorial 
transport of compound through the cells (Bartholome et al., 2007).
One area where modelling has become a common tool in drug development, is in the 
field of pharmacokinetics (PIQ. The Simcyp consortium has developed a model to 
simulate the PK of compounds in a virtual population in order to extrapolate in vitro PK 
data to the in vivo situation. It relies upon data from PK studies completed during drug 
discovery and development, such as Caco2 absorption, plasma-protein binding, 
lipophilicity and DME kinetics, to predict clearance and DDTs in a representative 
population, which accounts for different genders, ages, ethnicities as well as populations 
of people that express polymorphic DME’s. The program allows identification of 
individuals who may be exposed to very low or very high doses of compound based on 
their genetic make-up before that compound is tested clinically. Such a priori knowledge 
helps to reduce failures of compounds during clinical trials (Rostami-Hodjegan and 
Tucker, 2007).
However Simcyp doesn’t take drug transport processes into account, as the ability to use 
the in vitro data on drug transport is limited by inadequate knowledge of drug transporter 
expression levels (Rostami-Hodjegan and Tucker, 2007). Therefore Simcyp is only as 
good at predicting in vivo PK as the in vitro assays it relies on and as has already been 
shown in previous chapters, in vitro assays do not always provide a good representation of 
in vivo tissue with regards to drug transporter expression. It was the aim of this work to 
examine the utility of in silico modelling of drug transport processes. In the current work, 
which will form the foundation for further modelling work, a simple model of 
compound efflux in SC rat hepatocytes was developed using literature data and the drug 
transporter expression collated in earlier sections.
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6.2 An ia  wVro Assay to Measure Carboxydichlorofluroscein Efflux Via Abcc2
The vitro assay for measuring efflux of CDF described in the introduction was initially 
optimised regarding the length of time rat hepatocytes should be cultured for before 
measurements were made. The assay was then used to measure certain kinetic 
parameters of the transport, including the ability of an Abcc2 inhibitor to block CDF 
efflux. Previous work in this study has concentrated on the cellular uptake of pravastatin 
by OATPIBI (chapter 4), but Abcc2 mediates the efflux of pravastatin across the 
canalicular membrane of hepatocytes; alterations in the level of efflux transporters as 
seen in chapter 5 could significantly impact upon the rate of removal, and hence 
intracellular concentration of pravastatin. Therefore the ability of an Abcc2 substrate to 
reduce the efflux of CDF into büe canaliculi was shown using pravastatin as a test 
substrate.
6.2.1 Cell Culture Time
In order to optimise on which day the assay for CDF efflux was performed, rat 
hepatocytes were sandwich cultured for five days foUowing plating (where the day ceüs 
were plated was designated as day 0). On each day ceüs were dosed with 10 pM 
CDFDA for 30 minutes and the fluorescent intensity of CDF measured. Fluorescence 
increased with culture time untü it reached a maximal intensity 4 days after plating 
(Figure 6-2), which is in agreement with results in sections 5.22 and 5.21 where Abcc2 
RNA and protein were maximal after 4 days of culture. The büe canacHcular network 
(BCN) also becomes clearly defined under the microscope after 4 days.
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Figure 6-2 The effect of culture length on CDF efflux via Abcc2 into bile canaliculi.
Rat hepatocytes were plated on day 0 and sandwich cultured over the following 5 days. On each 
day cells were washed in HBSS and dosed with 10 pM CDFDA (0.1 % DMSO) before being 
incubated for 30 minutes at 37 °C, 5 % CO2 . Fluorescent intensity was measured using an 
Axiovert 100 microscope with FITC filter (485 nm) and supplied software. Data was fitted using 
non-linear regression analysis (n=l).
197
6.2.2 Incubation Time of Cells with CDFDA
After establishing the optimal culture time, rat hepatocytes were sandwich cultured for 4 
days post plating (where cells were plated on day 0 ) when they were dosed with 1 0  pM 
CDFDA for 0 — 35 minutes in order to establish the relationship of CDF fluorescence 
with time of incubation. Fluorescent intensity of CDF was measured following the 
incubation and was found to increase linearly with incubation time (Figure 6-3).
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Figure 6-3 Fluorescent intensity o f CDF over increasing incubation time o f cells with 
CDFDA.
Rat hepatocytes were plated on day 0 and sandwich cultured for 4 days, after which time cells 
were washed in HBSS and dosed with 10 pM CDFDA (0.1 % DMSO) before being incubated 
for 0-30 minutes at 37 °C, 5 % CO2 . Fluorescent intensity was measured using an Axiovert 100 
microscope with FITC filter (485 nm) and supplied software. Data is an average of two 
biological repeats and was fitted using linear regression analysis (R^  = 0.974).
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6.2.3 Concentration of CDFDA
The transport kinetics of CDF efflux were calculated by measuring the rate of CDF 
efflux over increasing CDFDA concentrations and fitting the data to Michaelis-Menton 
non-linear regression analysis. Rat hepatocytes were sandwich cultured for 4 days post 
plating (where cells were plated on day 0) and dosed with 0 - 1 0  pM CDFDA for 25 
minutes. Fluorescent intensity of CDF was measured and was found to increase in a 
dose dependent manner (Figure 6-4) with a of 0.77 pM (+/- 1.2 pM).
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Figure 6-4 The Rate o f CDF efflux with increasing concentrations of CDFDA.
Rat hepatocytes were sandwich cultured for 4 days post plating (where cells were plated on day 0) 
and dosed with 0- 10  pM CDFDA before being incubated for 25 minutes at 37 °C, 5 % CO2 . 
Fluorescent intensity was measured using an Axiovert 100 microscope with FITC filter (485 nm) 
and supplied software. The fluorescent intensity was converted to rate (RFU/minute). Data was 
fitted using non-linear regression analysis to give the Michaelis-Menten constant (Km) of 0.77 +/-
1.2 pM and a maximum rate (Vmax) of 23.13 +/- 5.0 RFU/minute (n=3; error bars = SEjM).
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6.2.4 Inhibition of CDF Efflux with MK571
MK571 is a broad-range inhibitor of the Abcc family of drug transporters, including 
Abcc2 (Gekeler et al., 1995; Honda et al., 2004). To assess the ability of MK571 to 
inhibit Abcc2-mediated efflux of CDF, rat hepatocytes were sandwich cultured for 4 
days post plating (where cells were plated on day 0) and dosed with 10 pM CDFDA and 
0 — 100 pM MK571 for 25 minutes. Fluorescent images were taken at each 
concentration of MK571 (Figure 6-5). The 100 pM dose of MK571 was not analysed for 
fluorescent intensity due to increased toxicity evidenced by an increased number of dead 
cells (rounded fluorescence) in the image. The fluorescent intensity of CDF was 
measured in each sample and was found to decrease in a dose dependent manner (Figure 
6 -6 ) with an IC5 0  of 1.9 pM + /-  3.7 pM.
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Figure 6-5 Representative fluorescent images of sandwich cultured rat hepatocytes dosed  
with 10 pM CDFDA and 0 - 100 pM MK571.
Rat hepatocytes were sandwich cultured for 4 days post plating (where cells were plated on day 0) 
and dosed with 10 pM CDFDA and 0 —100 pM MK571 and incubated for 25 minutes at 37 °C, 
5 % CO2. Fluorescent images were taken at lOx magnification with an Axiovert 100 microscope 
with the integral digital camera through a FITC (485 nm) filter. Values below each image refer to 
the concentration o f MK571. The 100 pM image was not analysed due to cellular toxicity at this 
dose.
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Figure 6-6 Fluorescent intensity o f CDF over increasing concentrations o f MK571.
Rat hepatocytes were sandwich cultured for 4 days post plating (where cells were plated on day 0) 
and dosed with 10 pM CDFDA and 0 — 30 pM MK571 and incubated for 25 minutes at 37 °C, 5 
% CO2 . Fluorescent intensity was measured using an Axiovert 100 microscope with FITC filter 
(485 nm) and supplied software. Data was fitted using non-linear regression analysis (IC5 0  =1.9 
pM +/- 3.7 pM; n=3; error bars = SEM).
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6.2.5 Inhibition of CDF Efflux with Pravastatin
Pravastatin is a substrate of Abcc2 (Yamazaki et al., 1997) and will therefore compete 
with CDF for efflux. In order to estabUsh if pravastatin would reduce the fluorescent 
intensity of CDF in the canahcuh rat hepatocytes were sandwich cultured for 4 days post 
plating (where cells were plated on day 0) and dosed with 10 pM CDFDA and 0 — 300 
pM pravastatin for 25 minutes. Fluorescent images were taken at each concentration of 
pravastatin (Figure 6-7). Fluorescent intensity of CDF was measured and was found to 
decrease in a dose dependent manner (Figure 6 -8 ) with an IC5 0  of 55.2 pM + /- 51.3pM.
0 3 |iM 10 fiM
30 uM 100 300
Figure 6-7 Representative fluorescent images of sandwich cultured rat hepatocytes dosed  
with 10 pM CDFDA and 0 - 300 pM pravastatin.
Rat hepatocytes were sandwich cultured for 4 days post plating (where cells were plated on day 0) 
and dosed with 10 pM CDFDA and 0 — 300 pM pravastatin and incubated for 25 minutes at 37 
°C, 5 % CO 2. Fluorescent images were taken at lOx magnification with an Axiovert 100 
microscope with the integral digital camera through a FITC (485 nm) filter. Values below each 
image refer to the concentration of pravastatin.
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Figure 6-8 Fluorescent intensity o f CDF over increasing concentrations o f pravastatin.
Rat hepatocytes were sandwich cultured for 4 days post plating (where cells were plated on day 0) 
and dosed with 10 pM CDFDA and 0 — 300 pM pravastatin and incubated for 25 minutes at 37 
°C, 5 % CO2 . Fluorescent intensity was measured using an Axiovert 100 microscope with FITC 
filter (485 nm) and supplied software. Data was fitted using non-linear regression analysis (IC5 0  =
55.2 pM +/- 51.3 pM; n=3; error bars = SEM).
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6.3 An in  silico  Model of CDF Efflux via Abcc2
In silico modelling of intracellular events can be helpful during ADME studies as a tool 
for understanding the effects of changes to a biological system on drug absorption, 
metabolism, disposition and excretion without the need to mn each experiment many 
times to account for variation in every part of a particular pathway. For example, the 
biliary excretion of drugs is affected by many factors, including the amount of drug 
within the cell, the rate of metabolism of compound and the presence of transport 
inhibitors. Drug transporter levels also change in the in vitro systems used to assess 
ADME properties of new compounds, as was shown in chapter 5 and this may effect the 
extrapolation of in vitro data to predict the pharmacokinetics of a compound in vivo.
Such factors can be included in an in silico model of a compounds route through a cell, 
allowing the effect of variation within the system to be simulated. Therefore a simple in 
silico model of CDF efflux via Abcc2 in rat hepatocytes was developed using Cell 
Designer (v. 3.5.1) from data collated from hterature and measurements made in the in 
vitro section of this chapter. Abcc2 and Abcc3 transcript expression in rat hepatocytes 
from chapter 5 was also incorporated into the model.
6.3.1 Michaelis Menten Kinetics
The Michaelis-Menten equation (Equation 6-1) is the most commonly used measure of 
enzyme kinetics where enzyme or transporter activity depends on the concentration of 
substrate.
V _[S ] 
v = ---------
Km [S]
Equation 6-1 Michaelis-Menten Equation
Where V = velocity or rate of reaction and [S] = concentration of substrate. The 
Michaelis-Meni 
velocity (V^J.
ten constant or is the concentration of substrate at half the maximum
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Initially a simple enzymatic reaction was modelled using Cell Designer in order to 
validate the programs use of Michaelis-Menten kinetics. The input and for the 
reaction were set at 5 and 10 respectively, and the simulation run through the Jarnac 
Simulation Service (v.2.26b) built into CellDesigner. Data from Jarnac can be plotted in 
GraphPad and analysed via non-liner regression for a Michaelis-Menten plot (Figure 6-9) 
allowing the actual and produced from the model to be calculated. The output 
values from the regression analysis were 6.65 + /-  0.2 and 10.07 + /-  0.07 for the Kj  ^and 
Vjnax respectively, thereby validating the use of CeU Designer to model Michaelis-Menten 
kinetics.
10 -
I
II
I
a
I I
o 8 o00
Concentration (pIVI)
Figure 6-9 Non-linear regression analysis o f  data produced from a m odel o f  a simple 
enzyme catalysed reaction.
A simple Michaelis-Menton reaction was created in Cell Designer and simulated via Jarnac. 
Substrate concentrations were modelled between starting concentrations of 0 pM and 1000 pM, 
generating 1000 data points over a period of 5 minutes. Quantitative data from Jarnac was 
converted to rate of production over the linear portion of the simulation and fitted to a 
Michaelis-Menten non-liner regression using GraphPad Prism. The Km and Vmax were calculated 
to be 6.65 +/- 0.2 and 10.07 +/- 0.07 respectively from input figures to the modelling program 
of 5 and 10 respectively.
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6.3.2 Designing an Abcc2 Efflux Model
The efflux of CDF via Abcc2 from rat hepatocytes into the bile canaliculi involves many 
processes prior to the final efflux step; for example CDFDA must diffuse into cells and 
be hydrolysed to CDF. Other factors include the possible basolateral efflux of CDF via 
Abcc3 and the ability of Oatp’s to actively transport CDF back into the cells. While the 
kinetics for most of these steps can be gained from literature, some parts of the process 
such as the rate of extracellular conversion of CDFDA to CDF and the rate of passive 
diffusion of CDF into and out of cells are not freely available and hence must be 
determined experimentally before they can be incorporated into any model.
6.3.2.1 Passive Diffusion of CDF
CDF has three negative charges and is therefore unlikely to passively diffuse across a 
lipid membrane. To show that this is true CDF was loaded in HBSS and mixed with an 
equal quantity of octanol. No appreciable partition of CDF into the octanol phase was 
observed over the concentration range tested (Figure 6-10). If CDF were able to move 
from the HBSS to octanol it would indicate that CDF would also be able to cross a lipid 
bilayer; however aU the CDF remains in the HBSS, indicating CDF cannot passively 
diffuse into cells.
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Figure 6-10 Correlation o f CDF in HBSS and octanol fractions with CDF added in HBSS.
0 - 2 0  mM CDF (in DMSG) was diluted 1:1000 in HBSS and added to an equal volume of 
octanol. The mixture was vortexed and allowed to separate before samples were taken from each 
fraction and the fluorescence measured (kex 485nm; A-em 590nm) in triplicate. The concentration 
of CDF was calculated from standard curves of CDF in HBSS or octanol and the calculated 
amount was correlated against the concentration added to HBSS. Error bars = SEM, where no 
error bars are observed they are contained within the limits of the data point.
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6.3.2.2 Extracellular Conversion of CDFDA to CDF
CDFDA is readily converted to CDF within a ceU due to intracellular esterase activity 
(Zamek-Gliszczynski et al., 2003). However, it is important to examine if CDFDA can 
non-enzymatically breakdown to CDF in HBSS. To measure the rate at which CDFDA 
is converted to CDF in HBSS, 0 — 20 mM CDFDA (in DMSO) was diluted 1:1000 in 
HBSS. Fluorescence was measured every 2 minutes over 60 minutes and compared to a 
CDF standard curve. No fluorescence was observed in the CDFDA samples over 60 
minutes indicating that CDFDA is not converted to CDF in HBSS (Figure 6-11).
Q
O
30
20-
c0
1
8 c
Ü
0 minutes 
30 minutes 
60 minutes
— i—  
10
—i—
15
—I 
20
Concentration of CDFDA (pM)
Figure 6-11 CDF produced from CDFDA after 0, 30 and 60 minutes in HBSS.
0 — 20 mM CDFDA (in DMSO) was diluted 1:1000 in HBSS and the fluorescence measured (X,ex 
485nm; A,em 590nm) in triplicate for each sample after 0 (•), 30 (♦) and 60 ( ) minute 
incubations at 37 °C. Relative fluorescence units were converted to CDF concentrations using a 
standard curve o f CDF in HBSS. Error bars = SEM, where no error bars are observed they are 
contained within the limits of the data point; data points obscure each other.
Following the determination of these two parameters it was possible to build a model for 
simulating CDF disposition within and efflux from a hepatocyte using Cell Designer 
v3.5.2. The kinetics of each reaction or transport process were found from literature 
sources and are described in Table 6-1. A visual representation of the model is given in 
Figure 6-12.
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Reaction 
Number 
in Model
Kinetics of Reaction
1 Hydrolysis of CDFDA (sl4) to CDF (s5) within the cell
All CDFDA was converted to CDF within 10 seconds^ 
Presume this is 20 half lives, therefore q / 2  = 0.5 seconds. 
For a first order reaction, tj/ 2  = ln2/k 
k = 0.693/0.5 = 1.39 sec^
2 Passive diffusion of CDFDA (sl3) into the cell
Uptake clearance of CDFDA into rat hepatocytes = 4.9 + /-  0.3 pl/min/mg 
protein and was not inhibited by low temperature (10 pM dose)\
In reference 1,100 pM and 500 pM CDFDA gave rate of 687 pl/min/mg 
protein and 3374 pi/min/mg protein respectively.
Assume to be a reversible first order process, so rate = k[s] 
k ~ 6.8 min ^
3 Efflux of CDF (sl2) via Abcc2 into the bile canaliculi
Using an Abcc2 overexpression system in HEK ceUs^ :
Km = 18.9 + /-  2 pM
Vmax — 95.5 + /-  14.8 pm ol/m in/m g protein
4 Uptake of CDFDA (sl3) into the cell via active transport.
As CDFDA is a very lipid soluble molecule, the presence of active transport into 
the ceU will be minimal^ supported by the fact that transport is unaltered by 
temperature^
Discounted in the model.
8 Binding of CDFDA (sl3) to extracellular proteins.
In vivo CDFDA is approximately 20 % protein bound\
The model simulates the in vitro assay and as hepatocytes were dosed with 
CDFDA in HBSS, containing no extracellular protein, this figure will be zero. 
Discounted in the model.
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10 Conversion of CDFDA (sl3) to CDF (s26) outside of the cell.
Measured as zero over 60 minutes in HBSS (section 6.3.2.2).
In PBS ti/ 2  — 7.6 + /-  0.1 hours\
For a first order reaction, ti/ 2  = ln2/k 
k = 0.693/456 = 0.00152 min^
11 Uptake of CDF (s26) into the cell via active transport.
Uptake clearance of CDF into rat hepatocytes = 1.9 + /- 0.1 pl/min/mg protein 
and was inhibited by low temperature (10 pM dose)\
Uptake was saturable with a of 22 +/-10 pM and = 97 + /-  9 
pm ol/m in/m g protein .
Inhibited by substrates of Oatp’s e.g. taurocholate and rifampicin\
12 Passive diffusion of CDF (s26) into the cell.
Measured as zero in section 6.3.2.I.
Minimal as low temperature inhibited uptake^ so assume transporter mediated. 
Discounted in the model.
13 Binding of CDF (s26) to extracellular proteins.
Again protein binding wiU be zero in HBSS. 
Discounted in the model.
14 Efflux of CDF (26) across the sinusoidal membrane via Abcc3.
Rate of efflux is approximately a quarter of efflux via Abcc2% so: 
Vmax ~ 24 pm ol/m in/m g protein.
Assume is the same as for Abcc2, so:
Km = 20 pM
Table 6-1 The kinetics of each reaction/transport step in the in silico model of CDF 
biliary efflux from sandwich cultured rat hepatocytes.
Each reaction or transport process is identified by a number in the model and refers to a specific 
step. The kinetics of each reaction have been collated from literature sources:  ^ (Zamek- 
Gliszczynski et al., 2003); 2  (Pratt et al., 2006); (^Wu and Benet, 2005). The kinetic values used in 
the model are shown in bold type.
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6.3.3 Simulating CDF Efflux
The Jarnac simulation service (v.2.26b) from the systems biology workbench of 
CellDesigner was used to simulate CDF disposition and efflux. The model was initially 
run using 1 unit of each drug transporter to simulate the rate of CDF accumulation in 
the büe canaliculi with concentrations of CDFDA ranging from 0.1 to 1000 pM. The 
resulting data was analysed by non-linear regression analysis (Michaelis-Menten kinetics) 
resulting in a of 98.12 + /-  1.28 pmoles/min/unit Abcc2 and Kj  ^of 44.50 + /-  2.84 
pM.
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Figure 6-13 The simulated rate of CDF efflux with increasing concentrations of CDFDA.
Substrate concentrations were modelled between starting concentrations of 0 pM and 5000 pM, 
generating 1000 data points over a period of 3 minutes with the kinetic parameters as described 
in Table 6-1. Quantitative data from Jarnac was converted to rate of production over the linear 
portion of the simulation and fitted to a Michaelis-Menten non-Mner regression using GraphPad 
Prism. The Km and Vmax were calculated to be 98.12 +/- 1.28 pmoles/min/unit Abcc2 and 
44.50 +/- 2.84 pM, respectively.
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6.3.3.1 Modelling the Effect of Differences in Drug Transporter Expression on 
Drug Disposition
In chapter 5 a clear difference in the expression levels of drug transporters was shown 
between rat liver and rat hepatocytes and between samples of rat hepatocytes cultured 
for different lengths of time. The advantage of an in silico model is that it can be used to 
examine how these difference could affect the disposition of CDF in the various systems.
To allow a comparison of the data obtained from the model when drug transporter levels 
are adjusted, the model was simulated using the relative transcript levels of Abcc2, Abcc3 
and the Oatp’s found in sandwich cultured rat hepatocytes after 4 and 5 days of culture 
relative to expression levels in liver (section 5.22).
Abcc2 Abcc3 Oatp’s (lal, la4 and lb2)
Day 4 85.25 18.04 2.64
Day 5 7.11 3.47 0.88
Table 6-2 The relative levels of Abcc2, Abcc3 and Oatp’s used to model the efflux of CDF 
in rat hepatocytes sandwich cultured for 4 or 5 days.
Relative transcript levels for each of the drug transporters included in the model from day 4 and 
day 5 sandwich-cultured hepatocytes were determined relative to the liver level where the liver 
level is equal to 1 unit.
The simulation was run using the levels of drug transporters given in Table 6-2 with 
concentrations of CDFDA ranging from 0.1 to 15000 pM. The resulting data was 
analysed by non-linear regression analysis (Michaelis-Menten kinetics) and shows a 
dramatic alteration in the Kj  ^and of CDF efflux into the bile canaliculi (Figure 6-14; 
Table 6-3).
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Figure 6-14 The simulated rate of CDF efflux with increasing concentrations of CDFDA 
when drug transporter levels were set to model transcript levels in rat hepatocytes 
cultured for four (A) or five (B) days.
Substrate concentrations were modelled between starting concentrations of 0 pM and 15000 pM, 
generating 1000 data points over a period of 1 minute with the kinetic parameters as described in 
Table 6-1 except amounts of Abcc2, Abcc3 and Oatp’s which were altered as described in Table 
6-2 to describe amounts after 4 or 5 days of culture. Quantitative data from Jarnac was 
converted to rate of production over the linear portion of the simulation and fitted to a 
Michaelis-Menten non-liner regression using GraphPad Prism.
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Km(iiM) VMax (liM /m in/unit Abcc2)
Initial Model 44.5 + /-  2.84 98.1 +/-1.28
SC Hepatocytes (Day 4) 1015 +/-188.6 9281 + /-  453.8
SC Hepatocytes (Day 5) 122 + /-  8.25 696.1 + /-  7.646
Table 6-3 Kinetic parameters of CDF efflux into the bile canaliculi when drug transporter 
levels were set to simulate transcript levels in rat hepatocytes cultured for four or five 
days.
The Km and Vmax of CDF efflux are given from three models where drug transporter levels were 
set at one unit (initial model) or when they were set at the relative transcript levels in rat 
hepatocytes sandwich-cultured for 4 or 5 days (Table 6-2). Values are stated with SEM.
As the simulation produces quantitative data for all of the species within the model it is 
possible to examine how these alter throughout the simulation period; carrying out such 
an analysis will examine whether in addition to an increase in the overall flow through 
the pathway caused by the altered transporter levels there is an alteration in the relative 
levels of each of the species within the pathway. A real time simulation of the model was 
undertaken to observe how the differences in expression affect disposition of CDF over 
the first minute of the reaction for the base model (Figure 6-15A), or for transporter 
levels corresponding to days 4 and 5 of SC (panels B and C respectively). The major 
difference between the three simulations is the reduction in intracellular CDF 
concentrations (s5; turquoise) when transporter amounts are increased. When day 4 
transporter levels are used in the model there is almost a complete loss of intracellular 
CDF compared to the initial model (Figure 6-15 B compared to A) as the increased rate 
of transport removes CDF from the cell as quickly as it is being produced. As would be 
expected, the rate of CDF accumulation in the büe canaliculi is increased in the day 4 
model compared to the initial model (si2; dark blue).
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Figure 6-15 The simulated 
disposition of CDFDA and CDF in 
the in silico model.
A kinetic simulation of the model was 
run for 1 minute with 10 p.M CDFDA 
and (A) 1 unit o f each transporter, (B) 
day 4 levels o f the drug transporters of 
(C) day 5 levels o f the drug 
transporters (day 4 and 5 levels given 
in Table 6-2). The graphs show a 
decrease in extracellular CDFDA (si3, 
dark green) as CDFDA passively 
diffuses into cells, followed by an 
increase in intracellular CDFDA (si4, 
purple), which is rapidly depleted as 
CDFDA is hydrolysed to CDF. 
Intracellular CDF (s5, turquoise) 
initially increases and is then depleted, 
as it is effluxed from the cell by Abcc2 
into the bile canaliculi (si2, dark blue). 
CDF may also be effluxed via Abcc3 
(s26, light blue). The kinetics of each 
step are altered by increasing the drug 
transporter levels (compare B and C to 
A).
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6.3.4 Inhibition of CDF Efflux via Abcc2 and Abcc3
An alternate method by which compound flux through a pathway could be altered is the 
inhibition of one or more of the steps within that pathway. Inhibition of Abcc-mediated 
transport in vitro through the use of competitive inhibitors such as MK571 reduces the 
efflux of compound across the bile canaliculi as was demonstrated in section 6.2.4. As 
shown in Figure 5-12 it is possible to include expressions for enzyme inhibition within 
the kinetic equations of the generated model, and this was done to examine how 
inhibition of Abcc-mediated transport might affect compound disposition by adding the 
IC5 0  of MK571 that was calculated in vitro in section 6.2.4. The model assumes that the 
ICgo of 1.9 pM is true for inhibition of Abcc2 and Abcc3-mediated efflux of CDF.
First, the rate of efflux of CDF resulting from a starting concentration of 10 pM 
CDFDA was simulated in the presence of 0.1 — 1000 pM MK571 over 3 minutes (Figure 
6-16). This was repeated using an excess of CDFDA (100 pM; Figure 6-16) to ensure 
fuU occupancy of Abcc2 and 3 by CDF. With both concentrations of CDFDA a dose 
dependent inhibition was observed, with 10 pM CDFDA producing an IC5 0  of 9.73 + /-  
0.63 pM , whereas 100 pM CDFDA resulting in an increased IC5 0  of 23.67 + /- 1.58 pM.
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Figure 6-16 Inhibition of CDF efflux by increasing concentrations of MK571 where the 
concentration of CDFDA was kept constant at 10 |iM (black) or 100 pM (grey).
MK571 concentrations were modelled between starting concentrations of 0.1 pM and 1000 pM 
with a constant concentration of 10 pM (black) or 100 pM (grey) CDFDA. One thousand data 
points were generated over a period of 3 minutes with the kinetic parameters as described in 
Table 6-1 and using an input IC5 0  of 1.9 pM for Abcc2 inhibition. Quantitative data from Jarnac 
was converted to rate of production over the linear portion of the simulation and fitted to a non­
linear regression (log [inhibitor] versus rate) using GraphPad Prism. The ICso’s were calculated as 
9.73 +/- 0.63 pM with 10 pM CDFDA and 23.67 +/- 1.58 pM with 100 pM CDFDA.
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As can be seen from the data generated, an IC5 0  is dependent on where on the dose- 
response curve the information is taken; it is therefore of only limited value for a 
simulation. A better measure is the inhibition rate constant of the inhibitor (IQ 
(Equation 6-2), which includes an expression for dose ratio (dr) (Equation 6-3) and 
hence is independent of where on the dose-response curve experiments are undertaken.
[inhibitor] 
K,= ---------------
dr - 1
Equation 6-2 The Inhibition Constant
Where [inhibitor] is the concentration of inhibitor and dr is the dose ratio defined in 
Equation 6-3.
Km with antagonist
Dose Ratio (dr) = ----------------------
Km without antagonist
Equation 6-3 Dose Ratio
Where the Km is the concentration of substrate at half the maximum rate.
Simulations were undertaken using increasing concentrations of CDFDA, from 0.1 pM 
to 15000 pM, with multiple concentrations of inhibitor at each dose (0 pM, 4 pM, 10 
pM, 40 pM or 100 pM). The log of the concentration was plotted against rate to plot a 
Schild graph, which shows the shift to the right in the rate of CDF efflux as the 
concentration of inhibitor increases (Figure 6-17 A); such a plot is typical of a 
competitive inhibitor, such as MK571 is for Abcc2 (Leier et al., 2000; Letschert et al., 
2005). Whereas a Schild plot shows competitive inhibition it is no longer used to 
calculate a rate constant as this requires linearisation of the data, which could introduce 
error. Therefore to calculate the K, the concentration of CDFDA was plotted against 
rate of accumulation of CDF for each concentration of inhibitor and fitted using non­
linear regression analysis for competitive inhibition (Figure 6-17 B). The data fit 
calculated the Kj of MK571 inhibition as 3.465 + /- 0.1227 pM, which is very close to the 
measured Kj of MK571 for inhibition of CDFDA transport by ABCC2 of 4.1 pM 
(Heredi-Szabo et al., 2008).
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Figure 6-17 The simulated rate of CDF efflux with increasing concentrations of CDFDA 
and increasing concentrations of the Abcc inhibitor, MK571.
CDFDA concentrations were modelled between starting concentrations of 0.1 jiM and 15000 
|iM over a period of 3 minutes with the kinetic parameters as described in Table 6-1 and using an 
input ICso of 1.9 pM for Abcc2 inhibition. The concentration of MK571 was kept constant at 0 
pM, 4 pM, 10 pM or 100 pM and each simulation generated 1000 data points. Quantitative data 
from Jarnac was converted to rate of production over the linear portion of the simulation and 
fitted to either Schild kinetics (A) or non-linear regression (competitive inhibition) (B) using 
GraphPad Prism. The latter analysis resulted in a Ki of 3.465 +/- 0.1227 pM for MK571 
inhibition of Abcc2-mediated efflux.
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A real time simulation of the model can be run to observe how increasing the 
concentration of inhibitor affects CDFDA and CDF disposition over 3 minutes (Figure 
6-18). The Kj value calculated above for MK571 inhibition of Abcc2-mediated efflux 
was used in place of the IC5 0  in the kinetic input of the model. The rate of accumulation 
of CDF in the büe canaliculi (si2; dark blue) is reduced as Abcc2 is inhibited leading to 
an increase in intraceUular CDF concentrations (s5; turquoise) when inhibitor is added. 
The extraceUular CDF (s26; light blue) concentration also faUs with increased inhibitor as 
Abcc3 is also inhibited by MK571 so the export of CDF across the basolateral 
membrane is reduced.
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Figure 6-18 The simulated disposition of CDFDA and CDF in the in  silico  model with 
increasing concentrations of the Abcc inhibitor, MK571.
A kinetic simulation of the model was run for 3 minutes with 1 0  [jlM  CDFDA and (A) 0  p M ,  (B) 
4 pM, (C) 10 pM or (D) 1 0 0  | i M  MK571. The graphs show a decrease in extracellular CDFDA 
(si3, dark green) as CDFDA passively diffuses into cells, followed by an increase in intracellular 
CDFDA (si4, purple), which is rapidly depleted as CDFDA is hydrolysed to CDF. Intracellular 
CDF (s5, turquoise) initially increases and is then depleted, as it is effluxed from the cell by 
Abcc2 into the bile canaliculi (sl2, dark blue). CDF may also be effluxed via Abcc3 (s26, light 
blue). The kinetics of each step are altered by increasing the concentrations o f MK571 (compare 
B, C and D to A).
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6.4 Discussion
Assessing the transcript level of drug transporters allows a vast amount of data to be 
collected relatively quickly; however, the generated data is remote from biological 
functionality and differences observed at the transcript level many not necessarily be 
reproduced at the level of transport functionality due to post-transcriptional control 
mechanisms. This section of work investigated the activity of one transporter, Abcc2, in 
detail, using SC rat hepatocytes as a model system and CDF as a probe fluorescent 
substrate; this data was then used to generate an in silico model of drug transport.
6.4.1 Measuring Biliary Efflux and Cellular Toxicity
The efflux of CDF by Abcc2 has been reported many times before and as Abcc2 locates 
only to the apical membrane of polarised hepatocytes, it has often been used to check the 
proper formation of a BCN in SC hepatocytes (Bi et al., 2006). Recendy an assay was 
developed at AstraZeneca to measure the substrate specificity of compounds for various 
transporters using fluorescent substrates specific for a certain transporter (Hopwood et 
al., 2006).
This study showed that CDF fluorescence reached a plateau after 4 days of SC 
hepatocyte culture, which is consistent with the Abcc2 RNA and protein expression data 
observed in the previous chapter, where maximal levels are seen after 4 days SC 
hepatocyte culture. At 10 pM CDFDA, CDF accumulation in the BCN was linear up to 
40 minutes indicating that 10 pM CDFDA approaches the of the pathway. When
increasing concentrations of CDFDA were added to cells, the corresponding increase in 
CDF fluorescence fitted to Michaelis-Menten kinetics with a value of 0.77 + /-  1.2 pM 
for the Km and a of 23.13 + /-  5.0 RFU/minute. The assay is limited by the fact that 
the amount of Abcc2 protein within the cells is not known and therefore a cannot 
be calculated in the usual units of unit concentration/unit time/unit protein. This 
obviously limits comparisons with literature data although values can be compared.
Efflux of CDF via ABCC2 was measured in HEK cells and found a K^ of 18.9 + /-  2.0 
pM (Pratt et al., 2006). Evidentiy this is somewhat higher than the value calculated in 
this study but this is probably due to differences in the method of measuring the K^ i.e. 
different systems will have different factors involved that would affect the observed K^. 
It is possible that the system used in this study has more factors ‘pulling’ the flow of
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compound forward across the cells than in HEK cells and therefore you get a lower K^, 
however only a full investigation of the two systems would tell. Alternatively, it could be 
due to species differences as the Pratt study was completed with human ABCC2 and the 
current work looks at rat Abcc2.
Such an assay could be used to measure biliary efflux of new compounds via Abcc2; one 
such Abcc2 substrate, pravastatin, was shown to effectively reduce CDF efflux into the 
BCN with an IC5 0  at 10 pM CDFDA of 55.2 pM. While there is no directly comparable 
study, Chen et al found an IC5 0  of over 100 pM for the inhibition of calcein AM via 
ABCC2 by pravastatin (Chen et al., 2005), which would suggest that pravastatin is not a 
substrate of ABCC2 although it has previously been shown to be transported by the 
protein (Yamazaki et al., 1997). However OATPIBI was not transfected into the 
MDCKII cells used in this particular study (Chen et al., 2005) so a more likely 
explanation would be that pravastatin was not able to enter the cells and could therefore 
not be effluxed by ABCC2. Another study by Hopwood et al. showed an effect on CDF 
efflux with the Abcc2 substrate fl-estradiol-17-D-glucoronide (Hopwood et al., 2006). 
Put together the literature data and the current work shows that inhibition of fluorescent 
dye efflux via transporters can determine if a compound, such as pravastatin or B- 
estradiol-17-D-glucoronide, is a substrate for that transport protein; however the ability 
of the compound to enter the test system should be carefully considered as was shown in 
chapter 4. The fact that an effect was seen with pravastatin in this study, suggests that 
pravastatin is getting into the cells, indicating that Oatplal is functional in SC rat 
hepatocytes.
Alternatively the assay can be used to look at inhibition of export, which could result in 
DDEs as Abcc2 also transports bile acids and bilirubin, meaning inhibition could result 
in cholestatic symptoms (Kostrubsky et al., 2001; Fouassier et al., 2002). This work 
showed that the ABCC inhibitor, MK571, inhibited CDF efflux into the BCN with an 
IC5 0  at 10 pM CDFDA of 1.9 pM MK571. Again there is no directly comparable value 
but an IC5 0  of approximately 4 pM was observed with MK571 inhibiting the efflux of the 
Abcc2 substrate para-aminohippurate (PAH; 0.1 pM) (Leier et al., 2000).
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Other transporters involved in bile acid and xenobiotic transport also have fluorescent 
substrates that can be used in similar assays to determine substrate or inhibitor 
specificity, for example rhodamine 123 can be used to assess ABCBl transport (Schinkel 
et al., 1997) and the fluorescent büe acid Cholyl-lysl-fluorescein (CLP) can be used for 
ABCBl 1 (Hopwood et al., 2006). The use of fluorescent probes has clear advantages 
over measuring substrates via mass spectrometry as it is usually quicker and doesn’t 
require compound to be extracted from the biological matrix as is often required before 
samples can be analysed via mass spectrometry. Radiolabelled probes are another 
alternative but have obvious safety issues. However not all transporters have specific 
fluorescent probe substrates and this method is only applicable to biliary efflux 
transporters in SC hepatocytes with enclosed BCN’s.
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6.4.2 In silico  Modelling of CDF Efflux
In silico models of ADME processes have a number of advantages in the development of 
drugs, such as allowing complex scenarios to be considered without the need for in vitro 
work. However simulations are not the same as predictions as the data produced from a 
model will only ever be as good as the input data, which invariably comes from initial in 
vitro work where not everything about the biological system is understood. For example 
the Simcyp program is used to assess compound PK in a virtual population but doesn’t 
take into account active drug transport processes, which can have important effects on 
compound ADME. Therefore an in silico model of CDF efflux via Abcc2 and Abcc3 was 
designed in Cell Designer and simulated by the Jarnac simulation tool.
The model was based on Michaelis-Menten kinetics for transporter activity and used 
literature values of and for CDF transport processes along with values for the 
passive diffusion of CDFDA into cells and its hydrolysis to CDF inside and outside of 
the cell. It should be noted that many of the kinetic values taken from literature for use 
in this work were derived from over-expression systems where protein levels of the 
transfected transporter may be higher than in vivo. As is dependent on the unit of 
protein, this may adversely affect the simulation results. A number of factors in the 
pathway were discounted within the model either through experimental analysis, 
information from literature or model design e.g. protein binding of CDF/CDFDA may 
occur in vivo but the compounds were dosed in HBSS so plasma binding wül be absent.
The model simulated a concentration curve of CDFDA against rate of CDF efflux into 
the BCN with a and of 44.5 + /-  2.8 pM and 98.12 + /-  1.3 pmoles/minute/unit 
Abcc2, respectively. The is to the same as the input for Abcc2 efflux of CDF 
indicating this is a rate-limiting step in the cellular disposition of CDFDA/CDF. The 
for the accumulation of CDF in the BCN differs to the Kj  ^ of Abcc2 efflux as it also 
accounts for ‘negative’ processes such as CDF efflux over the sinusoidal membrane by 
Abcc3.
One reason why in silico simulation programs such as Simcyp do not include drug 
transport processes in their calculations is a lack of information on drug transporter 
expression. Therefore levels of Abcc2 and Abcc3 were altered in the model to reflect the
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transcript levels of Abcc2 and Abcc3 in SC rat hepatocytes after 4 or 5 days of culture 
and compared to the initial model where all values of transporters are 1 unit.
The CDF efflux transporters Abcc2 and Abcc3 levels are increased relative to liver on 
day 4 and 5 of sandwich culture while the influx transporters of the Oatp family are 
higher on day 4 but slightly lower on day 5. These alterations resulted in a an increase in 
the Yjnax of CDF accumulation in the BCN, indicating that increasing Abcc2 levels results 
in the efflux via Abcc2 no longer being rate-limiting. On both days the increases as 
would be expected with increasing the The real time simulation shows the
increased rate of CDF accumulation in the BCN and corresponding falls in the 
intracellular concentration of CDF.
It is unlikely that the very large increases in Abcc2 and Abcc3 RNA would be seen at the 
protein level. It is hence expected that while the /« vitro model would overestimate 
values it would not be as severe as the initial in silico predication. An obvious extension 
to the model would be to accurately quantify protein levels for all species within the 
model over the culture period and then repeat the simulation; unfortunately such a body 
of work is outside the scope of the current project. A further limitation of the model is 
that it takes no account of compound metabolism. While this isn’t a problem with any 
of the compounds used in the model, as they are not metabolised, it may be an issue for 
further development and could be built into the model in the future.
The model also showed that inhibition of CDF efflux by MK571, an Abcc2 inhibitor, 
reduced the accumulation of CDF in the BCN. The amount of CDF outside of the cells 
or BCN also fell as transport via Abcc3 was inhibited. Inhibition of CDF through the 
cell was calculated as having a Kj of 3.465 + /-  0.1227 pM. Occasionally, the passage of 
drugs through biliary efflux transporters can lead to an accumulation of bile acids leading 
to toxicity; for example this is one of the proposed mechanisms of toxicity for 
troglitazone (Funk et al., 2001) and bosentan (Fattinger et al., 2001). Therefore, an assay 
assessing biliary efflux transporter substrates can be used to predict compounds that may 
cause drug-induced cholestasis.
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6.4.3 Summary
In summary, sandwich cultured rat hepatocytes, which were shown in the previous 
chapter to be a good representation of in vivo hepatocytes based on their transporter 
expression profile, can be used to measure the functional biliary efflux of drugs by using 
fluorescent probe substrates of specific transporters. This was used as the basis for an in 
silico model of drug disposition within hepatocytes, which allows the quick assessment of 
kinetic parameters of transport, such as the IQ, as well as simulation of the effects of 
dynamic changes to cellular systems. Both in vitro and in silico assays have a place in drug 
development, as in vitro assays can be designed to answer specific questions about a 
compound e.g. is the drug a substrate of Abcc2, while in silico assays can be used to assess 
what difference to the result is gained if variations associated with that in vitro assay are 
introduced e.g. different expression levels or the presence of inhibitor.
Changes to the system, such as the expression of drug transporters, also show how the 
flux of compound is altered and this could affect the disposition and metabolism of 
drugs in vivo. Therefore differences in expression between in vitro cell culture systems and 
the in vivo tissue they represent could result in false positives (e.g. a compound is classed 
as non-toxic because it can’t get into the ceU due to lack of influx transporter expression) 
or false negatives (e.g. a compound is predicted to be cleared rapidly due to high levels of 
efflux transporter being present in the cell line used compared to in vivo). It is therefore 
imperative that expression of key ADME proteins is understood in cellular in vitro 
systems if they are to be used as predictive tools in drug development. In silico models 
can be used to help bridge the gap and make more accurate predictions for drug 
disposition and metabolism.
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7 Discussion
Drug transporters are critical in determining the fate of xenobiotics as they impact upon 
their absorption, distribution and excretion. In addition, this affect on chemical 
disposition may impact upon the amount of the drug that is accessible to metabolic 
enzymes, effecting both efficacy and toxicology in a particular organ or cell type. While 
rational drug design aims to produce lipophilic compounds that reach their desired site of 
action by passively diffusing across membranes, the metabolites produced from parent 
drug will tend to be more hydrophilic to aid excretion. These metabolites will then 
require efflux transport in order to cross the bilayers.
During preclinical studies to establish efficacy and safety parameters for new drugs, in 
vitro cellular models and in vivo animal studies are undertaken. Predictions made from 
these studies are used to judge if a compound is likely to be efficacious and safe in 
humans, and thus guide the design of first-in-man studies. However predictions made 
from both in vitro cell culture and pre-clinical in vivo studies do not always extrapolate 
accurately to humans in vivo., and while this may be due to species differences in the 
animal in vivo studies, it is often unclear why ADME and toxicity predictions made in 
human cell lines are sometimes erroneous.
It is especially important that compound disposition in the liver can be accurately 
predicted as this is where the majority of drug metabolism occurs. Hepatocytes are also 
responsible for removing drugs and their metabolites from the blood into the bile for 
faecal excretion. However disposition of drugs in the liver can be complicated by the 
multiple transport processes that occur in hepatocytes. Therefore the current work 
focused on measuring the expression level of transporters in a number of human derived 
cell lines and rat hepatocytes compared to the levels found in human and rat liver with 
the aim of establishing if cells in culture maintain drug transporter expression; it was 
hypothesised that incorrect expression of transporters in in vitro systems would result in 
incorrect dmg disposition within the cell and could result in the production of both false- 
positive or false-negative results in vitro compared to the in vivo situation. In addition to 
comparing the levels of transporter expression in these various systems we have also 
examined whether it is possible to use this information to model drug transport in silico\ 
such an approach could possibly then be used to increase the accuracy of extrapolation 
of data from in vitro to in vivo.
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7.1 The Effect o f Variable Transporter Expression on Pre-clinical
Drug Development
This study found that overall transporter expression levels compared poorly to those in 
the in vivo liver samples. A poor correlation between transporter expression in cell lines 
and liver is compounded by a poor correlation of relative transporter expression in cell 
lines: i.e. some transporters are highly expressed compared to liver while others, 
especially the influx transporters, are expressed at very low levels. However this study 
showed that when the primary cells were sandwich cultured, the levels of influx 
transporters improved after four days of culture.
Low expression of influx transporters is a potential problem for assessing toxicity or 
metabolism of hydrophilic drugs in these cells, however cultured cells are not used for 
assessing the actual mechanism or rate of compound uptake into cells. Rather the rate of 
compound uptake can be assessed in suspensions of freshly prepared hepatocytes (Soars 
et al., 2007) while the mechanism of uptake can be elucidated in either ~Kenopus oocytes or 
cells lines that have been engineered to over-express a single transporter. With 
information on the mechanism and kinetics of compound uptake, coupled with the 
knowledge of the influx transporter expression in the cell Une being used and importantly 
how this compares to in vivo liver, a more accurate interpretation of in vitro data can 
hopefully be achieved.
Unlike studies of compound uptake, which can be measured in minutes or hours, drug 
induction and safety studies need to be performed chronically to allow changes to 
become apparent. Therefore new drugs are exposed to cell culture or animal models for 
as long as possible. This study showed that primary hepatocytes provide a good 
representation of hepatocyte transporter expression in vivo, especially when cultured 
between two layers of collagen and hence may be applicable for such experiments. 
During the initial culture period hepatocytes were found to express variable levels of 
drug transporters but after 96 hours (4 days) in sandwich culture transporter levels were 
found to be similar to those in rat liver and, where appropriate comparisons can be made 
between species, human liver too. In particular influx transporters return to a ‘liver-Hke’ 
level. However after this time efflux transporter levels deviate from the liver-normal and 
the influx transporters fall to very low levels. If primary rat hepatocytes were used in 
long-term studies with hydrophilic compounds the results may be doubtful.
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Cholestasis in the sandwich-cultured hepatocytes may be a likely cause of aberrant 
transporter expression as the biliary network formed in this type of cell culture is entirely 
enclosed. Therefore bile acids will build up in cells to toxic levels and effect biological 
function. This may explain the increase of some canalicular export transporters over 
time, as it is known that the nuclear receptor FXR is activated by bile acids (Parks et al., 
1999) to increase target gene expression. Some of these target genes are known to be 
transporters e.g Abcc2 (Kast et al., 2002). Therefore after 96 hours of culture the 
window for performing experiments is quite small as a balance must be struck between 
allowing the cells to return to a ‘liver-like’ state and being too old for successful 
experimentation. In order to use the cells over an extended experimental period, a way 
would need to be found to prevent cells from becoming cholestatic, for example washing 
the cells in calcium free buffer before every medium change would open the networks 
releasing bile acids. Biliary networks would reform once calcium was added back to cells 
(Denker and Nigam, 1998).
CeU Unes transfected with expression plasmids for specific transporters can be utiUsed in 
several ways; first, the transfection of a ‘missing’ transporter may help to make ceUs more 
Hke the tissue they represent e.g. transfecting influx transporter such as SLCOIBI into 
ceUs where expression is low or non-existent (current work); second, transfection of high 
levels of transporters where general transporter expression is low, makes that ceU a 
specific model for influx or efflux via that transporter e.g. ABCG2 efflux in HEK- 
ABCG2 ceUs (Kevin Jones, personal communication); third, transfection of multiple 
transporters as some laboratories have done with MDCKII ceUs aUows the vectorial 
study of compound transport across polarised ceUs (Cui et al., 2001a). However, caution 
should be taken when using these ceUs, because this work has shown that transporter 
levels in transfected ceU Unes may be unphysiological and therefore results from them 
would need to be extrapolated back to the ‘normal’. Again knowledge of the ‘normal’ 
expression level and the transfected expression level are vital. High levels of an efflux 
transporter, such as was seen in this work where HEK ceUs transfected with ABCG2 and 
MDCKII ceUs transfected with ABCBl, may mean that the compound is not within the 
ceU long enough to be efficacious or for the ceU to exert an effect on the compound. 
Importantly, this study showed that altering levels of one transporter might affect the 
expression of other transporters, which compUcates the situation further. For example, 
increasing the relative amount of an influx transporter such as SLCOIBI, as was
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achieved in Huh7 cells, resulted in the reduced expression of SLC02B1. Therefore 
while some transporter levels may be made more physiologically relevant, the effect this 
has on others may make the cells less ‘liver-Hke’.
With regards to drug transporter expression, none of the cellular systems tested in this 
work are a perfect representation of liver, although this is perhaps not surprising as no 
single system could be expected to model the complex architecture, microenvironments 
and cellular interaction that occur in the Ever in vivo. However, accurate characterization 
of these systems, and the comparison of them to in vivo situation, allows any differences 
to be taken into account when analysing results, especially when testing hydrophilic 
compounds, which are likely to be substrates for drug transporters. Other factors should 
also be taken into account, for example the effect of passage number on transporter 
expression levels in cell lines (Siissalo et al., 2007) and species differences in specificity 
and function when using primary rat hepatocytes (Tahara et al., 2005). Because of the 
limitations of the currentiy available systems it may be necessary to undertake several 
different assays to fully understand compound uptake and efflux; for example, cell lines 
with transfected transporters to understand individual transport processes and 
hepatocytes to understand the combination of transport and metabolic processes in a 
more physiological relevant model. However, there is a constant move towards better 
cell culture systems with new proprietary cell Unes such as HepaRG from BioPredic (Le 
Vee et al., 2006) and Fa2N4 from MultiCell Technologies (Mills et al., 2004), which show 
levels of drug transporters and metabolic enzymes that are more similar to in vivo tissue. 
In addition to the development of novel cell lines, an exciting advance in primary cell 
culture is the application of 3D hepatocyte culture in multiwell ‘bio-reactors’. Through 
the reconstruction of liver architecture in a 3D format it may be that ‘mini-livers’ with 
better expression of important ADME genes may be generated, which would provide 
data that showed a higher correlation to in vivo studies. However, even with these more 
complex systems, differences wül always remain and it wiU remain vital that we 
understand at a molecular level the way these cells differ to the ultimate system for drug 
development, ourselves.
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7.1.1 The Role of In Silico Assays
In silico assays allow dynamic changes to a cellular system to be made without running lots 
of in vitro assays, which can be costly in terms of time and labour. More importantly this 
work has shown that cell lines used in vitro are not always a good representation of the 
tissue they represent. In silico assays are currently used in the field of pharmacokinetics, 
for predicting ADME characteristics of new compounds in a model population that 
includes kinetics for individuals expressing polymoip)hic enzymes. However in silico 
models are only as good as the data that is used to generate them and they generally don’t 
take into account active transport processes (Rostami-Hodjegan and Tucker, 2007). This 
is an area of concern as drug uptake and efflux affects every stage of ADME for 
compounds that are substrates for these proteins. Therefore predictions made from in 
silico assays that do not take into account drug transport may be erroneous for 
hydrophilic compounds. In the current work, a simple in silico model of drug efflux was 
generated to examine the effects of differential transporter expression levels found 
between rat hepatocytes in vivo and those cultured for four or five days in vitro. The 
model was used to show that transporter levels and indeed the inhibition of transport 
processes can have a dramatic effect on compound disposition in an hepatocyte.
Another use of in silico modelling of transport processes has been in the study of vectorial 
drug transport across polarised cell lines. A recent study by Dietrich Keppler’s 
laboratory identified a ‘missing’ transport process in the vectorial transport of 
compounds across MDCKII cells transfected with known human transporters 
(Bartholome et al., 2007). The ‘missing’ transporter was identified as canine ABCC4, 
highlighting the fact that aU transport processes whether they are transfected human 
transporters or endogenous transporters already existing in a cell line should be taken 
into account when analysing results. In the current work this may be true of the HEK 
cells transfected with ABCG2, which are used in an assay to identify ABCG2 substrates 
(Kevin Jones, personal communication). The analysis of transporter expression in HEK 
cells showed they express significant levels of other transporters and these may affect 
results.
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7.2 Coordinate Regulation o f ADM E Genes
Cells exposed to exogenous compounds, including pharmaceutical drugs, must maintain 
a defence against potential toxicity elicited by the exposure. In order to do this 
effectively cells must have multiple lines of protection for example phase I and II DME’s 
make the potentially toxic compounds water soluble so they can be easily excreted from 
the body, while transporters actively efflux hydrophilic molecules across the lipid bilayer. 
For this system to work efficiently it must be borne in mind that required substrates or 
cofactors for enzymatic reactions must also be generated; for example glutathione is 
required for conjugation reactions and multiple enzymes are required to produce 
intracellular glutathione e.g. y-glutamyl transferase (GGl), which breaks down 
glutathione outside the cell allowing the amino acids that make up glutathione (cysteine, 
glutamine and glycine) to be transported into the cell (Marshall and Bangert, 2004) and y- 
glutamylcysteine synthetase, which is involved in the production of glutathione from its 
constituent amino acids (Tatebe et al., 2002).
This vast array of ‘detoxification’ processes, be it DME’s, drug transporters or 
‘associated-enzymes’ such as GGT, are in the main under transcriptional regulation by 
nuclear receptors, a super family of ligand activated transcription factors, including PXR, 
CAR and PPARa. The range of ADME genes involved in this coordinated response, 
and its regulation by nuclear receptors, has been exhibited by gene array studies using 
prototypical inducers of each of the nuclear receptors (Slatter et al., 2006). Certain 
groups of genes may have common regulatory pathways presumably because they have 
similar roles within the cell. For example the basolateral Abcc family members, which 
are involved in the efflux of compounds over the basolateral membrane of hepatocytes, 
were aU shown in this work to be induced via activation of PXR.
Using the hydrophilic compound pravastatin, it was shown that lack of influx transporter 
expression in cell lines could affect the biological effect of a compound; pravastatin 
could only activate the Abcc2 reporter gene when SLCOIBI had been transfected into 
Huh7 cells. Pravastatin, unlike simvastatin and lovastatin couldn’t activate the CYP3A4 
reporter gene, a result that has been previously reported in HepG2 cells (El-Sankary et 
al., 2001). This indicates the possibility of differential gene activation by the statin class 
of drugs either by activating the same nuclear receptor to transcribe different sets of
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target genes or by activating different nuclear receptors, which in turn activate 
transcription of overlapping, but unique, target gene sets. Previous studies have 
established that CYP3A4 (Blumberg et al., 1998) and Abcc2 (Demeule et al., 1999) are 
primarily PXR-regulated genes, suggesting that phenomenon observed herein is due to 
the activation of distinct gene sets by PXR following activation of PXR by these different 
ligands; such a system could be used to only upregulate those genes involved in the 
detoxification of a particular compound or type of compound. For example, simvastatin 
is metabolised by CYP3A4 (Prueksaritanont et al., 1997) and it and its metaboHtes are 
substrates for ABCC2 (Chen et al., 2005), whereas pravastatin doesn’t undergo CYP 
mediated metabolism in vivo but is a substrate for ABCC2 (Yamazaki et al., 1997; Sasaki 
et al., 2002). The most likely explanation for such an effect is that different ligands cause 
the recruitment of alternative co-regulatory proteins to form a complex with PXR, 
however definitive data to prove this is currently lacking.
Unlike other studies where PXR agonists were found to increase Abcc2 expression 
(Demeule et al., 1999), the current work found that dosing rat hepatocytes with CPA and 
dexamethasone did not increase Abcc2 expression. However previous studies have 
shown these compounds increased Cyp3al expression in primary rat hepatocytes (Kate 
Plant, personal communication) indicating that PXR is activated in this situation. The 
lack of Abcc2 induction by PXR ligands may help to explain the differential gene 
expression, as pravastatin may simply be acting through an alternative nuclear receptor to 
activate the Abcc2 reporter gene thus explaining the lack of CYP3A4 induction by 
pravastatin in Huh7 (current work) and HepG2 (El-Sankary et al., 2001). Other nuclear 
receptors such as Nrf2 have been shown to induce Abcc2 expression (Jigorel et al., 
2006); however Nrf2 is involved in the oxidative stress response and there is no 
indication that pravastatin effects this pathway.
Cells were also dosed with the PPARa agonist Wy-146,43 but only a single transporter, 
Abcg2, out of the 10 measured was induced by the treatment. This is confirmed by Hirai 
et al., who saw PPARa-dependent activation of Abcg2 in mouse liver (Hirai et al., 2007). 
Why PPARa should regulate expression of Abcg2 is currently unclear, but other 
members of the Abcg family are involved in lipid transport and so the presence of 
PPARa regulatory regions would not be entirely surprising in the promoter regions of 
members of this family, as PPARa is known to control the expression of a number of
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genes involved in lipid metabolism and transport. In bacterial cells ABCG2 has been 
shown to transport cholesterol (Janvilisri et al., 2003) but Abcg2 knockout mice were 
shown to have normal levels of cholesterol and phopholipids (Jonker et al., 2002). 
Therefore, whether Abcg2 is involved in lipid transport is a question of some debate.
In summary, the coordinate regulation of ADME genes by similar pathways helps the 
ceU to detoxify and remove xenobiotics. While some aspects of this regulatory pathway 
are well characterised e.g. the induction of CYP3A4 via activation of PXR (Lehmann et 
al., 1998), the regulation of transporters is less well understodd. In this work a 
connection was identified between Abcg2 and PPARa, while other data supports a 
theory of ligand-dependent differential gene regulation by the same nuclear receptor.
7.2.1 Drug Resistance and Induction of ADME Genes
Unfortunately, a cells response to defend itself against xenobiotics can lead to problems 
in drug delivery. This is most often seen in drug resistance during chemotherapy for 
cancer, but can be seen in any condition where chronic administration is required, such 
as epilepsy (Remy and Beck, 2006) and HIV (Turriziani et al., 2003). The general 
response to chronic chemical exposures is that efflux transporter levels are increased, 
which in turn increases compound efflux and reduced efficacy, sometimes to the point of 
a complete loss of efficacy. It is possible to inhibit an efflux transporter without causing 
major damage, as exhibited in mice, which are viable and appear healthy when Abcbla/b 
is knocked out (Schinkel et al., 1997). Intense efforts are being made to find potent and 
safe inhibitors of ABCBl for the treatment of drug resistance in cancer therapy; however 
to date no compound has successfully made it to market (Friedenberg et al., 2006; 
Derosa et al., 2007; Gandhi et al., 2007).
Whether transport inhibition would work in all cases of drug resistance is doubtful as 
inhibiting transporters may result in adverse effects due to disruption of endogenous 
processes that are mediated via the inhibited transporter; for example lack of ABCC2 
leads to Dubin-Johnson syndrome (Suzuki and Sugiyama, 2002), a condition 
characterised by hyperbilirubemia due to the reduced efflux of bilirubin (Dubin and 
Johnson, 1954). Therefore inhibition of ABCC2 in tumours might result in 
hyperbiHrubeamia as ABCC2 in the liver could also be affected. Drug resistance can be 
used to help patients undergoing chemotherapy, for example an innovative gene therapy
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technique has been developed in the treatment of breast cancer whereby healthy cells are 
taken from the patient and transduced with ABCBl. The healthy cells are thereby 
protected from chemotherapy with ABCBl substrates such as paclitaxel (Takahashi et al., 
2006), as the drug is effluxed from the healthy cells before it can kill them.
Ideally new drugs should aim to avoid activating nuclear receptors so as to minimise drug 
resistance, the effects of multiple gene upregulation and enable safe therapy with multiple 
drugs. One way to do this is to increase the potency of compounds so as to reduce the 
dose of drug needed in man. For example troglitazone was the first of the 
thiazolidinediones to be developed in the treatment of type II diabetes (Mimura et al., 
1994), however it exhibited fatal hepatotoxicity in man (Vella et al., 1998), which was not 
predicted preclinically. Later members of the ‘glitazone’ class of drugs, rosiglitazone and 
pioglitaszone, were much more potent activators of the target, PPARy, and hence were 
given at much lower doses (Balfour and Plosker, 1999; Rosenstock et al., 2002). While 
all three compounds are capable of activating PXR in vitro (Jones et al., 2000), the cellular 
concentrations of rosi- and pio-glitazone never reach the level needed to activate PXR in 
vivo unlike troglitazone, which was given at a much higher dose. Better drug design may 
therefore limit the influence of nuclear receptor activation on drug development.
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7.3 Future Work
There are many exciting new developments in the field of ADME and toxicity testing 
that could be explored for their ability to transport and metabolise drugs in a similar way 
to that which occurs in vivo. For example three dimensional cell cultures may produce a 
‘liver-like’ model that could be used for transport, metabolic and toxicity studies, as well 
as for assessing the activation of nuclear receptors by new drugs. Chimeric animal 
models, where hepatocytes have been genetically modified to be more human like, may 
reduce the problem of species difference in in vivo studies and provide a plentiful, and 
phenotypicaUy consistent, supply of ‘human’ hepatocytes for culture work.
Transporters are involved in drug resistance in a number of conditions such as epilepsy 
and HIV but most especially in cancer, where drug-induced aberrant expression of 
transporters in tumour cells can reduce the effectiveness of chemotherapeutic drugs. 
Therefore a better understanding of transporter expression in tumour tissue should be 
sought in order to improve the development of efficacious and safe drugs. For example 
it is unknown if the pattern of transporter expression changes across a tumour and how 
this may affect drug disposition both into and within the tumour mass. Also tumours 
provide relatively acidic conditions and this may affect the function of some transporters 
such as SLC02B1, which is known to transport a different range of substrates in the 
acidic environment of the duodenum than in hepatocytes where pH is higher.
In this study, drug transporter expression was measured primarily at the transcript level, 
which is ideal for the measurement of lots of genes in a number of samples. However, 
transcript levels do not always reflect the functional activity level due to modifications 
made to the transcript and after translation. Currently measuring the protein level of 
membrane proteins, such as drug transporters, can be difficult as antibodies often give 
poor quality results and in some cases a quantitative measure of RNA can give a better 
correlation with activity levels than a qualitative western blot (Taipalensuu et al., 2004). 
Better antibodies are now being developed giving the opportunity to make better 
assessments of transporter protein expression. Importantly immunofiuorescece should 
be used in primary cells and cell lines to look at localisation of the protein as this is a far 
better estimate of function than western blotting and can be used to compare different 
cell culture systems. It was demonstrated in this work that transporter proteins are not
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properly targeted to the cell membrane of rat hepatocytes cultured in monolyaers and 
therefore probably remains within the endoplasmic reticulum or Golgi. It would be 
interesting to assess cell lines based on the proper localisation of transporter protein and 
relate this to RNA level. Functional assays are of course the only definitive way of 
measuring transport activity but this is difficult to do for multiple transporters. It may be 
possible to develop an assay for biliary excretion using a fluorescent probe substrate, 
whereby cells are exposed to multiple fluorescent probe substrates, each specific for an 
individual transporter, and each with a discrete fluorophore. This could be designed as a 
high throughput, high content assay and might be used in several areas such as assessing 
biliary excretion or assessing toxicity caused by drug — drug interactions at transporters.
The use of in silico modelling in drug development wül continue to grow in importance as 
models improve. A vital facet of such models is that they incorporate drug transport 
mechanisms and more work is needed to refine and expand on the work started in this 
study. Other areas of drug disposition and activity within a ceü could also be included in 
a model, for example drug transport into the nucleus via karyopherins and interactions 
with nuclear receptors. Having a model of the effects of a drug activating PXR or 
PPARa would be of great interest to the drug discovery industry in deciding if such 
action is permissible in a new compound as weü as helping to explain results from in vitro 
or in vivo work.
One theory put forward in this work is that compounds may differentiaüy activate 
nuclear receptors to cause the transcription of variable sets of genes and this should be 
explored further. If true the system is much more compHcated than has previously been 
reaüsed and would require the presence of different complexes of co-regulators to form 
with nuclear receptors. Further work should be carried out to estabüsh if this 
hypothesis is true and ascertain how it works at a molecular level.
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7.4 Summary
In summary, this work has found that drug transporter expression is altered in cell 
culture systems, which may effect the disposition and metabolism of drugs such as 
pravastatin. Understanding how transporter expression varies in in vitro cell lines allows 
us to make better predictions for how a drug will act in man from pre-clinical study data, 
while work is underway to find hepatocellular models that are a more accurate 
representation of human liver. This study also showed that once dmgs enter a cell they 
can activate nuclear receptors such as PXR and PPARa to increase expression of 
transporters as well as drug metabolising enzymes. This produces a system of co­
ordinate regulation of ADME genes in order to clear potentially toxic compounds from 
the cell. One particularly interesting theory supported by this work is that different 
ligands may be able to activate the same nuclear receptor to induce expression of discrete 
gene sets, however this theory requires much more work to prove, or indeed, understand. 
Finally, in silico modelling was shown to be a useful tool to explore the complicated 
interactions between transporters, drug metabolising enzymes and nuclear receptors; this 
was demonstrated by the model of compound disposition in an hepatocyte, which 
showed the effect of alternative transporter expression in different systems. Further 
work wiU broaden the scope of such models so that they can be used to produce accurate 
ADME predictions of drug efficacy and safety in phenotypicaUy different human 
populations.
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